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The overall aim of the work presented in this thesis was to further characterise 
aspects of metabolic and immune system cross-talk in human subcutaneous 
adipose tissue, with a particular emphasis on the potential role of T-lymphocytes 
in adipose tissue dysfunction and insulin resistance. Chapter 3 characterised 
macrophage and T-lymphocyte populations residing in adipose tissue from lean 
through to class I obese men. This work demonstrated that T-lymphocytes display 
increased activation with increased adiposity and that potential compensatory 
mechanisms may be present to help counteract adipose tissue inflammation. In 
Chapter 4, the same participants were exposed to a meal-based stimulus in order 
to examine the postprandial metabolic and inflammatory responses in blood and 
adipose tissue. Despite increased glucose and insulin responses in blood with 
obesity, there were no differences in inflammatory cytokine gene expression 
responses in adipose tissue. This suggests that mechanisms may be present to 
limit or dampen inflammatory output from adipose tissue after feeding in 
individuals with modestly increased adiposity. Chapter 5 examined metabolic and 
immune system changes to 50 % calorie restriction for 3 days, resulting in 
reduced serum leptin which was temporally associated with a reduction in blood 
T-lymphocyte activation. In adipose tissue, however, leptin gene 
expression/secretion was not reduced and neither was resident T-lymphocyte 
activation, indicating that there may be local tissue-specific responses of immune 
cells to caloric restriction. Chapter 6 characterised differences between obese 
individuals with either normal or impaired glucose tolerance, and their respective 
responses to 10 days of diet and activity modification. Overall, this thesis 
highlights key differences in properties of T-lymphocyte populations with 
increasing levels of adiposity and insulin resistance together with responses in 
adipose tissue and the immune system in times of feeding, severe calorie 
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Review of Literature 
 
1.1 Overview 
Our knowledge of the many complex roles of adipose tissue in heath and disease 
is rapidly emerging and evolving. It is becoming widely acknowledged that in 
addition to being the body’s primary store for surplus energy in the form of 
triglycerides, adipose tissue is a dynamic organ that secretes and responds to 
various metabolic and inflammatory mediators. Within the last decade it has 
become apparent that adipose tissue contains a whole host of other cell types 
including immune cells in addition to adipocytes. Differences in the secretion of 
inflammatory and metabolic mediators from adipose tissue have been observed 
between lean and obese individuals, as have differences in certain adipose tissue 
resident immune cell populations. Adipose tissue metabolic dysfunction and 
inflammation are implicated in the development of obesity related diseases, 
although it is not necessarily the total fat mass, but the properties and interactions 
of the various cells located within it which may important in adipose tissue 
pathophysiology. A greater understanding of this metabolic and immune system 
‘cross-talk’ could ultimately lead to the development of a better means of 
prevention and treatment of obesity related disease. 
 
1.2 Context  
Overweight and obesity are caused by a positive imbalance between energy intake 
versus expenditure, resulting in excessive fat accumulation in adipose tissue. The 
latest statistics from the Health Survey for England shows that in 2008 nearly one 
in four adults and over one in ten children between the ages of 2-10 years are 
obese, as classified by a body mass index (BMI) >30 kg/m2 (Department of 
Health, 2010). Without intervention, the incidence of obesity is predicted to 
increase to over 50 % of adults and 25 % of children by 2050 (Department of 
Health, 2010). The rapid rise in prevalence suggests environmental influences are 
key, with genetics playing a minor role in modifying susceptibility (de Ferranti & 
Mozaffarian, 2008). The exact aetiology in the development of obesity is 
multifactorial. Aspects of modern Western lifestyles such as consumption of large 
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portions of calorie rich foods combined with low physical activity and 
technological advances contributing towards more sedentary lifestyles, are likely 
to be major contributors (de Ferranti & Mozaffarian, 2008).  
 
Given one of its primary roles, adipose tissue has evolved to have a great capacity 
for storing excess energy as triglycerides, and is capable of expansion to account 
for over 80 % body weight in obese individuals (Thompson et al., 2012). The 
excess adiposity observed in obesity, however, has a severe impact on health, 
predisposing to a number of inflammatory related diseases such as type 2 
diabetes, atherosclerotic cardiovascular disease (CVD), fatty liver disease, 
osteoarthritis, rheumatoid arthritis and cancer (Malnick & Knobler, 2006; 
Schelbert, 2009). Consequently, obesity poses a significant burden on the NHS 
and is estimated to cost £4.2 billion per year which could more than double by 
2050 if the predicted rise in incidence occurs (Department of Health, 2010), with 
the majority of this being accounted for by type 2 diabetes and CVD. A key factor 
linking obesity to its associated complications is chronic low grade inflammation. 
The adipose tissue itself is a source of inflammatory molecules such as TNFα and 
IL-6, which are increased in blood and adipose tissue with its expansion and are 
associated with the development of insulin resistance (Hotamisligil et al., 1993; 
Weisberg et al., 2003). In vivo experiments in humans have shown that infusion of 
TNFα impairs skeletal muscle insulin signalling and decreases whole body 
glucose uptake in healthy humans (Plomgaard et al., 2005) supporting the impact 
of inflammatory mediators on insulin resistance. Conversely, adipose tissue 
inflammation and whole body insulin resistance can be reduced by diet and 
exercise (Tuomilehto et al., 2001; Li et al., 2008). There is great controversy, 
however, regarding whether inflammation, particularly within the adipose tissue, 
is the cause or consequence of insulin resistance (Tam et al., 2010).  
 
The development of type 2 diabetes is a gradual process and it is the events 
occurring in the development of this particular obesity related complication that 
will be the focus of the work presented in this thesis. Throughout the course of 
this PhD, the underlying aim is to find out more about the potential role of the 
immune system in human adipose tissue and its involvement in the early stages of 
insulin resistance.  
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1.3 Insulin resistance, Pre-diabetes and Type 2 diabetes 
In line with increases in obesity, the global prevalence of type 2 diabetes is also 
increasing. It is estimated that 330 million individuals will have type 2 diabetes by 
2025 with a further 472 million of the global population having impaired glucose 
tolerance if current trends continue (Schrauwen, 2007). Type 2 diabetes accounts 
for approximately 90 – 95 % of cases of diabetes mellitus, the majority of whom 
are either overweight or obese (ADA, 2010).  
 
The increased low grade inflammation typically observed with increasing 
adiposity is implicated in the development of insulin resistance by its interference 
with insulin signalling (Shah et al., 2008). Insulin resistance is a pre-requisite to 
type 2 diabetes and refers to the resistance of various tissues including liver, 
muscle and adipose tissue, to the metabolic effects of insulin. The liver is 
important in maintaining fasting glucose concentrations in blood via regulation of 
glucose and glycogen synthesis. A fasting hyperglycaemia results from an 
insensitivity of the liver to the suppressive effects of insulin on gluconeogenesis 
and glycogenolysis (Lee et al., 2009). Insulin resistance in other tissues such as 
adipose tissue and skeletal muscle manifests as impaired glucose uptake from the 
bloodstream. Adipose tissue insulin resistance is also characterised by elevated 
levels of non-esterified fatty acids (NEFA) in plasma due to decreased 
suppression of lipolysis (Campbell et al., 1994; Jensen, 2008). In a vicious cycle, 
this elevation in NEFA exacerbates insulin resistance in liver and skeletal muscle 
(Abel et al., 2001) and may also have toxic effects on pancreatic β-cells and 
contribute to vascular dysfunction (Jensen, 2008). The initial peripheral insulin 
resistance is compensated for by an increased drive of the pancreatic β-cells to 
produce more insulin until they ultimately fail to meet the demands required and 
blood glucose levels remain elevated. The consequences of a persistently elevated 
blood glucose concentration include both micro-vascular complications; 
nephropathy, neuropathy and retinopathy as well as macro-vascular 
complications: coronary artery disease, peripheral arterial disease and stroke 
(Fowler, 2008). In those with type 2 diabetes, levels of insulin produced in 
response to a given concentration of glucose are inappropriately low. Clinically, 
this is usually assessed using measures of fasting blood glucose and the glucose 
concentration at 2 hours after consumption of 75g glucose in an oral glucose 
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tolerance test (OGTT).  Depending on the blood glucose test results (shown in 
Table 1.1), clinicians can assess the degree of insulin resistance/insulin sensitivity 
and whether treatment for type 2 diabetes or ‘pre-diabetes’ is required.  
 
 Fasting  
plasma glucose 
Plasma glucose 2h 











6.1-6.9 mmol/L 7.8 - 11.1 mmol/L Impaired fasting glycaemia and 
impaired glucose tolerance. 
Probable 
diabetes 
>7.0 mmol/L >11.1 mmol/L Diagnosis made if at least one of these 
criteria is met on 2 occasions 
 
Table 1.1. Target, pre-diabetic and diabetic ranges for fasting and 2 hours 
post oral glucose tolerance test. (Diabetes UK). 
 
 
1.3.1 Metabolic syndrome 
It is important to note that insulin resistance seldom occurs in isolation. It is part 
of a cluster of risk factors for cardiovascular disease which occur together more 
often than by chance alone and collectively form the ‘metabolic syndrome’ 
(Grundy et al., 2005). These risk factors include elevated fasting concentrations of 
glucose, triglycerides and insulin, reduced HDL cholesterol, raised blood pressure 
and increased waist circumference. In 2009, the American Heart Association and 
National Heart, Lung and Blood Institute and the International Diabetes 
Federation agreed a combined definition for the diagnosis of metabolic syndrome 
whereby individuals must meet a minimum of any 3 from the criteria shown in 
Table 1.2 (Alberti et al., 2009). It is important to identify individuals clinically at 
increased risk to allow initiation of interventions to reduce risk factors. The 
criteria used to diagnose metabolic syndrome cannot determine absolute risk, 
however, because it does not include age, sex, cigarette smoking, and low-density 
lipoprotein cholesterol levels which also contribute. Despite this, patients 
diagnosed with metabolic syndrome are at twice the risk of developing CVD over 
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the next 5 to 10 years compared to individuals without the ‘syndrome’ (Alberti et 
al., 2009). 
 
Criterion Categorical cut points 
Increased waist circumference* Population- and country-specific 
definitions 
Hypertriglyceridemia ≥ 1.7 mmol/L 
Hyperglycaemia ≥ 5.6 mmol/L fasting 
Hypertension Systolic ≥130 mm Hg 
and/or diastolic ≥85 mm Hg 
Reduced HDL cholesterol < 1.03 mmol/L in males  
< 1.29 mmol/L in females 
 
Table 1.2. Definition of metabolic syndrome according to the American Heart 
Association/National Heart Lung and Blood Institute and the International 
Diabetes Federation 2009. *The World Health Organisation identifies 2 levels of 
abdominal obesity in Europeans depending on risk for metabolic complications. 
An increased risk occurs at waist circumferences of ≥94 cm in men and ≥80 cm in 




1.4 Cellular mechanisms of insulin resistance 
Insulin resistance occurs due to impaired insulin signalling in various cell types. 
When insulin binds to the insulin receptor, the receptor becomes 
autophosphorylated and its tyrosine kinase is activated. Insulin signal transduction 
occurs via tyrosine phosphorylation of insulin receptor substrates (IRS) 1 and 2 at 
the cell membrane which subsequently activates PI3K. This generates a series of 
second messengers and activation/inactivation of downstream targets accordingly 
(Danielsson et al., 2005). Downstream of PI3K, signalling via PKB and PKC is 
involved in translocation of GLUT4 from an intracellular pool to the cell 
membrane, resulting in glucose transport into the cell and stimulation of glycogen 
synthesis (Schenk et al., 2008). Disruption to any part of this pathway can lead to 
insulin resistance. Insulin signalling is typically down-regulated by interference 
with the tyrosine phosphorylation or inhibitory serine phosphorylation of IRSs, 
both of which are increased with inflammation (Shah et al., 2008). Insulin can 
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also activate the mitogen-activated protein kinase (MAPK) family of protein 
kinases (p38 MAPK, ERK-1/2, JNK), which are involved in controlling 
transcription factors and may therefore have a role in long term development of 
insulin resistance with prolonged stimulation. It is thought that the low grade 
inflammation in obesity contributes to insulin resistance by activation of these 
particular pathways, ultimately leading to either serine phosphorylation or reduced 
tyrosine phosphorylation of IRS 1/2. TNFα, for example, can cause inhibitory 
phosphorylation of IRS-1 at serine 307 via the JNK pathway (Hirosumi et al., 
2002). In adipocytes, activation of P38 MAPK by inflammatory cytokines 
interferes with insulin signalling on genes controlling GLUT4 (Magne et al., 
2010), further implicating this pathway in both insulin resistance and 
inflammation. PKC-θ activation also increases serine phosphorylation of IRS-1, 
stimulated by fatty acid metabolites (Shah et al., 2008). NFκB is also an important 
kinase linking insulin resistance and inflammation, which is usually under 
inhibition from IκBα in the cytoplasm. With appropriate stimuli, particularly in 
the setting of obesity and high levels of dietary saturated fatty acids, this 
inhibition is removed (by the action of IκKβ and NFκB enters the nucleus where it 
stimulates transcription of inflammatory cytokines which further contribute to 
impaired insulin signaling (Shah et al., 2008). PPARɣ is another key transcription 
factor highly expressed in adipose tissue and influences both insulin sensitivity 
and inflammation in addition to adipogenesis and lipid metabolism. 
Thiazolidinediones, used in the treatment of type 2 diabetes, are activators of 
PPARɣ to increase insulin sensitivity. However, due to the widespread expression 
of PPARɣ there are numerous side effects so research for better treatment options 
is still required (Ahmadian et al., 2013). 
 
1.5 Adipose tissue distribution 
Although obesity is clearly a key risk factor for type 2 diabetes, it is not a simple 
matter of total fat mass that is important in the development poor metabolic health 
and obesity related disease. Since not all obese individuals exhibit poor metabolic 
health (Karelis et al., 2005). Further, despite adipose tissue typically representing 
approximately 30 % body fat in females and 20 % in males (Thompson et al., 
2012), women are not found to be at increased risk of obesity related disease 
(Geer & Shen, 2009; Logue et al., 2011). The anatomical location of adipose 
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tissue is an important factor and increased upper body fat is associated with higher 
disease risk than increased lower body fat, which holds true over a range of BMI 
(Kissebah & Krakower, 1994; Manolopoulos et al., 2010). Specifically it is an 
increased central/abdominal adiposity which is considered more pathogenic 
compared to lower body fat (Jensen, 2008) and as such waist circumference can 
often be a better predictor of type 2 diabetes than BMI (Diabetes Prevention 
Program Research, 2006). An increased proportion of gluteo-femoral fat 
compared to upper body adipose tissue is actually associated with lower 
cardiovascular risk and increased insulin sensitivity (Manolopoulos et al., 2010). 
The exact mechanisms that cause central fat to be more closely associated with 
metabolic and inflammatory complications are not known. Striking differences 
exist between the different adipose tissue depots particularly in their lipolytic 
activity, abilities to remove triglyceride from the circulation and their sensitivities 
to the suppressive effects of insulin on free fatty acid release. Upper body adipose 
tissue is considered to be more metabolically adverse since it has a higher basal 
rate of lipolysis (Jensen, 2008). Another important consideration is likely to be 
that the different adipose tissue depots within the body have depot and gender 
specific gene expression profiles and unique biological and inflammatory 
characteristics (Karelis et al., 2005; Karastergiou et al., 2013). The presence of 
increased visceral adipose tissue in particular is considered to be higher risk due 
to its elevated levels of inflammation and fatty acid output directly to the liver via 
hepatic portal vein (Jensen, 2008). However, abdominal subcutaneous adipose 
tissue usually represents a larger depot in comparison to the visceral depot (Hill et 
al., 2007; Thompson et al., 2012) making it is particularly important not to 
overlook its role in the development of obesity related complications. 
 
1.6 Adipose tissue health and dysfunction 
The last decade has shown a dramatic increase in our understanding of the roles of 
adipose tissue and how its dysfunction is involved in mediating the development 
of obesity related disease. Nevertheless, a major role of adipose tissue is storing 
energy in the form of triglycerides during periods of positive energy balance and 
secreting fatty acids during periods of fasting and long term energy depravation 
(Trayhurn et al., 2011). Adipose tissue metabolism is dynamic and the balance 
between triglyceride storage and lipolysis is complex and affected by various 
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factors such as insulin, catecholamines, adipose tissue blood flow and 
inflammatory cytokines such as TNFα and IL-6; all of which are dysregulated in 
obesity related insulin resistance (Manolopoulos et al., 2010; Frayn & Karpe, 
2014). It is important to understand the various roles of adipose tissue in health 
and disease and aspects of metabolic dysfunction occurring with its expansion are 
outlined below. 
 
1.6.1 The traditional role of adipose tissue 
Adipocytes are cells which are highly specialised for the storage of energy as 
triglycerides; a combination of fatty acids and glycerol. Since the body’s storage 
capacity for carbohydrate and protein is limited, excess energy is reflected as 
triglyceride stored in adipose tissue (Schrauwen, 2007). Fatty acid flux between 
tissues is largely regulated by insulin and therefore reflects the body’s current 
nutritional state. Following ingestion of dietary fats in the small intestine, they 
enter the circulation as triglyceride-rich chylomicrons via the lymphatic system. 
Fatty acids are taken up into adipocytes (and other cells including myocytes and 
hepatocytes) via the action of lipoprotein lipase (LPL). LPL is synthesised in 
adipocytes and is up-regulated in the postprandial state, stimulated by insulin, and 
transported to capillary endothelial cells within adipose tissue. LPL hydrolyses 
triacylglycerol from chylomicrons and once the free fatty acids are taken up into 
adipocytes they become esterified with α-glycerol-phosphate to reform 
triglycerides. The remaining chylomicron ‘remnant’ particles are then taken up by 
the liver and processed to form low-density lipoproteins (LDL) and very low-
density lipoproteins (VLDL). In times of fasting and when insulin levels are low, 
NEFA, particularly as palmitate and oleate, are released into the circulation 
following hydrolysis of stored triglycerides by the action of hormone-sensitive 
lipase (HSL) and adipose triglyceride lipase (ATGL). NEFA circulate bound to 
albumin and are taken up by the liver and skeletal muscle amongst other tissues 
where they are either used for β-oxidation or triglyceride synthesis (Frayn & 
Karpe, 2014). 
 
The balance between uptake and release of triglycerides is highly regulated 
according to energy balance. In times of weight gain, adipocyte hypertrophy 
occurs, reflecting an increased storage of triglycerides, however large adipocytes 
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are linked to an increased production of inflammatory mediators known to affect 
insulin resistance and lipolysis (Skurk et al., 2007). Although it is not a simple 
matter of adipocyte size being the link to insulin resistance since visceral adipose 
tissue is considered more inflammatory even though it is composed of smaller 
adipocytes (Cancello et al., 2006). Disruption to the regulation of blood flow to 
the adipose tissue, sensitivity of HSL to the suppressive effects of insulin and 
responsiveness to glucocorticoid and catecholamines are all thought to contribute 
to the elevated NEFA observed with insulin resistance (Manolopoulos et al., 
2010). However adipose tissue is capable of adapting via down-regulation of HSL 
and ATGL as an attempt by the whole tissue to prevent increased output of NEFA 
per unit fat mass and normalise blood levels (Karpe et al., 2011). Although insulin 
resistant individuals frequently show increased circulating NEFA, it is not clear 
whether this is due to impaired fat storage or dysregulation by inflammatory 
cytokines (Karpe et al., 2011). 
 
1.7 Adipose tissue as an endocrine organ 
A significant turning point in obesity research was the discovery that white 
adipose tissue acts as an endocrine organ (Hotamisligil et al., 1993; Zhang et al., 
1994). The hormones produced by adipose tissue are termed ‘adipokines’ and the 
expression of a number of these are altered with excess weight (Balistreri et al., 
2010). Adipokines have a key role in regulating inflammation, insulin sensitivity, 
glucose metabolism and a variety of other physiological processes. They can act 
locally in an autocrine and paracrine manner but also in an endocrine manner, 
eliciting effects on the rest of body (Balistreri et al., 2010). Many adipokines have 
been linked to insulin resistance (by interference with insulin signalling pathways 
discussed in section 1.4); particularly pro-inflammatory cytokines including 
leptin, IL-6, TNFα and MCP-1, which are increased in adipose tissue with 
increasing levels of adiposity (Weisberg et al., 2003; You et al., 2005) but can be 
reduced with weight loss (Clement et al., 2004; Cancello et al., 2005). In lean 
individuals, however, production of anti-inflammatory cytokines in adipose tissue 
such as adiponectin, IL-10 and IL-1Ra predominates. It is therefore likely that the 
balance between the production of pro- and anti-inflammatory cytokines in 
adipose tissue is key to the development of insulin resistance. 
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The majority of studies investigating cytokine production from adipose tissue and 
their respective appearance in the blood circulation are conducted in the fasting 
state and therefore reflect chronic changes at a systemic level. However, this is not 
necessarily an accurate reflection of metabolic health and postprandial changes 
may also be important, particularly since we now spend the majority of waking 
hours within 8 hours of consuming food. It is possible that repeated acute 
inflammatory changes in the adipose tissue and circulation following consumption 
of a meal may be responsible for the chronic low grade inflammation seen with 
increased adiposity and it is not known how this varies with differing levels of 
adiposity. This hypothesis is addressed to some extent in Chapter 4, in which 
postprandial responses in adipose tissue across varying levels of adiposity were 
examined. There are over 50 cytokines produced by adipose tissue that may be 
implicated in the development of obesity related insulin resistance, and it is 
beyond the scope of this PhD to investigate each of them. The adipokines that will 




Leptin is the product of the Ob gene and was one of the first proteins identified to 
be secreted by adipose tissue (Zhang et al., 1994). It is primarily produced by 
adipocytes in proportion to body fat mass and has a key role in regulating energy 
homeostasis by reducing food intake, stimulating energy expenditure and 
regulating glucose and lipid metabolism (Carbone et al., 2012). Its production is 
therefore largely regulated by nutrient intake and insulin, but its levels can 
conversely be dramatically reduced during periods of fasting (Friedman & Halaas, 
1998). Leptin and insulin overlap in their signalling pathways, implicating this 
hormone in the development of insulin resistance. Leptin shares structural 
homology with long-chain helical cytokines and the leptin receptor is widely 
expressed on immune cells. This hormone therefore represents an important link 
between metabolism and immune system function (Lord et al., 1998).  
 
1.7.2 Adiponectin 
Adiponectin is predominantly produced by adipocytes and has an inverse 
relationship with fat mass. It is particularly reduced with visceral adiposity and 
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correlates with levels of insulin sensitivity (Tilg & Moschen, 2006). Adiponectin 
is itself considered anti-inflammatory since it can suppress production of pro-
inflammatory TNFα and IFNɣ whilst increasing production of anti-inflammatory 
cytokines such as IL-10 and IL-1Ra (Tilg & Moschen, 2006). Obese animals 
treated with adiponectin show improvements in glucose control and reduced free 
fatty acids in blood (Berg et al., 2002). 
 
1.7.3 IL-6 
IL-6 is a pleiotropic cytokine secreted by white adipose tissue, skeletal muscle 
and liver. In healthy individuals, adipose tissue contributes to approximately one 
third of IL-6 in the circulation (Mohamed-Ali et al., 1997), with the majority of 
this being produced by macrophages present within adipose tissue (Weisberg et 
al., 2003). IL-6 is typically thought of as a pro-inflammatory cytokine as its 
expression is increased in adipose tissue with obesity, especially from the visceral 
depot (McLaughlin et al., 2008). Furthermore, IL-6 can stimulate production of 
the acute phase protein CRP from the liver and can induce insulin resistance in 
adipocytes (Rotter et al., 2003). With weight loss, IL-6 is reduced (Bastard et al., 
2000). There are, however, a number of studies describing anti-inflammatory 
effects of IL-6 (Frisdal et al., 2011) and that it may even have a role in improving  
insulin sensitivity in muscle (Carey et al., 2006). 
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Chemokine involved in the stimulation of monocyte/macrophage 
migration. Secreted by mature adipocytes and monocyte/macrophages 
for further monocyte recruitment. Expression of MCP-1 is sensitive to 
insulin, however, this chemokine can also interfere with insulin 
signalling (Sartipy & Loskutoff, 2003). 
Increased expression with obesity in mice with diet 
induced obesity (Xu et al., 2003). In humans, 
expression and secretion from adipose tissue are 
increased but not necessarily into the blood (Dahlman 
et al., 2005). 
Tumour 





First inflammatory cytokine identified in adipose tissue and increased 
with obesity (Hotamisligil et al., 1993). Can cause insulin resistance in 
adipocytes by interference with IRS phosphorylation via 
IKK/JNK/S6K/mTOR (Hirosumi et al., 2002). Promotes lipolysis and 
interferes with adipocyte differentiation (Zhang et al., 2002). 
In humans, increased in plasma and adipose tissue 
obese vs. lean, decreased with weight loss (Kern et al., 
1995). Correlates with measures of insulin resistance 
(Hivert et al., 2008). 
Macrophage 
inflammatory 
protein 1β  
(MIP-1β) 
 
Pro-inflammatory, potent chemokine, recruit immune cells to sites of 
infection and inflammation (Ren et al., 2010).   
MIP-1 proteins upregulated in adipose tissue with diet 




Anti-inflammatory cytokine associated with Th2 and T-regulatory 
CD4+ cells and M2 macrophages. Inhibits effects of proinflammatory 
cytokines on reduction of insulin signalling (Hong et al., 2009) 
Increased production by adipose tissue (mainly non-fat 
cells) with obesity, likely attempt to dampen 
inflammation (Fain, 2010). 
Table 1.3. Overview of the cytokines measured in the studies presented in this thesis. 
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Primarily produced by CD4+ helper (Th1) and cytotoxic CD8+ T-
lymphocytes (Schroder et al., 2004). Skews macrophage 
differentiation towards pro-inflammatory (M1) response, induces 
insulin resistance in mature human adipocytes via interference with 
insulin signaling pathway. Also interferes with triglyceride storage and 
pre-adipocyte differentiation into mature adipocytes (McGillicuddy et 
al., 2009). 
In human subcutaneous adipose tissue, waist 
circumference correlates with IFNɣ mRNA 
(Kintscher et al., 2008). 







Pro-inflammatory chemokine, primarily inducing chemotaxis of 
neutrophils, however, a variety of immune cells are sensitive to this 
hormone including monocytes. Production can be stimulated by pro-
inflammatory cytokines including TNFα and induces insulin resistance 
in adipocytes via PKB phosphorylation (Kobashi et al., 2009). 
IL-8 mRNA and secretion in obese adipose tissue 
is higher compared to lean and is mainly from non-
fat cells in adipose tissue. IL-8 production is 
particularly elevated in visceral compared to 






Pro-inflammatory cytokine, together with IL-12 can induce Th1 
differentiation of CD4+ helper T-lymphocytes and is implicated in the 
development of insulin resistance (Vandanmagsar et al., 2011). 
Product of NLRP3 inflammasome which is mainly expressed in 
monocytes/macrophages (Guarda et al., 2011).  
Production mainly from non-fat cells in adipose 
tissue. Elevated in obesity and correlates with 
measures of insulin resistance (Bruun et al., 2007). 
Decreased following calorie restriction and 
exercise (Vandanmagsar et al., 2011) 
Table 1.3 continued. Overview of the cytokines measured in the studies presented in this thesis. 
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Cytokine Main role Effect of obesity on adipose tissue levels 
Interferon gamma 
inducible protein 10  
(IP-10) 
 
Chemoattractant important in recruiting activated T-lymphocytes to 
site of inflammation, production regulated by IFNɣ. Widely expressed 
including immune cells and adipocytes (Herder et al., 2007). 
IP-10 may be increased in blood of obese compared 
to lean but not necessarily in adipose tissue (Herder 
et al., 2007). 
Regulated on 
activation, normal T 




Potent chemokine for T-lymphocytes, sustained production linked to 
other chronic inflammatory diseases including atherosclerosis. 
Particularly involved in trafficking and survival of inflammatory 
immune cells including M1 macrophages and Th1 CD4+ T-
lymphocytes (Baturcam et al., 2014). 
Increased expression in obese adipose tissue and 




Proinflammatory cytokine implicated in many chronic inflammatory 
diseases and linked to insulin resistance (Grant & Dixit, 2013). Along 
with IL-18, is a product of the NLRP3 inflammasome which is mainly 
expressed in monocytes/macrophages (Guarda et al., 2011).  
Adipose tissue expression increased with obesity 
and in type 2 diabetes, production is decreased 
following calorie restriction and exercise 








Anti-inflammatory cytokine, competes with cytokines from the IL-1 
family thereby antagonising the effects of IL-1β to reduce pro-
inflammatory signalling (Juge-Aubry et al., 2003). 
 
 
Adipose tissue is an important source of IL-1Ra, 
adipose tissue production and levels in blood are 
increased with adiposity. Increased expression as 
attempt to dampen inflammation (Juge-Aubry et 
al., 2003). 
Table 1.3 continued. Overview of the cytokines measured in the studies presented in this thesis. 
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1.8 Inflammatory cells in adipose tissue 
In addition to adipocytes, adipose tissue contains a whole range of cell types, 
including progenitor cells, endothelial cells, fibroblasts, and immune cells such as 
macrophages and lymphocytes which are collectively referred to as the 
stromavascular fraction (SVF). Due to their size, adipocytes represent 
approximately 80-90 % of the volume of adipose tissue and 60-70 % of the total 
cell population, with the remainder being attributed to the SVF (Thompson et al., 
2012).  These non-adipocyte cells may be responsible for the majority of cytokine 
secretions from adipose tissue (Fain, 2010). Current research suggests that the 
interaction between these different cell populations within adipose tissue and the 
balance of pro- and anti-inflammatory cytokines acting in a paracrine and/or 
endocrine manner may be a key determinant of an individual’s risk of developing 
obesity related disease. Immune cells often reside within tissues and tissue 
macrophages have specific functions, for example; kupfer cells line sinusoids in 
the liver, multinucleated osteoclasts are present in the periosteum (bone), 
microglia are interspersed around neurons in the central nervous system, 
mesangial cells are present in the kidney (Gordon, 1995). The role of immune 
cells within adipose tissue, however, is not yet fully understood.  
 
Despite observations that adipose tissue secretes and responds to pro-
inflammatory molecules, the infiltration of adipose tissue with immune cells was 
not described until 2003. Xu et al., (2003) and Weisberg et al., (2003) 
independently discovered that in obesity, macrophages accumulate in adipose 
tissue (attracted by chemokines such as MCP-1) and produce inflammatory 
mediators (including TNFα) which could contribute to metabolic complications 
including insulin resistance. For a long time it was thought that increased weight 
gain simply resulted in greater accumulation of macrophages in adipose tissue 
which were responsible for the observed systemic inflammation and this was 
initially the focus of much research. Mouse models genetically deficient in 
macrophages however, showed only partial protection from diet induced obesity 
and insulin resistance, suggesting that other cells may be implicated in adipose 
tissue inflammation and insulin resistance (Weisberg et al., 2003). It was not until 
2007 that T-lymphocytes were also identified in adipose tissue, so consequently 
relatively little is known regarding the mechanisms for their recruitment, 
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involvement in adipose tissue inflammation and any influences on ‘metabolic 
health’. A diagram summarising what is currently known about immune cell 
residence and recruitment into adipose tissue is shown in Figure 1.1. The studies 




Figure 1.1. Putative processes involved the accumulation of immune cells 
within adipose tissue and their pathogenic roles in obesity and associated 
pathologies. Blood circulating lymphocytes might be attracted through the 
production of the SDF-1 produced by endothelial cells. Extravasation of T-
lymphocytes and their accumulation within the fat mass might be the primary 
event involved in the further accumulation of macrophages through the IFNɣ-
stimulated production of MCP-1 by the stromal pre-adipocytes. In italics are the 










Chapter 1             Review of Literature
    
34 
 
1.8.1 Macrophages  
Macrophages typically have scavenger functions which are important in innate 
immune responses, where they recognise and remove infected cells/foreign 
material by phagocytosis. Through their secretions they attract further immune 
cells and also have a role in the adaptive immune system, whereby they can 
present foreign antigens to lymphocytes. Macrophages secrete various cytokines 
to regulate immune responses and wound repair/tissue remodelling. A number of 
these cytokines can also cause insulin resistance in adipocytes (Gordon, 1998).   
 
The studies by Xu et al. (2003) and Weisberg et al. (2003) investigated 
progressive changes in gene expression occurring in various tissues of mouse 
models with the development of diet induced obesity. In addition to increases in 
expression of various inflammatory genes, a number of macrophage related genes 
were specifically up-regulated in white adipose tissue and occurred prior to 
increases in fasting blood insulin and glucose. Both groups confirmed the 
presence of macrophages in murine adipose tissue using immunohistochemistry. 
However, Weisberg et al. (2003) additionally performed immunohistochemistry 
on human subcutaneous adipose tissue and showed that the accumulation of cells 
expressing the macrophage marker CD68 was correlated with body mass and 
adipocyte size. The accumulation of macrophages in all human adipose tissue 
depots and their relationship with body mass has been reported subsequently in a 
variety of populations (Curat et al., 2004; Cancello et al., 2006; Curat et al., 2006; 
Zeyda et al., 2007). In insulin resistant obese populations, adipose tissue 
inflammation and infiltration of macrophages may also be increased compared to 
‘metabolically healthy’ obese (Apovian et al., 2008). Furthermore, calorie 
restriction or gastric bypass surgery reduces inflammation and macrophage 
content of adipose tissue (Clement et al., 2004; Cancello et al., 2005). 
  
In mouse models of obesity there appears to be two separate polarisation states of 
macrophage with specialised functions that may be important in determining the 
inflammatory phenotype of lean and obese adipose tissue (Zeyda & Stulnig, 
2007). M1 ‘classically activated’ macrophages are increased in obese mice and 
release pro-inflammatory cytokines including TNFα and IL-6. M2 ‘alternatively 
activated’ macrophages, however, produce anti-inflammatory cytokines; IL-10 
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and IL-1Ra and represent a greater proportion of macrophages in lean mice 
(Lumeng et al., 2007). It was therefore suggested that a shift in cytokine profile 
with increasing obesity favours the conversion of M2 to M1 macrophages. In 
humans, the phenotype appears to be different, however, in that markers 
associated with each of these murine macrophage types are present on a single 
population of human macrophages but can modify their phenotype according to 
the local stimuli (Zeyda et al., 2007; Bourlier et al., 2008). It is suggested that the 
increased macrophages in human obesity are polarised towards an anti-
inflammatory phenotype as an attempt to counteract the elevated levels of 
inflammation and they may also have an important role in the re-modelling of 
adipose tissue (Zeyda et al., 2007; Bourlier et al., 2008; Fjeldborg et al., 2014). It 
may be the balance between the two phenotypes that is important in the 
development of obesity related complications. Species differences in macrophage 
phenotype are likely to be a factor in differences observed. The development of 
obesity is also much more acute for mouse models that are fed a high fat diet for a 
matter of weeks, as compared to in humans where obesity typically occurs over 
months/years, potentially allowing for adaptations to take place (Bourlier & 
Bouloumie, 2009). 
 
1.8.2 The origin of macrophages in adipose tissue 
The increased presence of macrophages in adipose tissue with obesity may either 
arise from blood monocytes recruited to the adipose tissue by changes in 
chemokines/cytokines or proliferation of resident tissue macrophages. Another 
potential source of macrophages is trans-differentiated pre-adipocytes, which 
share expression of a number of genes and have phagocytic properties (Weisberg 
et al., 2003). Transmigration experiments have shown that blood monocytes can 
be recruited to adipose tissue via endothelial cells activated by conditioned media 
from human adipocytes (Curat et al., 2004). Lipid depletion of the media used in 
these experiments had little effect on these observations, however protein 
degradation appeared to markedly reduce adhesion and diapedesis suggesting it is 
inflammatory mediators involved in the activation of endothelial cells and 
recruitment of monocytes rather than lipid. Within the adipocytes used to make 
the conditioned media, high expression of MCP-1, IL-8 and leptin was identified, 
all of which are increased with obesity. Leptin alone was able to induce the same 
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diapedesis of monocytes. However, since the Xu and Weisberg studies still 
reported macrophages in Leptin deficient mice models, other factors in addition to 
Leptin are therefore likely to be involved (Weisberg et al., 2003; Xu et al., 2003). 
Increased plasma concentrations of soluble cell adhesion molecules (E-selectin, 
VCAM-1, ICAM-1) are observed with increasing adiposity, which suggests that 
increased fat mass may be associated with increased endothelial activation. The 
work by Curat et al. (2004) supports the theory that factors released from 
adipocytes may be involved in activation of endothelial cells and further 
recruitment immune cells into adipose tissue.  
 
Weight gain is associated with adipocyte hypertrophy and remodelling within the 
expanding adipose tissue (Curat et al., 2004). It has been suggested that areas of 
local hypoxia as a result of this remodelling may promote adipocyte necrosis and 
could be important in the recruitment/proliferation of macrophages for their 
scavenger function (Villaret et al., 2010). In obese adipose tissue, this is proposed 
as the primary stimulus for macrophages since they are often found in ‘crown like 
structures’ (CLS) surrounding dead adipocytes, as shown in Figure 1.2 (Cinti et 
al., 2005). Macrophages are also implicated in the remodelling of the extracellular 
matrix, angiogenesis and regulation of adipocyte proliferation that occurs with 
adipose tissue expansion (Lumeng et al., 2007; Sun et al., 2011). 
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Figure 1.2. CLS formation at sites of adipocyte death in human adipose tissue 
and correlation between adipocyte death and adipocyte size. Human 
subcutaneous (A, B) and visceral (omental; C, D) fat depots demonstrating MAC-
2-positive (brown) macrophages (A, C) organized exclusively in CLS surrounding 
degenerate (perilipin-free; B, D) lipid droplets (asterisks). E: Representative 
electron micrograph showing necrotic degenerative features of obesity-associated 
adipocyte death in human WAT. F: Adipocyte death is correlated with mean 
adipocyte size in human subcutaneous (SC) and visceral (V) adipose tissue. Fat 
biopsies from human subjects (body mass index range of 20–45) were scored for 
the presence (+) or absence (−) of CLS Values shown are means ± SD. * P < 0.05 
for within-depot comparison. Bar = 27 μm for A–D, 3.7 μm for E, and 1.5 μm for 
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Dysregulated lipolysis due to adipocyte insulin resistance may also contribute to 
the increase in macrophages, particularly seen with type 2 diabetes. This has 
become apparent since short term calorie restriction results in increased lipolysis 
and is associated with an increased infiltration of macrophages to clear the 
increased lipid in adipose tissue (Capel et al., 2009; Kosteli et al., 2010). 
Furthermore, macrophages can be activated via toll-like receptor 4 (TLR4) 
receptors which are stimulated by free fatty acids, such that mice lacking TLR4 
are found to be protected from insulin resistance following lipid infusion and diet 
induced obesity (Shi et al., 2006) 
 
1.8.3 Adipose tissue depot differences 
Cancello et al. (2006) demonstrated that in humans the accumulation of 
macrophages correlates with fat cell size in visceral and subcutaneous adipose 
tissue. However, greater macrophage accumulation is found in visceral adipose 
tissue despite subcutaneous fat cells being 40 % larger in diameter (Cancello et 
al., 2006). This observed difference in cell size between the two depots is also 
supported by Villaret et al., (2010). Visceral adipose tissue exhibits a more pro-
inflammatory state, characterised by increased IL-6, IL-8, IL-1β and MCP-1 
(Bouloumie et al., 2005) and shows greater expression of hypoxia related genes 
(HIF-1α) compared to subcutaneous adipose tissue (Villaret et al., 2010). It was 
suggested that these may be a consequence of ‘hypo-perfusion’ as a result of 
rapidly expanding adipose tissue mass and may play a role in recruiting a greater 
number of macrophages to this depot (Villaret et al., 2010).  
 
1.8.4 Lymphocytes 
It is not surprising that macrophage accumulation and activation has been a main 
focus for research, especially since they can represent up to 40 % of cells in 
adipose tissue SVF (Weisberg et al., 2003). Although T-lymphocytes represent a 
comparatively lower proportion (~6 %) of adipose tissue immune cells (Duffaut et 
al., 2009b), they may have an important role in regulating macrophage 
differentiation, activation and insulin resistance, as in atherosclerosis (Witztum & 
Lichtman, 2014). T-lymphocytes are central to adaptive immunity and typically 
either reside in tissues to carry out ‘immune monitoring’ as resting memory T 
cells, or as effector T cells which are attracted to sites of inflammation. CD4+ T-
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lymphocytes are ‘helper T cells’ and recognise MHC class II on antigen 
presenting cells such as dendritic cells or macrophages. Their role is to activate 
and direct immune cells, with Th1 cells releasing pro-inflammatory cytokines like 
IFNɣ, IL-12 and TNFα and Th2 cells releasing anti-inflammatory cytokines 
including IL-10 and IL-4. Another subset of CD4+ lymphocytes are T-regulatory 
cells which have a key role in regulating the immune response via their suppressor 
activity (Josefowicz et al., 2012). CD8+ cells recognise antigens presented in 
MHC class I by antigen presenting cells. They are cytotoxic T-lymphocytes and 
typically have key roles in destroying virally infected cells and tumour cells. 
 
Wu et al. (2007) were the first to demonstrate the presence of CD3+ T-
lymphocytes in the visceral adipose tissue of diet-induced obese insulin-resistant 
mice, and morbidly obese humans together with the expression of the T cell 
specific cytokine; ‘regulated on activation, normal T cell expressed and secreted’ 
(RANTES) and its receptor CCR5. This was also one of the first investigations to 
suggest that T-lymphocytes may also have an important role in the development 
of insulin resistance in obesity. Mouse models have been used to monitor 
lymphocyte accumulation in adipose tissue and show that they increase at the 
onset of insulin resistance prior to the increase in macrophages; suggesting that 
macrophage infiltration may not be involved in the initiation of insulin resistance 
(Kintscher et al., 2008; Nishimura et al., 2009). Initially it was thought that it was 
the CD8+ T-lymphocytes that may accumulate at the initial onset of obesity 
(Nishimura et al., 2009), although not all mouse models support this (Strissel et 
al., 2010). In mice, it is thought that a loss of ‘protective’ T-regulatory cells and 
anti-inflammatory Th2 lymphocytes may be important in the development of 
obesity related insulin resistance (Feuerer et al., 2009; Nishimura et al., 2009). 
Furthermore, depletion of cytotoxic T-lymphocytes or increasing the proportion of 
T-regulatory cells can lead to an improvement in obesity induced insulin 
resistance (Feuerer et al., 2009). 
 
In humans, CD3+ mRNA in subcutaneous adipose tissue was initially found to 
correlate with waist circumference as well as expression of IFNɣ, suggesting an 
increase in pro-inflammatory T-lymphocytes with obesity (Kintscher et al., 2008). 
Subsequently, the presence of CD4+ and CD8+ T-lymphocytes has been 
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identified in human adipose tissue using gene expression and flow cytometry. 
Confocal microscopy suggests that the CD3+ cells may be present in clusters 
around adipocytes (Duffaut et al., 2009b). The consensus appears to be that both 
CD4+ and CD8+ T-lymphocytes are increased in human obesity and that visceral 
tissue is more enriched with these cell types than subcutaneous adipose tissue 
(Kintscher et al., 2008; Duffaut et al., 2009b; Zeyda et al., 2011). 
 
Further human studies have aimed to characterise T-lymphocyte subsets present in 
human adipose tissue, but results are not always consistent. Zeyda et al. (2011) 
identified the presence of cytotoxic, Th1, Th2 and T regulatory lymphocytes using 
gene expression analysis and showed that the expression of each of these T-
lymphocyte markers were higher in obese compared to well matched lean and 
overweight controls in both visceral and subcutaneous adipose tissue. In both 
visceral and subcutaneous adipose tissue, proportions of T-regulatory cells were 
increased, however, which is in contrast to the animal models of diet induced 
obesity. In visceral adipose tissue an increase in Th2 transcripts was also found, 
suggesting that there may be an increase in lymphocytes with an anti-
inflammatory phenotype, perhaps as an adaptive mechanism to counteract 
increased visceral adipose tissue inflammation (Zeyda et al., 2011).  The work by 
Goossens et al. (2012) suggests that there may be an increased proportion of Th1 
polarised CD4+ T-lymphocytes in glucose intolerant obese individuals compared 
to a lean control group. Furthermore, the group suggests that the proportion of 
Th1 T-lymphocytes may be directly related to adipose tissue inflammation and 
whole body insulin sensitivity (Goossens et al., 2012). Some groups however, 
have reported an increase in CD4+ T-lymphocytes skewed towards a Th17 
phenotype; another helper T-lymphocyte subset, typically involved in 
autoimmune diseases (Bertola et al., 2012; Fabbrini et al., 2013). These observed 
discrepancies may be a factor of the different populations being investigated. 
 
Few functional studies have been performed to investigate T-lymphocyte 
accumulation in human adipose tissue. In-vitro studies using adipocyte 
conditioned media, suggest that leptin, IL-6 and CCL20 may be involved in the 
recruitment of T-lymphocytes (Duffaut et al., 2009b) all of which are expressed to 
a greater extent with obesity. Moreover, conditioned media produced by adipose 
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tissue lymphocytes can down-regulate the insulin stimulated increase in 
lipogenesis (Duffaut et al., 2009b). Pre-adipocyte and endothelial cell factors such 
as SDF-1α may also have a role in inducing T-lymphocyte migration (Kintscher et 
al., 2008)  
 
Since this is such a new and evolving area of research, these discrepancies warrant 
further investigation and little is known about the extent of their activation and 
whether it is influenced by adiposity and adipose tissue inflammation. It is the 
functional roles of the various subsets of T-lymphocytes in the development of 
obesity related diseases that will form one of the main foci of this thesis. A 
schematic summarising the main observations in adipose tissue across varying 
levels of adiposity and some of the primary unanswered questions that this thesis 
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Figure 1.3. Schematic summarising the main observations in adipose tissue across varying levels of adiposity and some of the primary 
unanswered questions that this thesis aims to cover.
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1.8.5 Other immune cells in human adipose tissue 
Other cell populations from both the innate and adaptive immune systems have 
been identified in adipose tissue, however they appear to represent a much lower 
proportion of cells in the SVF and relatively few studies have investigated their 
potential roles in obesity related insulin resistance. These cells together with their 
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Immune cell Typical role Observations in adipose 
tissue expansion 







Granulocytic cells, release 
contents (antimicrobial) 
and phagocytose invading 
pathogens/foreign 
material. 
Increased early in diet 
induced obesity (at 3 
days) in mouse models 








Roles in asthma, allergy, 
response to parasites and 
Th2 immunity. Anti-
inflammatory. 
Present in adipose tissue, 
express IL-4 which may 
maintain M2 polarisation 
of macrophages. May 
decrease in mice on high 
fat diet (Wu et al., 2011). 
Mast cells 
 
Granulocytic cells, roles in 
allergic responses and 
wound healing. 
Increased with obesity in 
humans (Liu et al., 2009). 
   









CD1c+ dendritic cells 
may accumulate with 
insulin resistance in 








Recognise lipid antigens 
presented by CD1d. 
Present in murine and 
human adipose tissue but 
not dependent on BMI 
(Duffaut et al., 2009b; 




produce antibodies.  
Present in human adipose 
tissue (Duffaut et al., 
2009b). Accumulate in 
adipose tissue of diet 
induced obese mice  
(Winer et al., 2011). 
 
Table 1.4 Other immune cells present in adipose tissue SVF, in addition to 











This review has examined the evidence relating metabolic dysfunction and 
inflammation occurring within adipose tissue to the development of obesity 
related diseases such as type 2 diabetes. In the last decade or so, a better 
understanding of adipose tissue inflammation in obesity has emerged, which is 
characterised by an increased infiltration of immune cells, in particular 
macrophages and T-lymphocytes. Macrophages have been the main focus of work 
with relatively little being known about the role of T-lymphocytes and their 
potential involvement in the development of obesity related disease.  
 
The overall aim of the work presented in this thesis is to further characterise 
aspects of metabolic and immune system cross-talk in human adipose tissue with 
a particular interest in the role of T-lymphocytes and their potential implications 
























This chapter will describe generic protocols that were used throughout the PhD. 
Methods which are specific to a particular study will be detailed in the relevant 
chapter. Experimental procedures involving subjects were conducted in the 
‘Resting Metabolic Laboratory’ at the University of Bath. Each study received 
ethical approval from local NHS South West Research Ethics Committees 
(Frenchay/Southmead) prior to commencement. The analysis of blood and 
adipose tissue samples were carried out in the Applied Physiology Laboratory at 
the University of Bath and the Nutritional Immunology Laboratories within the 
Unilever Food and Health Research Institute (Vlaardingen, The Netherlands).  
  
For all studies, participants were actively recruited by local advertisement. 
Participants in study 1 (Chapter 3) included male volunteers aged between 35-55 
years, with adiposities ranging from lean through to obese based on waist 
circumference. These participants were well characterised according to various 
physical measures, metabolic/inflammatory profiles and immune cell subsets in 
blood and adipose tissue. These same participants then consumed a mixed meal, 
and metabolic and inflammatory responses were examined in blood and adipose 
tissue as detailed in Study 2 (Chapter 4). In study 3 (Chapter 5), overweight/obese 
males aged between 35-55 years underwent a short-term period of 50 % calorie 
restriction and the effects on resident immune cells and metabolic/inflammatory 
properties of blood and adipose tissue were examined. For study 4 (Chapter 6), 
overweight/obese males and postmenopausal females aged between 45-65 years 
were recruited and categorised into groups of ‘normal glucose tolerance’ and 
‘impaired glucose tolerance’ following results of a preliminary screen including 
an oral glucose tolerance test. Study 4 received additional support for recruitment 
via the Primary Care Research Network (PCRN), allowing GP surgeries within 
the Bath and North East Somerset (BANES) area to act as patient identification 
centres. Following database searches by Practice staff, letters of invitation to 
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participate along with study information were sent out to potentially eligible 
participants.   
 
In studies 1 and 2 females were excluded from the study since they are protected 
from chronic diseases to some extent until the menopause and also show 
significant metabolic differences to males, in particular with leptin concentrations, 
which may cause conflicting results within the otherwise more ‘homogenous’ 
group. In study 4, postmenopausal women were included in part due to the 
anticipated small numbers of people being identified with impaired glucose 
tolerance from the initial screen. 
 
For each study, participants were provided with an information sheet giving 
details of the specific study requirements. Each participant gave written informed 
consent to participate and was asked to complete a questionnaire related to their 
medical history and lifestyle (Appendix 1). Individuals were excluded if they 
smoked or had not been weight stable for more than 3 months, i.e. no weight 
change > 3 % (Stevens et al., 2006). Furthermore, no participants had any medical 
conditions or were taking any medications that are known to interfere with 
lipid/glucose metabolism or immune system function.  
 
2.2 Anthropometry 
Height was measured with the participant barefoot using a fixed stadiometer 
(Holtain Ltd, UK) to within 0.1 cm. Body mass was measured to the nearest 0.1 
kg (post- void mass on the morning of the trial) using digital mass scales 
(TANITA corp. Japan). Body mass index was calculated for all subjects using the 
equation BMI = mass (kg) / height2 (m2). Waist and hip circumferences were 
measured in triplicate using a plastic non-stretch measuring tape (SECA, 
Germany) and mean value calculated. Waist circumference was measured as mid-
way between the lowest rib and the iliac crest (WHO, 2008). The tape was passed 
around the waist parallel to the floor with the subject standing at the end of gentle 
expiration. Hip circumference was measured horizontally around the widest 
portion of the buttocks (WHO, 2008). For both circumference measurements, the 
participants were stood with feet close together, arms at sides and weight 
distributed evenly with the tape snug around the body but not pulled so tight that 
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it is constricting. Classification of participants based on their waist circumference 
measurements was according to the WHO criteria (2008) shown in Table 2.1. 
 
Table 2.1. Classification ranges for waist circumference for lean, overweight 
and obese individuals according to sex. Based on WHO criteria (2008). 
 
 
2.3 Blood Pressure 
Blood pressure was measured using an automated blood pressure monitor (Alvita, 
MC101, UK) whilst participants were upright in bed after resting for at least 10 
minutes. Three readings were taken and mean values of systolic and diastolic 
blood pressure calculated. 
 
2.4 Dual Energy X-ray Absorptiometry 
Participant body composition was characterised using dual energy X-ray 
absorptiometry (DEXA). Participants were asked to consume 1 pint of water to 
rehydrate upon waking on the morning of the scan, then void bladder immediately 
before the scan to minimise variations in hydration status between individuals 
because body water affects lean mass estimates (Lohman et al., 2000). 
Participants were permitted to wear only lightweight clothing for the analysis. 
Before each scan, a quality control check was performed using material provided 
by the manufacturer. Descriptive statistics for each participant including date of 
birth, height and weight were entered into the QDR for Windows software 
(Hologic, Bedford, UK). Participants were asked to lay supine on the DEXA 
scanning table (Discovery, Hologic, Bedford, UK) and were positioned centrally 
with feet spread apart and arms with an even gap from the trunk. It was requested 
that participants remained as still as possible during the 7 minute scan. The scan 
was performed by an individual who had completed training in ionising radiation 
(medical exposure) regulations (IR(ME)R). Following completion of the scan, 
whole body composition analysis was performed with regions sectioned as 









Men < 94 cm 94-102 Cm > 102 cm 
Women < 80 cm 80-88 cm > 88 cm 
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were analysed for total and percentage fat mass and lean mass, and ‘Central 
adipose tissue’ (abdominal subcutaneous and visceral adipose tissue) was 
estimated from a central region between L1-L4. This region (L1-L4) has 
previously been shown to be comparable to estimates of central adipose tissue 
measured by computerised tomography (CT) (Glickman et al., 2004) and 
correlates with measures of metabolic health (Paradisi et al., 1999). Fat mass 
index (FMI) was calculated using the equation FMI = total fat mass (kg) / height2 
(m2) and interpreted using the ranges shown in Table 2.2 that match the 







Table 2.2. Classification ranges for fat mass index ‘FMI’. Established by 
matching to prevalence at age 25 for each threshold of WHO classification of 




2.5 Physical activity assessment 
Participants were fitted with a combined heart rate/accelerometer (Actiheart, 
Cambridge Neurotechnology Ltd., Cambridge, UK) to determine habitual 
physical activity. The monitor was worn for 7 whole consecutive days and 
subjects were asked to record a corresponding diary of their physical activity 
during the monitoring period to aid its interpretation. Subjects were asked to 
maintain their normal lifestyle habits/routines during the monitoring period. Data 
was downloaded and analysed using associated software (Actiheart 2.0 
Cambridge Neurotechnology Ltd. Cambridge, UK) and was used to plot heart rate 
and accelerometry. The software estimates activity energy expenditure (AEE) 
using measurements of R waves detected in 60 second epochs whilst an internal 
accelerometer simultaneously senses intensity and frequency of the subject’s torso 
movements. The Actiheart monitor has previously been validated using the 
branched model equations for estimating low-to-moderate intensity physical 
 Fat deficit Normal Excess fat Obese 
Male < 3 3 - 6 6 - 9 > 9 
Female < 5 5 - 9 9 - 13 > 13 
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activity energy expenditure which is likely to be typical of the ‘general 
population’ as included in these studies (Thompson et al., 2006). Total energy 
expenditure (TEE) is then calculated as AEE + resting metabolic rate as measured 
using indirect calorimetry (General Methods, 2.6) + diet induced thermogenesis 
(estimated as a constant 10 % of TEE). Physical activity level (PAL) was then 
determined using the formula PAL = Total energy expenditure/basal energy 
expenditure. 
 
2.6 Gas collection and analysis for indirect calorimetry 
Resting metabolic rate (RMR) was determined using substrate oxidation under 
resting conditions as described by Frayn, (1983). Expired O2 (1 d.p) and CO2 (2 
d.p) was analysed using a Servomex 1400 gas analyser with the participant lying 
in a bed at rest. The analyser was calibrated on the day of the trial using 100 % 
Nitrogen and mixed gas of 15.9 % Oxygen and 5.00 % Carbon Dioxide, and 
checked against atmospheric values 20.9 % Oxygen and 0.04 % Carbon Dioxide. 
During collections, participants were required to wear a nose clip and breathe into 
a mouthpiece with breathing valves to ensure all expired gas was collected into 
evacuated Douglas bags. During each gas collection, samples of ambient CO2 and 
O2 were measured to account for small changes observed throughout the day in an 
enclosed room rather than assuming outside atmospheric values (Betts & 
Thompson, 2012). The gas sampling tube was held as close as possible within 1 
metre of the participant for the final 2 minutes of each separate gas collection 
(read after 1 minute 30 seconds of ambient sampling allowing sufficient time for 
values to stabilise). Participants were given the mouthpiece and nose clip at least 
30 seconds before the collection began to flush the associated tubing of any 
atmospheric air and to settle any initial changes to breathing. The stopwatch was 
started as soon as the stopcock was turned, diverting expired gases into the 
Douglas bag. Expired gas samples were collected for 5 minutes and CO2 and O2 
within the Douglas bag were sampled for 2 minutes at a flow rate of 2.1 L/min 
with values recorded after 1 minute 30 seconds of sampling when values had 
stabilised. The Douglas bag was then completely evacuated using a dry gas meter 
(Harvard Apparatus) and total volume of expired gas and its temperature 
(measured using Checktemp thermometer attached to the dry gas meter) were 
recorded. Barometric pressure and ambient laboratory temperature were also 
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measured and adjustments to temperature made as necessary to maintain it 
between 20 – 25 °C. Estimation of RMR was made using a minimum of 4 
separate consecutive collections to ensure 3 readings within 100 kcal (Compher et 
al., 2006; Betts et al., 2011). The mean of the values within 100 kcal was used as 
RMR. Measurements were made early in the morning with as little participant 
exertion prior to gas sampling as possible. Time was given for participant 
recovery as necessary prior to sampling (minimum 10 minutes).  
 
2.7 Dietary analysis 
Subjects received a diary and set of digital weighing scales (model 1306, Salter, 
Kent, UK) to record their food and fluid intake during diet monitoring periods. 
Detailed nutritional analysis was performed using the software COMP-EAT Pro 
(version 5.8.0, Nutrition systems, UK) whereby users can input average and 
‘custom’ food information for a more accurate dietary analysis. For study 2 it was 
anticipated that 3 days would be sufficient to capture a representative example of 
macronutrient intake without being too time consuming for participants 
(Whybrow et al., 2008; Fyfe et al., 2010). For studies 3 and 4 a full week of diet 
recording was required to be used in conjunction with activity monitoring or 
glucose monitoring data respectively to inform the specific changes to be made 
during the 2 interventions. 
 
2.8 Restrictions for participants pre-trial day 
Subjects were asked to refrain from performing any strenuous physical activity 
and consuming alcohol/caffeine for 48 hours and 24 hours before the main trial, 
respectively. Trial days were scheduled so participants had been free from any 
self-reported illness for a minimum of 2 weeks in order to reduce immune system 
disturbance. Subjects were asked to arrive at the laboratory after fasting for a 
minimum of 10 hours and to consume 1 pint of water upon waking on the day 
scheduled for testing. 
 
2.9 Blood sampling  
An appropriately sized cannula (18G-21G; BD Venflon Pro, Becton Dickenson & 
Co., Sweden) was inserted into an antecubital forearm vein and blood samples 
obtained via stopcock (BD connecta, Beckton Dickenson, Sweden) and syringe(s) 
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at the required time points. Venous blood samples were collected using syringes 
and dispensed into blood collection tubes (Sarstedt Ltd., Leicester, UK) 
containing either serum separator beads for serum collection or  Potassium-
ethylenediaminetera acetic acid (K3-EDTA) as an anticoagulant for plasma 
samples. Blood was dispensed into serum tubes first to avoid EDTA 
contamination which may affect some metabolite and enzyme measurements. 
Patency of the cannula was maintained by flushing with sterile isotonic saline (0.9 
% sodium chloride solution (B Braun, UK) following blood sampling. Prior to 
obtaining the subsequent sample, 3 mL waste was taken from the cannula to 
remove this saline that would otherwise dilute the sample. For venepuncture 
sampling a single-use 21G needle (BD Valu-Set, Beckton Dickenson & Co., 
Plymouth) was inserted into antecubital forearm vein and syringes used to draw 
the blood sample. 
 
2.10 Blood analysis 
Following gentle mixing by inversion, EDTA tubes were immediately spun at 
3465 g (5000 rpm) for 10 minutes at 4 °C (Heraeus Biofuge Primo R, Kendro 
Laboratory Products Plc., Bishops Stortford, UK). Venous blood added to the tube 
containing serum separation beads was mixed by inversion and allowed to clot for 
45 minutes at room temperature prior to centrifugation. Samples were then 
transferred to 1.5 mL eppendorf tubes and frozen at -80 °C for later analysis. 
Whole blood differential leukocyte counts were obtained using an automated 
haematology system (SF300 Sysmex Ltd. Milton Keynes, UK). Glucose, total 
cholesterol, HDL-cholesterol, triglycerides, non-esterified free fatty acids (NEFA) 
and hs-CRP concentrations and ALT activity were measured using commercially 
available assay kits (Randox Laboratories, Crumlin, NI) with the Daytona 
automated analyser (Rx Series, Randox Laboratories, Crumlin, NI). LDL-
cholesterol was calculated using Friedwald equation (Friedwald, 1972); 
 
 LDL-cholesterol = Total-cholesterol – HDL-cholesterol – (0.456 x triglycerides)  
 
ELISA was used for the measurement of serum insulin (Mercodia, Sweden), 
Leptin and Adiponectin (both R&D Systems Inc., UK) according to manufacturer 
instructions. All samples for each participant (i.e. baseline and follow-up) were 
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included on the same ELISA plate or batch for analysis. Where samples were 
measured as below the measureable range, they were assigned the value of the 
lowest limit of detection for statistical analysis. Coefficients of variation and 









precision (CV)  
Glucose 0.54 mmol/L < 5 % < 6 % 
NEFA 0.04 mmol/L < 5 % <5 % 
Triglycerides 0.134 mmol/L < 4 % < 4 % 
Total-Cholesterol 0.865 mmol/L < 4 % < 2 % 
HDL-Cholesterol 0.189 mmol/L < 4 % < 3 % 
ALT 9.70 U/L < 6 % <5 % 
CRP 0.477 mg/L < 3 % < 5 % 
Insulin 1 mU/L <4 % <4 % 
Adiponectin 0.246 ng/mL <5 % < 8 % 
Leptin 7.8 pg/mL < 3 % < 5 % 
 
Table 2.3. Sensitivity and coefficient of variation data for the assays used to 
measure blood parameters. Where there were multiple quality controls used to 
analyse CV, the highest of these values is shown (Manufacturers values). 
 
 
2.11 Isolation of Peripheral Blood Mononuclear Cells 
Viable peripheral blood mononuclear cells (PBMCs; lymphocytes and monocytes) 
were isolated from blood using a density separation medium Lympholyte-
Mammal (Cedarlane Laboratories Limited, Burlington, Canada). The method 
results in a greater non-selective recovery of viable lymphocytes and monocytes 
whilst removing most granulocytes (including neutrophils) and dead cells by 
using Sodium Diatrizoate combined with Dextran to induce erythrocyte 
aggregation but reduce platelet aggregation (Lympholyte kit insert). Blood was 
first collected into tubes containing EDTA and diluted with an equal volume of 
saline (1:1) before carefully layering over Lympholyte (1.5 x volume of undiluted 
blood) with as little mixing as possible to ensure distinct interface formation in an 
RNase/DNase-free, non-pyrogenic, sterile centrifuge tube (Corning, NY). The 
sample was centrifuged for 20 minutes at 800 g at room temperature (22 °C) on 
the slowest acceleration setting. Using a Pasteur pipette, cells were carefully 
removed from the interface and transferred to a new centrifuge tube. The 
transferred cells were then diluted with PBS to reduce the density of the solution 
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and centrifuged for 10 minutes at 800 g (22 °C) using the fastest acceleration 
setting to pellet the lymphocytes. The supernatant was discarded and lymphocytes 
washed in this manner a further 3 times in PBS. Cells were stored in 1 mL 
PBS:FCS:DMSO in ratio 5:4:1 respectively and frozen at a rate of -1 °C/minute to 
–80 °C using a freezing container (Mr Frosty, Nalgene, Thermo Fisher Scientific 
Inc.) filled with isopropanol. Cells were stored at –80 °C until subsequent analysis 
by Flow cytometry (Materials and Methods sections 2.15 – 2.18). 
 
2.12 Oral glucose tolerance test 
In some studies, participants were required to consume a glucose drink consisting 
of 75 g (113 mL) anhydrous glucose (maltodextrin) solution (Polycal, Nutricia, 
UK), diluted to 200 mL with water within 5 minutes. Participants received a 
further 100 mL in the same glass to ensure the entire glucose solution had been 
consumed. Cannula blood samples were taken every 15 minutes for the following 
2 hours for measurement of plasma glucose and serum insulin. The results of the 
OGTT were used to calculate total areas under the curve (tAUC) using the 
trapezium rule (Matthews et al., 1990). Homeostasis model assessment for insulin 
resistance (HOMA-IR) was calculated using the equation: fasting glucose (mmol 
l−1) × fasting insulin (mU l−1)/22.5  (Matthews et al., 1985) and insulin sensitivity 
index (ISI comp/Matsuda index) was calculated as 10,000/√[fasting glucose 
(mg/dl) × fasting insulin (μU/mL) × mean OGTT glucose value (mg/dL) × mean 
OGTT insulin value (μU/mL)] (Matsuda & DeFronzo, 1999). 
 
2.13 Adipose tissue sampling  
Adipose samples were collected from the area around the waist, approximately 5 
cm lateral to the umbilicus, using a well-established ‘needle aspiration’ technique. 
The area was thoroughly disinfected with Videne, before injection of anaesthetic 
(approximately 5 mL Lignocaine hydrochloride 1 %) into a small fan shaped area 
beneath the skin using a 27G needle (PrecisionGlide, Beckton Dickinson, USA). 
Five minutes later, a larger 14G needle (Kendall Monoject, Tyco Healthcare, 
USA) was inserted into the subcutaneous fat tissue around the waist in order to 
collect ~1-2 g of fat tissue. Swabs and pressure were then applied to the area once 
the sample has been collected and before a dressing is applied.  
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Visible connective tissue and blood vessels were removed from the adipose tissue 
with scissors before the remaining adipose tissue was washed with PBS over 
single-use sterile gauze membrane to remove any further blood, clots and 
connective tissue. All re-usable equipment used for tissue handling was pre-
sterilised by autoclaving. 
 
2.14 Whole adipose tissue culture 
Adipose tissue was minced into approximately 5-10 mg explants using sterilised 
scissors and transferred to sterile culture plates (Nunclon surface, Nunc, 
Denmark) containing Endothelial cell Basal media (ECBM; Promocell, Germany) 
supplemented with 0.1 % fatty acid free BSA and 100 units/mL penicillin and 0.1 
mg/mL streptomycin (Sigma Aldritch, UK). Tissue was incubated at a final 
concentration of approximately 100 mg tissue per 1 mL (Fain et al., 2004). 
Explants were then transferred to an incubator (MCO-18A1C CO2 incubator, 
SANYO) at 37 °C, 5 % CO2 and 95 +/-5 % relative humidity. After 3 hours, 
media was removed and transferred to sterile eppendorfs and stored at -80 °C. A 
short incubation period was chosen since relative proportions of cytokine 
production dramatically changes between 4 and 48 hours and not in a 
linear/predictable manner (Fain et al., 2004). From preliminary work, 3 hours was 
shown to be sufficient time for measureable concentrations of cytokines of 
interest to be measured.  
 
A fluorescent bead (Bio-Plex) multiplex system (Luminex, BIO-RAD) was used 
for the measurement of cytokines (GCSF, MCP-1, IP-10, IL-8, IL-6, IL-10, IL-
1Ra, MIP-1β, TNFα, IL-18) secreted by adipose tissue (Chapters 3, 4 and 5) and 
present in serum (Chapter 5). Coefficients of variation and lower limits of 
detection for each cytokine measured by Luminex are shown in Table 2.4. 
Secretion of cytokines by 100 mg adipose tissue explants was multiplied by 
central fat mass (L1-L4) estimated using DEXA to predict total central adipose 
tissue secretion. This accounts for the profound differences between individuals in 








Table 2.4. Sensitivity and coefficient of variation data for the cytokines 




2.15 Preparation of the stromavascular fraction 
Adipocytes were isolated from the other cells contained within the adipose tissue 
comprising the stromavascular fraction by collagenase digestion based on a 
protocol by Curat et al., (2004). Whole tissue was minced using sterilised scissors 
and digested using an equal volume (to tissue mass) of buffer containing type 1 
collagenase with specific activity of 250 u/mL (Worthington Biochemical, NJ) in 
PBS / 2 % BSA at pH 7.4 in a shaking water bath (220 rpm) at 37 °C for 
approximately 45 minutes (or until digestion complete). The digestion was 
terminated by addition of 2 volumes 10 % NBCS in PBS. The suspension was 
filtered into a sterile plastic tube through a sterilised nylon mesh with pore size 
400 µm to remove undigested connective tissue. Adipocytes were allowed to float 
by gravity for a minimum of 10 minutes at 37 °C  to ensure all were at the top 
(Skurk et al., 2007) before being harvested using a pipette with a wide bore tip to 
reduce cell lysis. Once the adipocytes were removed, the remaining sample was 
centrifuged at 300 g for 10 minutes at 4 °C to pellet the SVF. The supernatant was 
removed and the pellet re-suspended in Erythrocyte Lysis Buffer (155 mM 
NH4Cl, 5.7mM K2HPO4, 3H2O, 0.1M EDTA H2O, pH 7.3) for 10 minutes. The 
sample was then centrifuged at 300 g for 5 minutes at 4 °C, and the supernatant 
discarded. The SVF pellets were resuspended in 1 mL PBS:FBS:DMSO in a ratio 




precision (CV) % 
Inter-assay 
precision (CV) % 
GCSF 1.7 10 5 
MCP-1 1.1 9 7 
IP-10 6.1 11 9 
IL-8 1.0 9 4 
IL-6 2.6 7 11 
IL-10 0.3 5 6 
IL-1Ra 5.5 9 8 
MIP-1β 2.4 8 8 
TNFα 6.0 8 6 
IL-18 0.2 4 5 
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freezing container (Mr Frosty, Nalgene, Thermo Fisher Scientific Inc.). Samples 
were stored at -80 °C until subsequent analysis by flow cytometry. 
 
2.16 Thawing and counting of SVF and PBMCs 
Frozen SVF and PBMCs were rapidly thawed and added drop wise to 10 mL 
DMEM (Lonza) supplemented with 10 % FBS. Once thawed, samples were kept 
on ice at all times between each step in the procedure.  Samples were centrifuged 
at 300 g for 5 minutes at room temperature and the supernatant removed using 
suction. Samples were then resuspended in 5 mL DMEM. SVF samples only, 
were filtered through a 100 µM mesh, rinsed with a further 10 mL DMEM and 
centrifuged at 300 g for 5 minutes. SVF samples were then re-suspended in 2 mL 
FACS buffer; 0.1 % (w/v) fatty-acid free BSA in PBS (Lonza) and transferred to 
5 mL FACS tubes (Beckton Dickenson) for staining with a single mixture of 
antibodies. For PBMC samples, cells were counted using an automated cell 
counter and the appropriate volume for 250,000 cells dispensed into a 96 well 
plate, with samples dispensed in duplicate across separate rows for simultaneous 
staining with the 2 different antibody cocktails. 
 
2.17 Staining of PBMCs for flow cytometry analysis  
The SVF and PBMC samples were centrifuged at 350 g for 5 minutes at room 
temperature and supernatant discarded. Cells were blocked with 25 µL of mouse 
serum (20 %) and incubated for 10 minutes prior to addition of 25 µL of the 
appropriate mixture of fluorescently labelled antibodies (described below) and a 
further 10 minute incubation in the dark. Samples were then diluted with 225 µL 
FACS buffer and centrifuged at 330 g for 5 minutes at room temperature. This 
final step was repeated once more using 250 µL buffer, and samples were 
resuspended in a final 250 µL for analysis by flow cytometry. 
 
2.18 Flow Cytometry 
Flow cytometry (using the FACSverse, Beckton Dickenson) was used to identify 
CD4+/CD8+ T-lymphocytes (CD45+CD3+ cells) and macrophages/monocytes 
(CD45+CD14+/CD45+HLA-DR+CD16+ cells) in SVF and PBMCs together with 
respective levels of activation. Due to the limited size of SVF samples for analysis 
by flow cytometry, cells were labeled using a single cocktail comprising the 
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following antibodies; CD4-FITC, CD163-PE, CD14-PerCP, CD8-PE-Cy7, CD69-
APC, CD25-APC-Cy7, CD3-V450, CD45-V500 (Beckton Dickenson).  PBMCs 
were labeled using 2 separate cocktails to identify monocytes; CD45-V500, 
CD295-FITC, CD220-PE, CD14-PerCP, CD16-APC and T-lymphocytes; CD45-
V500, CD3-V450, CD295-FITC, CD220-PE, CD25-APC-Cy7, CD69-APC, CD4-
PerCP, CD8-PE-Cy7 (Beckton Dickenson) (Duffaut et al., 2009b). Compensation 
settings were adjusted using CompBeads (Beckton Dickenson) prior to sample 
measurement. Monocytes/macrophages were identified using the CD45 versus 
side scatter (SSC) plot and a gate drawn to include all CD45+ cells. CD45 was 
then plotted against CD14 and gated on the CD45+ population previously 
identified. A gate was then drawn around the CD45+CD14+ cells and these were 
taken to be monocyte/macrophage populations.  For an example of T-lymphocyte 































Figure 2.1. Gating strategy to identify T-lymphocytes (CD45+CD3+ cells). 
From the total SVF cells present (a), the CD45+Low-SSC population was 
identified (b) and lymphocytes (CD45+CD3+ cells) selected (c) for further 
analysis of CD4+ and CD8+ lymphocytes (d) and their respective activation (e). 
 
 
2.19 Adipose mRNA; sample preparation and analysis 
Approximately 200 mg whole adipose tissue was transferred to an RNase/DNase 
free sterile centrifuge tube, homogenised in 5 mL Trizol reagent (Invitrogen) and 
frozen on dry ice before being stored at – 80 °C (in study 1 only, however, 
samples were frozen immediately and homogenised in 5 mL Trizol before 
thawing). The homogeniser was washed with ethanol and then distilled water 
between samples. Once thawed, samples were centrifuged at 2500 g at 4 °C for 5 
minutes. After removal of the lipid layer (top), the remaining supernatant was 
removed and transferred to a new RNase/DNase free sterile centrifuge tube and 
200 µL of chloroform was added per 1 mL of Trizol. The mixture was shaken 
vigorously for 15 seconds and incubated at room temperature for 3 minutes before 
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centrifugation at 2500 g at 4 °C for 15 minutes. The aqueous (top) phase was 
removed and mixed with an equal volume of 70 % ethanol before being 
transferred to RNA extraction columns (RNeasy mini kit; Qiagen, Crawley, UK) 
and total RNA extracted according to manufacturer instructions. Samples were 
quantified (Qubit 2.0 fluorimeter, Life Technologies, UK) and 2 μg reverse 
transcribed to cDNA using a high capacity cDNA reverse transcription kit 
(Applied Biosystems, Warrington, UK). Real-time PCR was performed using a 
StepOneTM (Applied Biosystems) with pre-designed primers and probes obtained 
from Applied Biosystems for measurement of macrophages (CD68; 
Hs02836816_g1), T-lymphocyte populations and subsets (CD3G; 
Hs00962186_m1, CD4; Hs01058407_m1, CD8A; Hs00233520_m1, FOXP3; 
Hs01085834_m1, GATA3; Hs00231122_m1 and TBX21; Hs00203436_m1) and 
for expression of GLUT4 (Hs00168966_m1), IRS2 (Hs00275843_s1), HSL 
(Hs00193510_m1), Leptin (Hs00174877_m1), Adiponectin (Hs00605917_m1), 
LPL (Hs Hs01012567_m1), PPAR-Ɣ (Hs01115513_m1), MCP-1 
(Hs00234140_m1), RANTES (Hs00982282_m1), IP-10 (Hs01124251_g1), IL-6 
(Hs00985639_m1), IL-8 (Hs99999034_m1), IL-10 (Hs00961619_m1), IL-1Ra 
(Hs00893626_m1), TNFα (Hs99999043_m1), IL-1β (Hs01555410_m1) and IL-
18 (Hs00155517_m1). Peptidylpropyl isomerase Aα (PPIA) was used as an 
endogenous control (Neville et al., 2011). Results were analysed using the 
comparative Ct method and expression normalized to an internal calibrator 




 gene of 
interest – C
T
 PPIA) – lowest ∆CT for gene of interest] and statistical analysis 
performed on LN transformed values (Livak & Schmittgen, 2001). Individuals 
were excluded from analysis where one or both samples were outside the 













The impact of adiposity on adipose tissue-resident 
lymphocyte activation in humans 
 
3.1 Introduction 
The presence of immune cells within human adipose tissue was only discovered a 
decade ago when macrophages were first identified in abdominal subcutaneous 
adipose tissue (Weisberg et al., 2003). Since then, macrophages have taken centre 
stage in this field of research (Xu et al., 2003; Curat et al., 2004; Zeyda et al., 
2007; Bourlier et al., 2008) whereas the roles of lymphocytes and other cells of 
the immune system have been largely overlooked in human studies. This is 
despite the fact that lymphocytes are key players in the initiation and regulation of 
immune responses within conditions such as atherosclerosis, asthma and 
rheumatoid arthritis (van Oosterhout & Bloksma, 2005; Cope et al., 2007; 
Witztum & Lichtman, 2014). Most investigations of T-lymphocytes in human 
adipose tissue have used immunohistochemistry, gene expression and/or flow 
cytometry to identify the presence of these cells (Wu et al., 2007; Kintscher et al., 
2008; Duffaut et al., 2009b; Feuerer et al., 2009; Nishimura et al., 2009; Zeyda et 
al., 2011; Goossens et al., 2012). Indeed, other than the documented presence of 
activated T-lymphocytes in adipose tissue (Duffaut et al., 2009b; Bertola et al., 
2012), little is known about the extent of lymphocyte activation and whether this 
is influenced by levels of adiposity and adipose tissue function.  
 
Studies using rodent models of diet-induced obesity to investigate the time course 
of immune cell accumulation in adipose tissue suggest that T-lymphocytes 
precede macrophage infiltration/proliferation (Kintscher et al., 2008; Nishimura et 
al., 2009). Cytotoxic (CD8+) lymphocytes in particular may be key mediators of 
early adipose tissue inflammation, insulin resistance and macrophage migration, 
activation and differentiation (Nishimura et al., 2009). These animal models 
provide extremely useful insights but require confirmation in humans, especially 
since obesity typically occurs over a much longer period than diet-induced obesity 
in rodents. Importantly, these rodent studies reinforce the hypothesis that 
lymphocytes play a central physiological role during the early stages of adipose 
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tissue expansion. Much of the available information about immune cells in human 
adipose tissue comes from morbidly obese individuals where the state of 
dysfunction is already profoundly apparent at a systemic level, characterised by 
insulin resistance/type 2 diabetes with adipose tissue showing a pro-inflammatory 
phenotype (Kintscher et al., 2008; Duffaut et al., 2009b; Zeyda et al., 2011; 
Goossens et al., 2012). Less is known however, about the role of adipose tissue 
resident immune cells during more ‘common’ forms of overweight and obesity. 
This is important from a mechanistic and clinical perspective since approximately 
62 % adults in the UK are overweight with less than 3 % of people having a BMI 
>40 kg/m2 (HSE tables, 2012). Additionally, interventions targeting people with 
modest obesity and ‘early’ metabolic dysfunction would yield the greatest rewards 
given the relative prevalence of modest obesity and the opportunity to prevent the 
development of future adiposity-related chronic disease. 
 
Thus, the aim of the present study was to investigate human adipose tissue 
resident T-lymphocyte subsets and their activation in lean to moderately obese 
individuals who have been carefully characterised in terms of metabolic health. 
Furthermore, to put these findings into context, we also determined whether T-
lymphocyte activation was related to either pro- or anti- inflammatory properties 






Chapter 3  Study 1 
63 
 
3.2 Materials and Methods 
3.2.1 Experimental design 
Thirty men aged between 35 and 55 years were recruited by local advertisement 
and visited the laboratory for preliminary anthropometric measurements including 
waist circumference, which was used to classify participants as lean <94 cm, 
overweight >94 cm but <102 cm, and obese >102 cm (WHO, 2008). Recruitment 
continued until there was an equal distribution of 10 participants in each waist 
circumference category. Participants also attended the laboratory on one separate 
occasion for sampling of blood and adipose tissue. Blood samples were collected 
for measurement of clinical markers of metabolic health and isolation of 
peripheral blood mononuclear cells (PBMCs). Adipose tissue samples were 
divided into three portions for gene expression analysis, culture or isolation of the 
stromavascular fraction (SVF). The protocol was reviewed and given approval by 
the South West, Southmead NHS Research Ethics Committee (REC Reference: 
11/SW/0193) and all participants provided written informed consent. 
 
3.2.2 Participants 
Participants were grouped according to waist circumference and individuals were 
excluded if they had any medical conditions or were taking any medication known 
to interfere with immune function or lipid/glucose metabolism. Individuals were 
also excluded if they smoked or had not been weight stable for more than 3 
months (i.e., weight change >3 %). 
 
3.2.3 Pre-trial requirements  
Participants were asked to refrain from performing any strenuous physical activity 
and consuming alcohol/caffeine for 48 h and 24 h prior to testing respectively. 
Trial days were scheduled so participants had been free from any self-reported 
illness for a minimum of 2 weeks in order to reduce immune system disturbance. 
Participants arrived in the laboratory in the morning after an overnight fast 
(minimum 10 h) and consuming 1 pint of water upon waking and rested in the 
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3.2.4 Body composition analysis 
Participant waist circumference, body mass and height were measured as 
described in General Methods, 2.2. Body composition analysis was performed 
using DEXA with central adipose tissue (L1-L4) and fat mass index estimated as 
described in General Methods, 2.4.  
 
3.2.5 Blood and adipose sampling and preparation 
A venous blood sample was taken from an antecubital vein and dispensed into 
tubes containing either K3EDTA or serum separation beads and processed as 
described in General Methods, 2.9-2.10. PBMCs were isolated by density gradient 
separation according to the protocol described in General Methods, 2.11. 
 
Subcutaneous adipose tissue samples (~1 g) were obtained under local anaesthetic 
(1 % lidocaine) approximately 5 cm lateral to the umbilicus with a 14 gauge 
needle using an ‘aspiration’ technique and processed as described in General 
Methods, 2.13. Approximately 200 mg whole adipose tissue was transferred to an 
RNase/DNase free sterile centrifuge tube and frozen immediately on dry ice and 
later homogenised in Trizol (Invitrogen, UK). The remainder was used for 
adipose tissue culture (General Methods, 2.14), and preparation of SVF (General 
Methods, 2.15).  
 
3.2.6 Real time-PCR 
Total RNA was extracted from whole adipose tissue, quantified and 2 μg reverse 
transcribed as described in General Methods, 2.19. Real-time PCR was performed 
using a StepOneTM (Applied Biosystems) with pre-designed primers and probes 
obtained from Applied Biosystems for measurement of macrophages (CD68), T-
lymphocyte populations and subsets (CD3G, CD4, CD8A, FOXP3, GATA3 and 
TBX21) and for expression of GLUT4, IRS2, HSL, Leptin, Adiponectin, MCP-1, 
RANTES, IP-10, IL-6, IL-8, IL-10, IL-1Ra, TNFα, IL-1β and IL-18. 
Peptidylpropyl isomerase A (PPIA) was used as an endogenous control (Neville et 
al., 2011). Results were analysed using the comparative Ct method and expression 
normalized to an internal calibrator specific to each gene using the formula 2- 
∆∆CT; where ∆∆CT is [(CT gene of interest – CT PPIA) – lowest ∆CT for gene of 
interest] and statistical analysis performed on LN transformed values (Livak & 
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Schmittgen, 2001). Data for adipose tissue expression of GCSF, MIP-1β and IFN 
are not shown because they were only detectable in 4-8 individuals. Details of 
specific primer Hs numbers can be found in General Methods, 2.19. 
 
3.2.7 Analysis of SVF and PBMCs by flow cytometry 
Flow cytometry (using the FACSverse, Beckton Dickenson) was used to identify 
CD4+/CD8+ T-lymphocytes (CD45+CD3+ cells) and macrophages/monocytes 
(CD45+CD14+/CD45+HLA-DR+CD16+ cells) in SVF and PBMCs together with 
respective levels of activation. Due to the limited size of SVF samples remaining 
for analysis by flow cytometry, cells were labeled using a single cocktail 
comprising the following antibodies; CD4-FITC, CD163-PE, CD14-PerCy5.5, 
CD8-PE-Cy7, CD69-APC, CD25-APC-Cy7, CD3-V450, CD45-V500 (Beckton 
Dickenson). PBMCs were labeled using 2 separate cocktails to identify 
monocytes; CD45-V500, CD16-APC, HLA-DR-FITC, CD11b-PeCy5 and CD86-
PE-Cy7 and T-lymphocytes; CD45-V500, CD3-V450, CD4-FITC, CD8-PE-Cy7, 
CD69-APC, CD25-APC-Cy7, CD220-PE (Beckton Dickenson) (Duffaut et al., 
2009b). Gating strategies are described in General Methods, 2.18.  
 
3.2.8 Biochemical analysis 
Plasma glucose and serum total cholesterol, HDL cholesterol and triglyceride 
concentrations and ALT activity were measured using commercially available 
assay kits and analyser (Daytona Rx, Randox). ELISA was used for the 
measurement of serum insulin (Mercodia, Sweden) and adiponectin (R&D 
Systems, UK) and both serum and adipose tissue leptin secretion (R&D systems). 
Adipose tissue secretion of GCSF, MCP-1, IP-10, IL-8, IL-6, IL-10, IL-1Ra, MIP-
1β, TNF, and IL-1 were measured using Luminex (BIO-RAD) and multiplied 
by central fat mass (L1-L4) estimated using DEXA to predict total central adipose 
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3.2.9 Statistical analysis 
All data are presented as mean and standard error of the mean (SEM). 
Comparisons were made between the lean, overweight and obese groups using 
one-way ANOVA irrespective of normality (Maxwell and Delaney, 1990, p. 109). 
Relationships between parameters were analysed using Pearson’s correlation. 
Statistical analysis was performed using SPSS version 20 and p<0.05 was 
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3.3 Results  
3.3.1 Participant characteristics 
Participants in each group differed in terms of physical measures of adiposity and 
blood concentrations of glucose, insulin and leptin (Table 3.1). 
 
Classification based on 
waist circumference 
Lean                    
n = 10 
Overweight           
n = 10 
Obese                   





    
Age (y) 43.5 ± 1.7 48.0 ±  1.8 45.2 ±  1.9 0.218 
Waist Circumference (cm) 87.0 ± 1.4 97.7 ± 0.8 109.4 ± 1.8 <0.001 
Body Mass Index (kg/m2) 23.6 ± 0.6 26.7 ± 0.4 30.7 ± 0.9 <0.001 
Fat Mass Index (kg/m2) 4.5 ± 0.3 6.9 ± 0.2 9.5 ± 0.6 <0.001 
L1-L4 (%) 19 ± 1 30 ± 1 37 ± 2 <0.001 
     
Fasting Metabolic 
Characteristics 
    
Leptin (ng/mL) 10.0 ± 1.6 26.6 ± 3.4 40.1 ± 4.4 <0.001 
Adiponectin (µg/mL) 9.6 ± 1.3 8.7 ± 1.2 8.5 ± 1.3 0.834 
Glucose (mmol/L) 4.4 ± 0.3 4.8 ±  0.3 5.3 ± 0.2 0.043 
Insulin (pmol/L) 27.3 ± 4.8 39.6 ± 7.0 59.5 ± 10.1 0.020 
HOMA-IR 0.9 ± 0.2 1.4 ± 0.3 2.4 ± 0.4 0.012 
Total-Cholesterol 
(mmol/L) 
4.6 ± 0.3 5.1 ± 0.3 4.4 ± 0.3 0.267 
Triglycerides (mmol/L) 0.9 ± 0.1 1.3 ± 0.2 1.0 ± 0.1 0.123 
HDL-Cholesterol 
(mmol/L) 
1.3 ± 0.1 1.1 ± 0.1 1.1 ± 0.1 0.091 
NEFA (mmol/L) 0.33 ± 0.04 0.48 ± 0.13 0.43 ± 0.05 0.469 
ALT (U/L) 18.5 ± 1.3 27.4 ± 2.6 28.5 ± 5.0 0.087 
 
Table 3.1. Participant descriptive statistics. Data presented as mean ± SEM. 
Effects of adiposity analysed by one-way ANOVA (p-values shown). L1-L4 = 
central fat mass within the lumbar region L1-L4 as determined by DEXA scan, 
HOMA-IR = homeostasis model assessment-established insulin resistance, HDL 
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3.3.2 Lymphocyte numbers and activation in adipose tissue 
Gene expression analysis of whole adipose tissue (n=30) revealed the presence of 
T-lymphocytes on the basis of CD3, CD4 and CD8 expression (Figure 3.1a). 
Relative expression of CD4+ was significantly increased with adiposity and 
further analysis using CD4+ lymphocyte lineage markers; FOXP3, (T-regulatory 
cells), GATA3 (Th2) and TBX21 (Th1)  revealed an increase only in the relative 
expression of T-regulatory cell transcripts (Figure 3.1b).  
 
There was sufficient adipose tissue from 17 of the 30 participants to perform flow 
cytometry of the SVF to characterise these T-lymphocyte populations by both 
proportion of total cells and activation status. Flow cytometry confirmed the 
presence of both CD4+ and CD8+ lymphocytes within the CD45+CD3+ 
population. As a percentage of total cells present in the SVF, CD4+ cells ranged 
from 0.3 to 4.7 % and CD8+ cells ranged from 0.5 to 5.6 % but there were no 
correlations between cell percentages and measures of adiposity (data not shown).   
 
The lymphocyte subsets were further characterised using activation markers 
CD69 and CD25. Activated T-lymphocytes were assessed according to both the 
proportion of cells that were activated and their mean level of activation (mean 
fluorescent intensity of each activation marker). Proportions of activated CD4+ 
and CD8+ T-lymphocytes (CD25+ or CD69+) as a percentage of either total SVF 
cells or percentage CD4+/CD8+ T-lymphocytes (CD45+CD3+ cells) within the 
SVF were not related to measures of adiposity (Figure 3.1c). When examining the 
level of T-lymphocyte activation, however, significant correlations were found 
between central adiposity and the level of expression of CD69 and CD25 on 











Figure 3.1. Lymphocyte phenotype and 
activation in adipose tissue according to levels 
of central adiposity. a) Relative gene expression 
of cluster differentiation markers to identify T-
lymphocytes (n=30), b) CD4+ T-Lymphocyte 
subsets present within the adipose tissue (n=30),  
c) Proportions of activated T-lymphocytes in 
adipose tissue SVF as a percentage of CD4+ and 
CD8+ cells measured by flow cytometry (n=17). 
Gene expression data presented as mean 2
-∆∆Ct 
± 
SEM. Effects of adiposity analysed by one-way 
ANOVA, *p<0.05, **p<0.001. MFI denotes mean 
fluorescence intensity. d i)-iv) Correlations 
between waist circumference and activation status 
of CD4+ and CD8+ T-lymphocytes in the adipose 
tissue (n=17).  Pearson’s (R) correlation 
coefficients shown along with significance values.  
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3.3.3 Macrophage numbers and activation in adipose tissue 
Macrophages were identified using gene expression analysis of CD68 (n=30) 
which was significantly increased with greater levels of adiposity (Figure 3.2a). 
Using flow cytometry of the available samples (n=17), macrophages 
(CD45+CD14+) represented 2.9 to 15.5 % of total cells present in the SVF. The 
proportion of macrophages was positively related to central adiposity (Figure 
3.2b). Flow cytometric analysis of CD163 expression on CD45+/CD14+ cells was 
used as a measure of macrophage ‘alternative/anti-inflammatory’ activation, but 




































Figure 3.2. Macrophage numbers and activation in adipose tissue with varying levels of adiposity. a) Relative gene expression of CD68 used to 
identify macrophages (n=30), b) Proportions of macrophages in adipose tissue SVF as a percentage of the total cells (n=17). Data presented as mean 2
-
∆∆Ct 
± SEM. Effects of adiposity analysed by one-way ANOVA, *p<0.05, **p<0.001. c) Correlations between waist circumference and proportion of 
macrophages present in the adipose tissue stromavascular fraction (n=17) Pearson’s (R) correlation coefficients shown, MFI denotes mean fluorescence 
intensity. 
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3.3.4 Metabolic and inflammatory properties of adipose tissue 
To identify potential factors within the adipose tissue that may contribute to this 
increased T-lymphocyte activation and macrophage accumulation with increased 
adiposity, gene expression and protein secretion from whole adipose tissue was 
examined. With greater levels of adiposity, relative gene expression of the 
adiposity-related hormone leptin was increased as expected, with reduced 
expression of adiponectin, GLUT4 and HSL (Figure 3.3). The majority of adipose 
tissue inflammatory cytokines showed a trend towards increased expression with 
adiposity; however, this only reached statistical significance for the typically pro-
inflammatory cytokine IL-18, anti-inflammatory IL-1Ra and MCP-1, a 


































Figure 3.3. Relative gene expression of proteins related to metabolism, appetite/adiposity and inflammatory cytokines by whole adipose tissue 
samples with varying levels of adiposity.  Data presented as mean 2
-∆∆Ct 
± SEM with participants classified equally based on waist circumference 
(n=30). Effects of adiposity analysed by 1-way ANOVA, *p<0.05, **p<0.005. Note that IL-10 was expressed in 3 lean, 8 overweight and 7 obese 
individuals. IL-6, IL-8 and IL-1β were detected in all overweight and obese individuals but only 8, 6 and 9 lean individuals respectively. 
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Adipokine secretion from whole adipose tissue explants was determined per 100 
mg cultured tissue (Figure 3.4a) and multiplied by L1-L4 fat mass to predict total 
central adipose tissue adipokine secretion (Figure 3.4b). Adjusted adipokine 
secretion accounts for the profound differences between individuals in absolute 
levels of adiposity and is thus more representative of secretion in vivo. Adjusted 
adipokine secretion increased with adiposity for the majority of measured 
adipokines (Figure 3.4b) and adjusted values better correlated with systemic 
concentrations (e.g. adipose tissue leptin secretion normalised to L1-L4 fat mass 
was more strongly correlated with serum leptin than unadjusted leptin secretion: 
r=0.9 vs. r=0.6 respectively (Figure 3.5). 
  
 



















Figure 3.4. Cytokine secretion by whole adipose tissue explants cultured for 3h with varying levels of adiposity. a) Adipokine secretion 
normalised per 100 mg adipose tissue cultured, b) Adipokine secretion multiplied by L1-L4 fat mass to predict total central adipose tissue adipokine 
secretion. Mean and SEM values shown for groups based on waist circumference. Effects of adiposity analysed by 1-way ANOVA, *p<0.05,  
**p<0.005 (lean n =8, overweight n=6, obese n=10).













Figure 3.5. Improvement in correlation between serum leptin and adipose 
tissue when a) adjusted to central fat mass compared to b) secretion per 
100mg adipose tissue. Pearson’s (R) correlation coefficients and significance  
(p-values) shown, n = 24.
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3.3.5 Relationships between adipose tissue resident immune cells, 
inflammatory cytokines and clinical systemic markers of metabolic health 
A comprehensive unbiased approach was used to investigate relationships 
between immune cell properties and pro- and anti- inflammatory adipokines in 
adipose tissue. We also explored relationships between measures of metabolic 
health that are commonly used in clinical practice. A number of consistent 
significant positive correlations were observed between levels of T-lymphocyte 
activation and relative levels of gene expression and adipose secretion of IL-18, 
IL-10, IL-1Ra, leptin and MCP-1 and serum leptin (Table 3.2). Relationships 
between the percentage of macrophages in the SVF and adipokines were less 
consistent at the gene expression and secretion levels and, instead, appeared to be 
more closely related to leptin in serum and secretion from adipose tissue as well 






















Table 3.2. Associations between adipose tissue immune cell characteristics, blood markers of metabolic health and adipose tissue gene 
expression and secretion of pro- and anti- inflammatory adipokines. Data presented as Pearson’s r value (n=17). MFI denotes mean fluorescent 
intensity. *p<0.05, **p<0.005, $ p=0.05-0.1. 
 Serum  mRNA  
Whole AT protein secretion (3h) adjusted to 







Chol. Ratio  
ALT 
(U/L) 
 Leptin IL-6 TNFα MCP-1 
IL-10 
(N=13) 
IL-1Ra IL-18  Leptin IL-6 TNFα MCP-1 IL-10 IL-1Ra 
T-lymphocytes                    
CD4+CD69+ 
MFI 
.557* 0.303 0.219 .273  .483* .195 .127 .596* .644* .674** .742**  .574* .410 .403 .633** .727** .523* 
CD4+CD25+ 
MFI 




 .291 0.264 .349  .313 .020 .067 .647** .624* .795** .703**  .703** .351 .036 .684** .718** .222 
CD8+CD25+ 
MFI 
.305 .200 0.238 .476
$
  .161 .121 .293 .757** .587* .836** .609**  .447
$
 .233 .221 .536* .450 
$
 .360 
                    
Macrophages                    
CD45+CD14+ 
%Total cells in 
SVF 
.626** .485* 0.539* .621**  .449 
$
 .024 .283 .383 .278 .519* .667**  .769** .346 .097 .479*  .671** .205 
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3.3.6 Blood immune cell subsets 
To investigate the specificity of these relationships to adipose tissue resident 
immune cells, paired blood samples were obtained and PBMCs isolated for 
characterisation according to cell subset and activation by flow cytometry. None 
of the correlations observed in the SVF regarding lymphocyte activation with 
waist circumference were found for paired PBMC samples, indicating that 
increased activation with increased adiposity is specific to adipose tissue (Figure 
3.6).  Furthermore, in contrast to findings for immune cells in SVF, there were no 





Figure 3.6. Correlations between waist circumference and activation status of 
blood CD4+ and CD8+ T-Lymphocyte populations a) – d). Pearson’s (R) 
correlation coefficients and significance (p-values) shown, n=30. MFI denotes 
mean fluorescence intensity. 
 
 




This is the first study to demonstrate that in men with moderately increased 
adiposity typical of common overweight and obesity, there is increased activation 
of adipose tissue-resident T-lymphocyte populations. At the whole tissue level, an 
increase in FOXP3 gene expression with adiposity and reduced pro-inflammatory 
cytokine production per gram of fat in obese compared to overweight participants 
indicates the emergence of potential compensatory mechanisms, possibly through 
an increase in T-regulatory cells.                 
 
3.4.1 T-lymphocytes and their activation in human adipose tissue 
Our results from both gene expression and flow cytometry document the presence 
of CD4+ and CD8+ T-lymphocyte populations together with the well described 
accumulation of macrophages in human subcutaneous adipose tissue SVF 
(Weisberg et al., 2003; Xu et al., 2003; Curat et al., 2004; Zeyda et al., 2007; 
Bourlier et al., 2008; Kintscher et al., 2008; Duffaut et al., 2009b; Feuerer et al., 
2009; Nishimura et al., 2009; Zeyda et al., 2011; Goossens et al., 2012). Earlier 
rodent studies investigating the time course of immune cell infiltration with diet-
induced obesity suggested an early increase in CD8+ T-lymphocytes may be 
important and linked to the development of systemic insulin resistance (Nishimura 
et al., 2009). Our cross-sectional analysis of immune cells in human adipose 
tissue with varying levels of adiposity, however, showed no differences in levels 
of CD8+ T-lymphocytes by either gene expression or flow cytometry analysis. 
Instead our results showed an accumulation of CD4+ T-lymphocytes at the gene 
expression level. From the 30 participants, there were sufficient cells to perform 
further analysis by flow cytometry on 17 samples. A substantial fraction of both 
CD4+ and CD8+ T cells were in an activated state (CD25+ and/or CD69+) in the 
men recruited in the present study, as previously reported for women (Duffaut et 
al., 2009b; Bertola et al., 2012). Interestingly, although no differences were 
detected in the proportion of activated CD4 and CD8 T-lymphocytes within 
adipose tissue SVF, the level of CD25 and CD69 expression on activated T-
lymphocytes showed a positive correlation with waist circumference. Importantly, 
the increased T-lymphocyte activation with overweight/obesity was not observed 
with lymphocytes isolated from paired blood samples, therefore indicating that 
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this finding is specific to adipose tissue and not a systemic or whole-body 
response. 
 
In parallel, our gene expression data showed a gradual increase in FOXP3 
transcripts with increasing adiposity. The limited number of cells in our SVF 
samples prevented intracellular staining for FOXP3 or cell sorting of CD25(hi) 
cells for subsequent ex-vivo suppression assay. Therefore, although the increase in 
FOXP3 transcripts cannot be formally linked to an increase in T-regulatory cells 
(Schmetterer et al., 2012), this observation gives a strong indication of a possible 
increase in T-regulatory cells with increased levels of adiposity. The presence of 
T-regulatory cells in adipose tissue has been shown in other human studies 
(Duffaut et al., 2009b; Feuerer et al., 2009; Goossens et al., 2012), and one other 
study reported increased T-regulatory cells in men and women with morbid class 
III obesity (Zeyda et al., 2011). T-regulatory cells control both adaptive and 
innate immune responses via their suppressor activity and are therefore vital for 
immune function and homeostasis (Josefowicz et al., 2012). Human obesity tends 
to occur over much longer periods of time compared to mouse models where diet-
induced obesity develops over just a few weeks (Kintscher et al., 2008). The more 
gradual adipose tissue expansion in humans may allow for compensatory 
mechanisms such as the accumulation of T-regulatory cells as an attempt to limit 
local inflammation. Indeed, in mouse models, a loss of T-regulatory cells in 
adipose tissue accompanies the development of insulin resistance, (Feuerer et al., 
2009; Nishimura et al., 2009) with gain-of-function experiments improving 
insulin sensitivity, confirming the potential importance of T-regulatory cells in 
obesity-related insulin resistance (Feuerer et al., 2009).  
 
3.4.2 Adipose tissue genotype/phenotype and resident T-lymphocyte 
activation  
The presence of relationships between leptin, IL-18, IL-10, IL-1Ra and MCP-1 
with levels of CD8+ and CD4+ T-lymphocyte activation and proportion of 
macrophages suggests there may be complex interactions between the adaptive 
and innate immune system within adipose tissue. Our results suggest that leptin 
may be important in adipose tissue T-lymphocyte activation and indeed, in-vitro 
work has shown that leptin enhances T-lymphocyte homeostasis/function (Lord et 
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al., 1998) with dose-dependent increases in CD4+ and CD8+ expression of CD25 
and CD69 (Martin-Romero et al., 2000; Sanchez-Margalet et al., 2003). 
Relationships between CD4+ activation and IL-18 and IL-10 adipose gene 
expression/secretion in the present study are also of particular interest. IL-18 is a 
pro-inflammatory cytokine produced by the NLRP3 inflammasome in response to 
‘danger signals’ and is implicated in the differentiation of CD4+ T-lymphocytes 
into Th1 cells (Vandanmagsar et al., 2011; Witztum & Lichtman, 2014). IL-10 
conversely is typically anti-inflammatory and indicative of Th2/T-regulatory 
lymphocyte differentiation (Witztum & Lichtman, 2014). This supports the 
hypothesis that, in addition to pro-inflammatory changes in adipose tissue, there 
are potential protective compensatory responses involving T-lymphocytes (Zeyda 
et al., 2011; Goossens et al., 2012). The absence of relationships between IL-6 or 
TNFα with T-lymphocyte activation and macrophages may provide further 
evidence to support this contention. In mouse models of obesity, macrophages 
switch from an anti-inflammatory M2 phenotype (producing IL-10) to a pro-
inflammatory M1 phenotype which overexpress inflammatory cytokines including 
IL-6 and TNFα (Lumeng et al., 2007) and are likely to be a major contributing 
source of these cytokines in murine adipose tissue.  Human data regarding 
macrophages suggests that with increased levels of adiposity, macrophage 
numbers are increased and exhibit an anti-inflammatory phenotype associated 
with tissue re-modelling (Zeyda et al., 2007; Bourlier et al., 2008; Fjeldborg et 
al., 2014). In this context, the absence of relationships between T-lymphocyte 
activation and macrophage accumulation may not be so surprising, particularly 
given our focus on modest overweight and obesity. Together, these data suggest 
that the development of a pro-inflammatory phenotype as seen in obesity is 
associated with adaptive responses and an attempt to develop a protective, more 
anti-inflammatory profile which is presumably lost or overcome with either 
further increases in obesity or a further deterioration of metabolic health.  
 
3.4.3 Adipose tissue compensation with increased adiposity 
Adipose tissue is dynamic and undergoes adaptations in times of both calorie 
restriction and chronic over-nutrition. During chronic energy surplus, adipose 
tissue expands and regulates expression of proteins related to fatty acid trafficking 
at the cellular level to prevent increases in fasting blood free fatty acids (McQuaid 
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et al., 2011). Our observed down-regulation of adipose tissue HSL gene 
expression with increasing adiposity supports this suggestion. This ability of 
adipose tissue to adapt with its expansion may also extend to regulating secretion 
of a number of adipokines measured in this study. At the per unit fat mass level, 
secretion of some adipokines including IL-6, IP-10 and MIP-1b was actually 
reduced in obese individuals (relative to their overweight counterparts). Thus, in 
the context of modest overweight and obesity, adipose tissue appears to adapt per 
unit of tissue in an attempt to regulate overall adipokine output to the circulation, 
although whether this is in any way linked to the down-regulation of free fatty 
acid delivery is far from certain.  
 
3.4.4 T-lymphocytes and systemic markers of metabolic health 
In contrast to our findings for adipose tissue resident macrophages, there were no 
relationships between T-lymphocyte subsets and their activation with systemic 
measures of health that are routinely used in clinical practice (e.g., HOMA-IR). 
This supports findings from another study where no correlations were found 
between T-lymphocyte subsets in subcutaneous adipose tissue and HOMA-IR 
(Zeyda et al., 2011). In the present study, the percentage of macrophages in 
adipose tissue was significantly related to HOMA-IR, Total:HDL-cholesterol ratio 
and ALT. This could indicate that macrophages have a more direct role than 
lymphocytes in obesity-mediated changes in systemic inflammation/insulin 
resistance. However, there may be temporal considerations to these comparisons 
which make such conclusions difficult. Macrophages may reside in tissues much 
longer than T-lymphocytes and therefore have time to influence/become 
influenced by changes in local and systemic metabolism and inflammation (Galli 
et al., 2011). In contrast, effector T-lymphocytes can have relatively shorter life-
spans and some lymphocyte subsets (e.g., memory T-lymphocytes) transit through 
tissue prior to their recirculation (Mora & von Andrian, 2006). The dynamic 
nature of lymphocytes in adipose tissue may make it difficult to draw conclusions 
about their role based on a snapshot but, may also indicate that these fast-
changing cell populations represent an exciting opportunity for intervention. 
  
These relationships have been demonstrated across lean to modestly obese 
middle-aged men, but whether these relationships hold true with further increases 
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in adiposity, in women or men of a different age and in people with metabolic 
complications such as insulin resistance warrants further investigation.  
 
3.4.5 Conclusions 
Following the discovery of immune cells in adipose tissue, macrophages have 
taken centre stage whereas other cells such as lymphocytes have been somewhat 
overlooked. The present study demonstrates for the first time that modest adipose 
tissue expansion is characterised, not by an increase in the proportion of activated 
T-lymphocytes but rather by a stronger state of activation in the T-lymphocytes 
already expressing CD69 and/or CD25. Importantly, this increased activation was 
not observed in circulating blood T-lymphocytes. In addition to positive 
relationships with pro-inflammatory cytokine production, we show that T-
lymphocyte activation is also positively related to anti-inflammatory cytokine 
production at both the gene expression and secretion level – providing further 
evidence of attempts by adipose tissue and resident T-lymphocytes to limit pro-
inflammatory output from adipose tissue at least with modestly increased levels of 
overweight/obesity. From our results, one of the possible mechanisms that could 
drive this anti-inflammatory compensation is an increased presence of T-
regulatory cells. T-lymphocytes are therefore likely to play a key role in the 
regulation of adipose tissue inflammation and important adaptations seen even 















Metabolic and inflammatory responses to a mixed meal in 
lean, overweight and obese men 
 
4.1 Introduction  
Obesity is associated with adipose tissue expansion, low-grade chronic 
inflammation and deteriorating metabolic health, but the underlying pathogenesis 
linking these factors is not well understood (Esposito & Giugliano, 2004; Lumeng 
& Saltiel, 2011). Adipose tissue is a highly dynamic organ responsible for 
regulating the storage of surplus energy as it secretes and responds to various 
adipokines (Balistreri et al., 2010). With its expansion, a more pro-inflammatory 
gene expression profile develops within adipose tissue (Shah et al., 2008), along 
with increased secretion of inflammatory cytokines (Fain, 2010), which contribute 
to the low-grade inflammation and complications of obesity including systemic 
insulin resistance. These inflammatory changes come not only from the 
adipocytes but also from the repertoire of cells comprising the stromavascular 
fraction present within the adipose tissue including macrophages and T-
lymphocytes (Fain, 2010). 
 
Measures of metabolic health and inflammation in blood and adipose tissue across 
varying levels of adiposity are often investigated in the fasted state. However, the 
majority of the waking day is often spent in a fed (i.e., postprandial) state and vital 
information regarding the progression of obesity-related diseases may be gained 
from investigations conducted following the consumption of a meal. Obese 
individuals typically exhibit exaggerated postprandial responses in blood, with 
peak glucose, insulin and triglyceride concentrations that are higher and remain 
elevated for longer when compared to lean individuals (Manning et al., 2008a; 
Jonk et al., 2011). There is, however, much conflicting evidence regarding 
whether inflammatory mediators are acutely increased in the circulation following 
consumption of a meal (Nappo et al., 2002; Poppitt et al., 2008; Dixon et al., 
2009). It is possible that, even in the absence of changes in inflammatory 
cytokines at a systemic level, changes may occur at the level of adipose tissue and 
it is not known whether metabolic differences seen with increasing levels of 
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adiposity will reflect/dictate processes within adipose tissue. It is also possible 
that inflammatory responses in adipose tissue after the consumption of each meal 
could contribute to systemic inflammation.  
 
The only studies to date investigating the presence of postprandial inflammation 
within adipose tissue in humans have either compared postprandial responses to 
differing qualities/quantities of lipids in people with metabolic syndrome 
(Meneses et al., 2011) or compared responses in (non-obese) relatives of people 
with type 2 diabetes versus controls (Pietraszek et al., 2011).  In both studies, 
significant increases in adipose tissue gene expression of a number of 
inflammatory genes including MCP-1, TNFα, IL-1β and IL-6 were detected, 
suggesting that there may indeed be postprandial inflammatory responses in 
adipose tissue (Meneses et al., 2011; Pietraszek et al., 2011). Interestingly, no 
such work has been undertaken to compare such postprandial responses within 
adipose tissue between lean and obese individuals. Thus, it is unclear whether 
these changes in inflammatory markers in adipose tissue represent a ‘normal’ 
phenomenon or something that is influenced by increased levels of adiposity in 
line with other more systemic changes (e.g., postprandial insulin concentrations). 
This is of particular importance to understanding the pathology of obesity-related 
inflammation and chronic disease. 
 
The main aim of this study was to investigate whether the greater postprandial 
metabolic response (i.e. hyperinsulinaemia) observed with increased adiposity 
leads to an increased inflammatory response within adipose tissue. In this study, 
postprandial metabolic and inflammatory responses were compared in the blood 
and adipose tissue following consumption of a high fat, high carbohydrate meal 
amongst carefully-characterised men covering a range of adiposities from lean 
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4.2 Materials and Methods 
4.2.1 Experimental design 
This study is based on the same participants that were recruited and described in 
Chapter 3. Thirty men aged between 35 and 55 years were recruited by local 
advertisement and visited the laboratory for preliminary anthropometric 
measurements including waist circumference, which was used to classify 
participants as lean <94 cm, overweight >94 cm but <102 cm, and obese >102 cm 
(WHO, 2008). Recruitment continued until there was an equal distribution of 10 
participants in each waist circumference category. Participants were characterised 
according to body composition, diet and physical activity since each of these 
factors can independently affect metabolic health. Participants attended one main 
trial in which blood and adipose tissue samples were obtained before and 6 hours 
after consumption of a mixed meal.  Blood samples were taken at regular intervals 
throughout. The protocol was reviewed and given approval by the South West, 
Southmead NHS Research Ethics Committee (REC Reference: 11/SW/0193) and 
all participants gave their written informed consent. 
 
4.2.2 Participants and sample size determination 
Participants were grouped according to waist circumference and individuals were 
excluded from participation if they had a history of/existing diabetes, 
cardiovascular disease or dyslipidaemia, were taking any medications known to 
interfere with immune function or lipid/carbohydrate metabolism, if they smoked, 
or had not been weight stable for >3 months (i.e. weight change >3 %; Stevens, 
2006). In addition, participants were excluded if they reported food 
intolerances/allergies to any component of the meal (e.g. dairy or wheat) and 
habitually performed more than 6 hours of vigorous-intensity physical activity or 
10 hours of moderate-intensity physical activity per week, assessed via a self-
report questionnaire (as these individuals would not fit the meal standardisation 
procedure – see below for details).  
 
The sample size for this study was determined using a clinically relevant 
difference in serum insulin response to a meal between lean (AUC 93 µU/mL (+/- 
29 SD)) and obese (AUC 169µU/mL (+/- 51 SD)) individuals with an effect size 
of 1.8 (G*Power 3.1.5, Germany) (Hudgins et al., 2000). Thus, with 95 % power 
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and 5 % alpha, 18 participants (9 lean and 9 obese), would be required to detect a 
statistically significant difference in serum insulin AUC between groups. An 
intermediate (overweight) group was also included for comparison and to account 
for participant re-distribution/allocation between groups based on other 
parameters (e.g., other measures of body composition which may provide a 
different picture to waist circumference alone), and to allow for more powerful 
correlations of adiposity against study outcome measures to be made. Participant 
characteristics within the categories lean, overweight and obese based on 
measurements of waist circumference are shown in Table 4.1. 
 
 
Classification based on waist 
circumference 
Lean                    
n = 10 
Overweight           
n = 10 
Obese                   




Age (y) 44 ± 2 48 ± 2 45 ± 2 0.218 
Height (m) 1.78 ± 0.02  1.77 ± 0.02 1.81 ± 0.03 0.469 
Body mass (kg) 74.8 ± 1.6 83.7 ± 1.8 100.2 ± 3.3 <0.001 
Body Mass Index (kg/m2) 23.6 ± 0.6 26.7 ± 0.4 30.7 ± 0.9 <0.001 
Waist Circumference (cm) 87.0 ± 1.4 97.7 ± 0.8 109.4 ± 1.8 <0.001 
Fat Mass Index (kg/m2) 4.5 ± 0.3 6.9 ± 0.2 9.5 ± 0.6 <0.001 
L1-L4 fat (%) 19 ± 1 30 ± 1 37 ± 2 <0.001 
Resting Metabolic Rate 
(kcal/day) 
1644 ± 65 1722 ± 55 1882 ± 74 0.045 
PALa 1.94 ± 0.10 1.66 ± 0.06 1.67 ± 0.10 0.066 
 
Table 4.1. Descriptive statistics of participants classified according to waist 
circumference. Mean ± SEM values shown and statistical differences between 
the 3 groups were assessed by one-way ANOVA, p-values shown. Abbreviations 
used; L1-L4 = central fat estimated between Lumbar regions 1-4 using DEXA, 
PAL = Physical activity level which is the product of Total Energy Expenditure ÷ 
Basal Metabolic Rate (a lean n=9). 
 
 
4.2.3 Preliminary tests 
Participant waist circumference, body mass and height were measured as 
described in General Methods, 2.2. Participants were fitted with a combined heart 
rate and accelerometry monitor (Actiheart) for a period of 9 consecutive days to 
determine habitual physical activity level (PAL; total energy expenditure/basal 
metabolic rate; General Methods, 2.5). Participants were asked to maintain their 
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normal lifestyle habits/routines during this period with the first 2 days of activity 
monitoring being excluded from analysis to account for potential reactivity 
(Loney et al., 2011). Participants received a diary and set of digital weighing 
scales to record their food and fluid intake during the 3 days prior to the trial day 
with nutritional analysis performed using COMP-EAT (General Methods, 2.7).  
 
4.2.4 Pre-trial requirements 
Participants were asked to refrain from performing any strenuous physical activity 
for 48 hours and consuming alcohol/caffeine for 24 hours prior to testing. Trial 
days were scheduled so participants had been free from any self-reported illness 
for a minimum of 2 weeks in order to reduce immune system disturbance. 
Participants arrived in the laboratory in the morning after an overnight fast 
(minimum 10 h) and after consuming 1 pint of water upon waking.   
 
4.2.5 Body composition analysis 
Body mass (post-void on the morning of the trial) was determined with 
participants wearing lightweight shorts. Body composition analysis was 
performed using DEXA with central adipose tissue (L1-L4) and fat mass index 
estimated as described in General Methods, 2.4.  
 
4.2.6 Resting metabolic rate 
Participants rested supine in bed for 10 minutes before estimation of resting 
metabolic rate (RMR) using the protocol described in General Methods, 2.6.  This 
value was used to adjust estimates of total energy expenditure and PAL, and to 
calculate the energy requirements for the test meal given to participants.  
 
4.2.7 Meal composition and energy requirements 
Participants were given a breakfast meal relative to their resting metabolic rate 
comprising brioche, strawberry jam (both Sainsbury’s, UK) margarine (Stork, 
Unilever), a milkshake (fresh chocolate milk and whipping cream; both 
Sainsbury’s, UK, with added icing sugar; Silver Spoon) and a cup of 
decaffeinated tea (PG tips, Unilever) with semi skimmed milk (Sainsbury’s, UK). 
The total energy content of the meal represented approximately 65 % RMR and 
comprised 39 % calories from carbohydrate, 54 % calories from fats and 7 % 
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calories from protein. The exact composition of the meal was designed to ensure 
that an average 80 kg man with an RMR of 1791 kcal/day (estimated from 
Schofield equation (Schofield, 1985)) received 1.5 g/kg carbohydrate (Betts et al., 
2011). A worked example showing exact proportions of each meal item is 
available in Appendix 2. During the trial, participants were free to consume water 
ad-libitum but consumed no further food until the end of the trial. 
 
The standardised mixed meal with a high carbohydrate and fat content was 
intended to produce a more ‘physiological’ response compared to glucose or fat 
only challenges (Selimoglu et al., 2009). The meal was given relative to each 
individual’s resting metabolic rate to standardise energy intake for inter-individual 
differences in body weight/composition and thus resting energy requirements. In 
the general population, RMR is a good reflection of daily energy requirements, 
however, this would not hold true and would be an underestimate for people who 
perform very large amounts of physical activity (hence why people who engaged 
in greater than 6 hours of vigorous or greater than 10 hours moderate-intensity 
physical activity per week were excluded).  
 
4.2.8 Blood and adipose sampling before and after meal consumption 
A venous blood sample was taken from an antecubital forearm vein and dispensed 
into separate tubes containing either K3EDTA or serum separation beads (Sarstedt 
Ltd., Leicester, UK) for analysis of plasma and serum measures of metabolism 
and inflammation (General Methods, 2.9 – 2.10). Subcutaneous adipose tissue 
samples (~1 g) were obtained under local anaesthetic (1 % lidocaine) 
approximately 5 cm lateral to the umbilicus using a ‘needle aspiration’ technique 
and processed as described in General Methods, 2.13.  
 
After baseline blood and adipose tissue sampling, the meal was consumed within 
15 minutes and blood samples taken from the cannula at 15, 30, 60, and 90 
minutes and then at every hour until 6 hours after consumption of the meal. A 
second adipose sample was also taken at 6 hours on the opposite side of the 
umbilicus to the sample collected at baseline. At both sampling time points, 
approximately 200 mg adipose tissue was processed for gene expression analysis 
(General Methods, 2.19) and small portions minced (~5-10 mg explants) for 
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analysis of adipokine secretion (General Methods, 2.14). Additional blood 
samples were obtained at 2 and 6 hours post meal by venepuncture from the 
contralateral arm for analysis of inflammatory markers as there is evidence that 
the cannula can stimulate local inflammation (Dixon et al., 2009).  
 
4.2.9 RT-PCR 
After extraction and quantification, 2 μg total RNA was reverse transcribed to 
cDNA and real-time PCR performed (General Methods, 2.19) to measure 
expression of GLUT4, IRS2, HSL, leptin, adiponectin, MCP-1, RANTES, IP-10, 
IL-6, IL-8, IL-10, IL1Ra, TNFα, IL-1β and IL-18. Data for adipose tissue 
expression of GCSF, MIP-1b and IFNɣ are not shown because they were only 
detectable in 4-8 individuals. Peptidylpropyl isomerase A (PPIA/Cyclophilin A) 
was used as an endogenous control (Neville et al., 2011). Results were analysed 
using the comparative Ct method and expression normalised to an internal 
calibrator specific to each gene using the formula 2-∆∆CT (where ∆∆CT is [(CT gene 
of interest – C
T
 PPIA) – lowest ∆CT for gene of interest] and statistical analysis 
performed on LN transformed values (Livak & Schmittgen, 2001). Details of 
specific primers used can be found in General Methods, 2.19. 
 
4.2.10 Biochemical analysis 
Plasma glucose and serum insulin, adiponectin, leptin, total cholesterol, HDL 
cholesterol and triglyceride concentrations and ALT activity were measured using 
techniques described in General Methods, 2.10. Plasma CRP, SAA, sVCAM-1, 
and sICAM-1 were measured as a 4-plex and IFNɣ, TNFα, IL-10, IL-12p70, IL-
1β, IL-8 and IL-6 were measured as a 7-plex using an ‘electrochemiluminescence 
detection and patterned array’ technology (MULTI-ARRAY®, Meso Scale 
Discovery). This analysis was kindly performed by TNO Triskellon as part of the 
ADMIT study run in collaboration with Unilever Food and Health Research 
Institute, NL. Adipose tissue secretion of Leptin was measured by ELISA (R&D 
Systems) and GCSF, MCP-1, IP-10, IL-8, IL-6, IL-10, IL-1Ra, MIP-1b, TNFα, 
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4.2.11 Statistical analysis 
All data are presented as mean ± standard error of the mean (SEM). Total area 
under the curve (AUC) for insulin, glucose, triglycerides and NEFA and 
homeostasis model assessment for insulin resistance (HOMA-IR) were calculated 
using the formulae described in General Methods, 2.12. Comparisons were made 
between the lean, overweight and obese groups at baseline and for measures of 
AUC using one-way ANOVA. Adipose tissue responses to the meal, with only 2 
time-points available, were compared between the 3 groups using 2-way mixed-
model ANOVAs irrespective of normality (Maxwell and Delaney, 1990, p. 109). 
For blood measures of metabolism and inflammation where more than 2 time-
points were available, mixed-model ANOVA was also used to compare responses 
between the 3 groups. The Greenhouse–Geisser correction was applied to intra-
individual contrasts where ε < 0.75, however, for less severe asphericity the 
Huynh–Feldt correction was selected (Atkinson, 2002). Where mixed model 
ANOVA identified significant effects (and more than 2 timepoints available), 
multiple t-tests were applied to identify which specific time points were different 
from baseline and to identify the location of any variance between groups at level 
time points, with p-values subject to a Holm–Bonferroni correction (Atkinson, 
2002). Statistical analysis was performed using SPSS version 20 and p ≤ 0.05 was 
considered to be statistically significant. The symbols used to identify significant 
differences are as follows; * denotes a main effect of time, † denotes a main effect 

















4.3.1 Fasting and postprandial blood glucose and insulin 
As reported in Chapter 3, measures of glucose control increased in line with 
adiposity as confirmed by fasting levels of glucose (lean 4.4 ± 0.2 mmol/L, 
overweight 4.8 ± 0.3 mmol/L and obese 5.3 ± 0.2 mmol/L, one-way ANOVA 
p=0.043) and insulin (lean 27.3 ± 4.8 pmol/L, overweight 39.6 ± 7.0 pmol/L and 
obese 59.5 ± 10.1 pmol/L, one-way ANOVA p=0.020). In addition, main effects 
of group revealed that postprandial responses for both glucose (p=0.030, F=3.998) 
and insulin (p=0.056, F=3.220) were affected by adiposity (Figures 4.1a and c 
respectively). Post-hoc t-tests (of mean responses of participants within each 
group) revealed that glucose (p=0.022) and insulin (p=0.038) responses were 
significantly higher in the obese group compared to lean. Total areas under the 
curve for glucose and insulin also increased in line with adiposity (Figures 4.1b 























Figure 4.1. Blood glucose and insulin responses over the 6 hours following 
consumption of the meal for lean, overweight and obese individuals classified 
based on waist circumference. Measures of glucose following the meal 
according to a) mean group responses over time, and b) total AUC for glucose. 
Corresponding measures of c) mean insulin by group, and d) total AUC for 
insulin. Mixed-model ANOVAs were performed with post-hoc t-tests applied to 
identify which specific time points were different from baseline; * denotes effect 
of time (p<0.05) compared to t=0; † denotes main effect of adiposity (p <0.05), 
with no interaction effects identified (n=30). Total-AUC compared using one-way 
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4.3.2 Changes in adipose tissue gene expression at 6 hours following the meal 
Levels of baseline gene expression in subcutaneous adipose tissue according to 
levels of adiposity have been presented in Chapter 3. Mixed-model ANOVA also 
identified main effects of adiposity for the gene expression of GLUT4 (F=9.9, 
p=0.001), IRS2 (F=5.2, p=0.012) and HSL (F=4.8, p=0.016), whereby each was 
reduced with increased levels of adiposity (Figure 4.2). At 6 hours after the meal 
only IRS2 gene expression was down-regulated relative to baseline in all groups 
(F=23.9, p<0.001; Figure 4.2b). No significant adiposity x time interactions were 
identified for the gene expression of GLUT4, IRS2 or HSL in subcutaneous 




Figure 4.2. Relative expression of GLUT4, IRS2 and HSL by whole adipose 
tissue samples pre (0h) and post (6h) meal consumption.  Data presented as LN 
2
-∆∆Ct 
mean ± SEM with participants classified equally based on waist 
circumference (n=30). Mean and SEM values shown for groups based on waist 
circumference. Groups compared by mixed-model ANOVA; †denotes main effect 
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Gene expression responses for a number of adipokines related to inflammation 
following the meal were also examined and are shown in Figure 4.3 (again, results 
at baseline are presented in Chapter 3). With increased adiposity, gene expression 
in subcutaneous adipose tissue was elevated for pro-inflammatory IL-18 (F=8.3, 
p=0.002), anti-inflammatory IL-1Ra (F=6.1, p=0.006), monocyte chemo-
attractant MCP-1 (F=8.8, p=0.001), and IP-10 (F=4.1, p=0.029). Significant time 
effects reflected an increase in gene expression of both IL-6 (F=13.8, p=0.001) 
and MCP-1 (F=8.3, p=0.008) for all groups as shown in Figure 4.3, however, no 
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Figure 4.3. Relative gene expression of pro- and anti- inflammatory cytokines 
by whole adipose tissue samples pre (0h) and post (6h) meal consumption.  
Data presented as LN 2
-∆∆Ct 
mean ± SEM with participants classified as lean, 
overweight or obese based on waist circumference (n=30). Mean and SEM values 
shown for groups based on waist circumference. Groups compared by mixed-
model ANOVA; † denotes main effect of adiposity, p<0.05, * denotes main effect 
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4.3.3 Adipose tissue secretion before and after the meal 
Adipokine secretion from subcutaneous adipose tissue explants was adjusted to 
central fat mass (L1-L4 from DEXA) as described in Chapter 3. The overall main 
effects of group identified by mixed-model ANOVA showed that secretion of 
leptin, MCP-1, IP-10, MIP-1b, IL-10, IL-6 and GCSF is elevated with increased 
levels of adiposity. These results are in line with the results presented at baseline 
in Chapter 3 indicating that these differences were maintained over time and from 
a different sample site in the abdominal subcutaneous adipose tissue. Despite 
changes in gene expression of IL-6 and MCP-1 at 6 hours following the meal, no 
such responses were found at the level of adipokine secretion from whole adipose 
tissue explants as shown in Table 4.2. The only significant adiposity x time 
interaction (after post-hoc t-tests and Holm-Bonferroni corrections) was found for 
IL-10, whereby levels of IL-10 secretion from the obese group was significantly 
reduced to a level that was similar to the overweight group at 6 hours (p<0.05). 
Due to the limited size of some adipose tissue samples obtained, there was only 
sufficient to culture tissue for 6 lean and 5 overweight individuals. Thus, these 






















Table 4.2. Adipokine secretion by whole adipose tissue explants over 3 hours; 
pre and 6h post meal. Participants were classified as lean (n=6), overweight 
(n=5) or obese (n=10) based on waist circumference. Mean and SEM values 
shown with p values for effects of adiposity, time and adiposity x time 
interactions analysed by mixed-model ANOVA. 
 
  T=0h T=6h 
Main effect of 
adiposity  
Main effect 





central fat mass 
ng/3h/estimated 
central fat mass (p-value)  (p-value) 
 
(p-value) 
Leptin Lean 2946 ± 713 2887 ± 371     
 Overweight 8217 ± 2658 9348 ± 3108 0.004  0.560 0.153 
 Obese 14799 ± 2106 12373 ± 2472     
        
IL-6 Lean 2672 ± 543 6517 ± 1977     
 Overweight 16776 ± 5295 14035 ± 3222 0.002  0.764 0.345 
 Obese 15573 ± 2091 15982 ± 1591     
        
MCP1 Lean 1985 ± 380 2381 ± 774     
 Overweight 7033 ± 1588 5260 ± 598 0.002  0.284 0.525 
 Obese 8155 ± 1298 6969 ± 1242     
        
G-CSF Lean 487 ± 112 987 ± 439     
 Overweight 1763 ± 320 1481 ± 232 0.001  0.954 0.311 
 Obese 2133 ± 285 1876 ± 195     
        
IL-8 Lean 463 ± 208 1144 ± 505     
 Overweight 2479 ± 695 1481 ± 346 0.300  0.212 0.149 
 Obese 3414 ± 1450 1614 ± 517     
        
IP-10 Lean 639 ± 183 1278 ± 578     
 Overweight 3746 ± 770 2238 ± 650 0.014  0.099 0.029 
 Obese 3867 ± 709 3251 ± 631     
        
IL-1Ra Lean 167 ± 73 161 ± 60     
 Overweight 279 ± 40 763 ± 417 0.159  0.661 0.086 
 Obese 1418 ± 563 626 ± 172     
        
MIP-
1b Lean 220 ± 29 401 ± 167    
 
 Overweight 1119 ± 101 852 ± 143 0.003  0.874 0.469 
 Obese 1180 ± 194 1341 ± 279     
        
TNFα Lean 230 ± 110 180 ± 87     
 Overweight 130 ± 15 221 ± 107 0.451  0.692 0.253 
 Obese 450 ± 182 355 ± 135     
        
IL10 Lean 14 ± 2 12 ± 3     
 Overweight 24 ± 2 35 ± 9 0.004  0.765 0.017 
 Obese 55 ± 8 43 ± 8     
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4.3.4 Fasting and postprandial blood measures of lipid metabolism and 
inflammation  
With increasing levels of adiposity there were no differences between the groups 
when examining either fasting values or total areas under the curve for measures 
of lipid metabolism (NEFA or triglcerides), vascular markers of inflammation 
(CRP, SAA, s-ICAM1 and s-VCAM1), or cytokines IL-8, IL-6, and TNFα (Table 
4.3). Furthermore mixed model ANOVA confirmed there were no main effects of 
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 Fasting One-way 
ANOVA 
 Total-AUC (6h) One-way 
ANOVA 
 Lean Overweight Obese P  Lean Overweight Obese p 
 
Markers of lipid metabolism 
 
        
Triglycerides (mmol/L) 0.9 ± 0.1 1.3 ± 0.2 1.0 ± 0.1 0.123  8.8 ± 1.1 12.3 ± 1.9 10.5 ± 0.2 0.192 
NEFA (mmol/L) 0.33 ± 0.04 0.48 ± 0.13 0.43 ± 0.05 0.469  1.99 ± 0.23 2.31 ± 0.39 2.74 ± 0.41 0.339 
 
Markers of Inflammation 
        
CRP (mg/L) 716 ± 328 1234 ± 290 1897 ± 775 0.282  3851 ± 1711 7011 ± 1545 10935 ± 4866 
 
0.288 
SAA (ng/mL) 1416 ± 688 1119 ± 205 1248 ± 270 0.894  8094 ± 3863 6798 ± 1108 7339 ± 1529 
 
0.934 
s-ICAM1 (ng/mL) 245 ± 24 223 ± 17 235 ± 15 0.708  1378 ± 110 1370 ± 58 1324 ± 61 
 
0.877 
s-VCAM1 (ng/mL) 430 ± 35 342 ± 29 428 ± 29 0.087  2439 ± 148 2132 ± 87 2420 ± 142 
 
0.186 
IL-6 (pg/mL) 2.2 ± 0.7 1.6 ± 0.3 1.7 ± 0.4 0.614  14.6 ± 3.4 11.7 ± 1.7 12.5 ± 1.7 
 
0.675 








Table 4.3. Fasting and total area under the curve (6h) measures for blood markers of lipid metabolism and inflammation following a mixed meal 
for participants classified based on waist circumference. Mean (SEM) values shown and one-way ANOVAs performed to identify significant 
differences; * denotes significant difference compared to lean p<0.05). Abbreviations used: AUC = area under the curve, NEFA = non-esterified free fatty 
acids. 
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Only SAA and TNFα showed significant changes in blood in the 6 hours 
following the meal, whereby SAA increased by approximately 27 % (p=0.008) 
above baseline at t=300 minutes in all groups (Figure 4.4a) and TNFα was 
significantly reduced at each of the measured time points following the meal as 
compared to baseline (all p<0.05) (Figure 4.4b). IL-6 was significantly increased 
at t=240 minutes (p=0.001) and t=360 (p<0.001) minutes compared to baseline 
(Figure 4.4c). Based on previous observations by our group, it was suspected that 
the rise in IL-6 may be due to the presence of local inflammation caused by the 
cannula which was confirmed in the separate venepuncture samples taken from a 






















Figure 4.4. Changes in blood levels of a) SAA, b) TNFα and c) IL-6 for lean, 
overweight and obese individuals classified based on waist circumference at 
baseline and over the six hours following the meal (n=30). Mixed-model 
ANOVAs were performed to identify significant time, group and interaction 
effects with post-hoc t-tests applied; * denotes main effect of time (p<0.05) 
compared to t=0 (n=15). d) Analysis of venepuncture samples for IL-6 revealed 
that the increase was due to local inflammation at the cannula site since there was 
no change in samples taken by venepuncture from the contralateral arm; main 
effect of time (*) (F=7.714, p=0.011), condition (†) (F= 6.178, p=0.026) and time 
x condition (#) (F= 6.278, p=0.019) as analysed by 2-way repeated measures 
ANOVA.  




The present study investigated metabolic and immune responses to the 
consumption of a mixed meal in the circulation and adipose tissue between men 
with varying levels of adiposity. As anticipated, the glucose and insulin responses 
to the meal were increased in line with increased adiposity. However, in general, 
the adipose tissue responses were not influenced by adiposity, for example, the 
expression of IL-6 and MCP-1 RNA transcripts in subcutaneous adipose tissue 
were increased and expression of IRS2 decreased to a similar extent in lean 
through to obese men at 6 hours following consumption of the meal.   
 
4.4.1 Postprandial responses in adipose tissue with adiposity and insulin 
resistance 
The main aim of the present research was to determine whether an increased 
postprandial metabolic response typically seen with increased levels of adiposity 
corresponds with increased inflammatory responses in adipose tissue. Indeed with 
increased levels of adiposity from lean through to class I obesity, the anticipated 
elevated magnitudes of glucose and insulin responses following consumption of 
the meal were observed (Manning et al., 2008a). Within adipose tissue, gene 
expression of IL-6 and MCP-1 were increased at 6 hours following consumption 
of the meal, which supports findings from Meneses et al. (2011) who examined 
postprandial responses in adipose tissue gene expression from participants with 
metabolic syndrome and work by Pietraszek et al. (2011) who compared 
responses in non-obese relatives of people with type 2 diabetes to a control group. 
The magnitude of changes in IL-6, MCP-1 and IRS2 gene expression observed in 
the present study was equal across all groups from lean to class I obese despite 
poorer glucose control/poorer insulin sensitivity with increasing levels of 
adiposity. This may suggest that an increase in these parameters is part of a 
‘normal’ postprandial response within adipose tissue, at least within 6 hours 
following a meal.  
 
4.4.2 Regulation of postprandial inflammation in adipose tissue 
Despite changes in IL-6 gene expression in adipose tissue, there was no 
corresponding change in either adipose tissue secretion of IL-6 or levels in the 
blood, at least over the 6 hours following the meal. It is possible that there may be 
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important post-transcriptional/translational modifications to prevent increased 
systemic inflammation from adipose tissue each time a meal is consumed. It is 
interesting that no differences were found in the magnitude of responses at the 
level of gene expression/secretion following the meal, even with increased levels 
of adiposity and both insulin and glucose responses in blood. It may be argued 
that the greater postprandial glucose and insulin responses in blood may have 
been due to the obese group ingesting more calories compared to lean/overweight 
groups since the meal was given relative to RMR. However, this is likely to be 
closer to typical energy intake and thus preferable to the provision of an 
unadjusted standardised meal. Moreover, despite the larger meal being consumed, 
there were no differences in gene expression in adipose tissue between groups. 
This does not exclude systemic insulin and/or glucose concentrations as mediators 
of the postprandial response in adipose tissue, since the increased level of insulin 
resistance in obese adipose tissue (suggested by the chronic down-regulation of 
GLUT4, HSL and IRS2 as identified in this study) may counteract the increased 
insulin response resulting in the same overall effect as in lean ‘insulin sensitive’ 
tissue.  
 
It could also be argued that the obese adipose tissue is adapted to cope with a 
greater caloric challenge and there is greater storage capacity for the increased 
triglycerides (and glucose). Given the increased relative mass of adipose tissue in 
obese individuals compared to lean, exposure of each gram of obese adipose 
tissue to insulin may actually be comparable to lean. It would be interesting to 
investigate whether there may be greater levels of postprandial 
inflammation/stress in times of weight gain/overfeeding compared to times of 
weight maintenance, especially since this study gave the meal relative to 
requirements. Greater postprandial inflammation and stress may instead occur in 
adipose tissue during times of rapid weight gain/consuming more than 
requirements, where there is insufficient adipose tissue to immediately deal with 
and buffer  the challenge. This cannot be deduced from this study population since 
it was required that participants had been weight stable for at least 3 months for 
their inclusion. Perhaps if the lean group were given the same amount of the meal 
as the obese group, greater levels of inflammation may have been observed 
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compared to obese individuals, but this would have addressed a different research 
question. 
 
4.4.3 Potential origin and roles of IL-6 and MCP-1  
The meal used in this study was relatively high in both carbohydrates and fats. 
However, it cannot be determined from this study whether either of these or 
another factor related to the ingestion of either of these meal components (e.g. 
insulin) is the main stimulus for the increase in adipose tissue expression of IL-6 
and MCP-1. Adipose resident immune cells, endothelial cells, preadipocytes (etc.) 
comprising the stromavascular fraction, rather than adipocytes, are likely to be the 
major sources of adipokines such as MCP-1 and IL-6 (Fain, 2010). MCP-1 and 
IL-6 are produced primarily by macrophages (Moro et al., 2007; Bourlier et al., 
2008), however, it is estimated that mature adipocytes also contribute 
approximately one third of the IL-6 present in the circulation of patients who are 
obese (Fantuzzi, 2005) so their contribution cannot be excluded. Each of the 
components of the meal and the associated insulin response have been shown in-
vitro to affect inflammation in both macrophages and adipocytes. For example, 
experiments using (murine) 3T3-L1 adipocytes have shown that insulin can 
dramatically enhance MCP-1 expression from these cells and may therefore be an 
important contributing factor driving the observed increase. MCP-1 can also 
induce insulin resistance in adipocytes (Sartipy 2003). The increase in MCP-1 
may be a contributing factor to enhance macrophage recruitment to adipose tissue 
(via repeated stimulation) as is observed in adipose tissue of obese individuals 
(Chapter 3, and well documented in the literature (Weisberg et al., 2003; Xu et 
al., 2003; Curat et al., 2004; Zeyda et al., 2007). In-vitro work has shown that IL-
6 production can be induced in macrophages following high levels of glucose 
uptake via GLUT1 (Freemerman et al., 2014). Fatty acids (and 
lipopolysaccharides (LPS) produced by gram-negative bacteria present within the 
intestine following ingestion of triglycerides) may also have a role in regulating 
infiltration of macrophages into adipose tissue and stimulating their production of 
pro-inflammatory IL-6 (Makowski et al., 2001; Sampey et al., 2011; Johnson et 
al., 2012).  
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Over longer periods of time, with repeated stimulation, these temporal changes in 
gene expression seen after the consumption of a single meal may contribute to the 
chronic increases in adipose tissue inflammation, although it is also possible that 
levels of postprandial inflammation may continually adapt over the course of a 
day to meal components. It would be interesting to investigate postprandial 
inflammatory changes in adipose tissue following subsequent calorie intake, since 
blood glucose and insulin responses are known to be much lower after subsequent 
feeding (Staub-Traugott effect), a phenomenon which is preserved in normal 
glucose tolerance through to type 2 diabetes (Bonuccelli et al., 2009; Jovanovic et 
al., 2009a; Jovanovic et al., 2009b) and could help identify whether 
glucose/insulin are indeed key drivers of the postprandial adipose tissue 
responses. 
 
The effect of hyperglycaemia alone (in the absence of increased insulin) has been 
examined on adipose tissue gene expression and immediately after 3 hours of 
hyperglyaemia (Meugnier et al., 2007). The majority (>80 %) of genes examined 
in that particular study actually showed down-regulation and neither IL-6 or 
MCP-1 were reported to be up-regulated (Meugnier et al., 2007). If the meal was 
indeed the key stimulus for the inflammation, another component to consider are 
the triglycerides, which, like the changes in adipose tissue gene expression, 
showed no differences in magnitudes of response with increased levels of 
adiposity. High-fat meal challenges also induce inflammation in adipose tissue 
(Magne et al., 2010; Meneses et al., 2011) although composition/quality of fat 
(i.e. saturated or unsaturated fats) is not necessarily important in determining the 
levels of postprandial inflammation in adipose tissue (Meneses et al., 2011). It is 
possible that adipose tissue may respond to glucose, insulin and triglycerides (and 
other associated stimuli not examined in this study, e.g. LPS) ‘independently’ of 
each other over the course of their respective postprandial responses and adipose 
tissue sampling at different time points may have produced a different pattern of 
results.   
 
4.4.4 Inflammatory responses in circulation 
No differences in fasting vascular markers of inflammation, cytokine 
concentrations or their respective postprandial responses were found between the 
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three groups. The only temporal changes observed were for TNFα, which was 
reduced at all time-points, and SAA which was increased only at 5 hours after the 
meal. These results are consistent amongst other studies covering ranges of 
adiposity (Blackburn et al., 2006; Poppitt et al., 2008). Both these previous 
studies found a transient decrease in TNFα and increase in IL-6 after the meal and 
similarly they also report no change in CRP. There is, however, much conflicting 
evidence regarding the role of acute inflammatory mediators in the circulation 
following consumption of a meal as several studies report increases in several 
inflammatory cytokines including IL-6 (Nappo et al., 2002; Blackburn et al., 
2006; Manning et al., 2008b; Poppitt et al., 2008; Laugerette et al., 2011), 
although this was most likely due to localised inflammation at the site of the 
cannula as identified by our results in this study and previously (Dixon et al., 
2009). Gene expression of TNFα in adipose tissue was not altered at 6 hours after 
the meal, neither was there any change in tissue secretion ex-vivo, suggesting that 
the adipose tissue may not be directly linked to these inflammatory changes in the 
circulation in the hours following the meal.  
 
4.4.5 Limitations 
The lack of a control group remaining fasted for the duration of the postprandial 
response means we cannot be certain that the meal directly caused any of the 
reported changes. Such comparisons have been made previously in rats, which 
demonstrated that gene expression of inflammatory markers IL-6 and NF-κB were 
significantly increased (at 2 hours) specifically following a high-fat meal 
compared to water (Magne et al., 2010). Furthermore, since we only included 2 
time points for adipose tissue sampling, this is clearly not a full reflection of what 
is occurring within adipose tissue over the entire duration following consumption 
of the meal. For example, there may not have been sufficient time for synthesis of 
RNA transcripts/proteins for secretion into the circulation by the 6 hour time-
point and later sampling may have shown an increase in secretion in response to 
the meal. Conversely, 6 hours may have been too late to observe some changes 
since a greater number of changes had been identified at 4 hours following lipid 
challenges (Meneses et al., 2011) and after only 3 hours of hyperglycaemia 
(Meugnier et al., 2007).  
 




Participants were recruited to cover a range of postprandial responses for glucose 
and insulin according to varying levels of adiposity. However, despite these 
differences and differences in adiposity, the adipose tissue responses were broadly 
similar in lean, overweight and obese middle-aged men. Thus, a single feeding 
exposure does not appear to provoke a greater acute inflammatory response in 
expanded subcutaneous adipose tissue. Based on these results, acute feeding will 

























Impact of calorie restriction on leptin and T-lymphocyte 




Leptin is a cytokine-like hormone primarily produced by adipocytes in proportion 
to body fat mass. In humans, it is predominantly produced by subcutaneous 
adipose tissue due to the increased relative size and secretion rate of this depot 
(Margetic et al., 2002; Fain et al., 2004). Leptin concentrations in blood typically 
reflect energy stored in adipose tissue and this hormone acts centrally on the 
hypothalamus to regulate energy intake and expenditure (Friedman & Halaas, 
1998). Leptin also influences a variety of peripheral physiological functions, 
however, including immune system function (La Cava & Matarese, 2004) and the 
leptin receptor (Ob-R) is expressed by neutrophils, monocytes, macrophages, T-
lymphocytes, B-lymphocytes, mast cells, dendritic cells and NK cells (La Cava & 
Matarese, 2004). Leptin can (with co-stimulation) elicit dose dependent effects on 
T-lymphocyte expression of ‘early’ activation marker CD69 and ‘late’ activation 
maker CD25, in-vitro, after 12 hours and 48 hours respectively (Martin-Romero et 
al., 2000). Results from our previous research investigating the properties of T-
lymphocytes across differing levels of adiposity suggested that adipose tissue 
resident CD4+ and CD8+ T-lymphocytes show greater levels of activation with 
increasing adiposity and this activation (levels of CD69 and CD25 expression) 
was further related to the increased serum concentrations of leptin (Chapter 3). 
Whether leptin per se is a key factor in determining the levels of T-lymphocyte 
activation in adipose tissue in humans is unclear. Given the role of leptin on CD69 
and CD25 expression (Martin-Romero et al., 2000), there is the exciting 
possibility that leptin-related modifications to T-lymphocyte activation could 
influence (improve) inflammation in adipose tissue and in blood in-vivo. 
 
Leptin can be dramatically reduced with short periods of ‘severe’ calorie 
restriction to levels much lower than the corresponding change in adiposity would 
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predict (Boden et al., 1996; Dubuc et al., 1998; Haluzik et al., 2001; Mars et al., 
2006). Importantly, expression of T-lymphocyte activation markers CD69 and 
CD25 are also rapid to respond to stimulation, with changes being detectable after 
just a few hours (Hashemi et al., 1999; Martin-Romero et al., 2000). Thus, a short 
period of severe calorie restriction and a reduction in leptin may provide a route to 
test whether T-lymphocyte activation in adipose tissue and blood can be modified 
in-vivo in humans.  
 
The main aim of this research was therefore to investigate whether calorie 
restriction and the associated reduction in leptin leads to a reduction in T-
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5.2 Materials and methods 
5.2.1 Experimental design 
Twelve abdominally overweight/obese males aged between 35-55 years were 
recruited from the local community following ethical approval from the South 
West, Frenchay NHS Research Ethics Committee (REC Reference: 12/SW/0324). 
Each participant gave written informed consent. Only overweight and obese 
participants were recruited since results from our previous study suggested that 
these individuals showed greatest activation of T-lymphocytes within adipose 
tissue (Chapter 3). After a 1-week period of monitoring energy intake and 
expenditure to confirm a sufficient state of ‘energy balance’, participants reduced 
their caloric intake to 50 % of their normal intake for 3 consecutive days. 
Participants attended the Laboratory before and after this intervention for analysis 
of immune cell activation and markers of inflammation and metabolism in blood 
and adipose tissue. An oral glucose tolerance test was also performed to assess 
glucose control before and after the 3 day calorie restriction intervention. 
 
5.2.2 Participants 
Participants were abdominally overweight/obese with waist circumference >94 
cm (Lean et al., 1995) and had been weight stable for more than 3 months (no 
change in weight +/- 3 %) (Stevens et al., 2006). Individuals were excluded from 
participation if they smoked, had personal history of/existing cardiovascular 
disease, metabolic disease or dyslipidaemia or were taking medications that may 
influence lipid or carbohydrate metabolism or immune system function.  
 
5.2.3 Sample size determination 
There are no data regarding changes in T-lymphocyte activation in human adipose 
tissue in response to calorie restriction. However, we observed significant 
differences in T-lymphocyte activation between lean and obese individuals in our 
previous study. A short period of calorie restriction can reduce serum leptin 
values by around 40 % ((Mars et al., 2006) and from pilot work in Appendix 3), 
which is sufficient to reduce typical values for an obese person to those of a lean 
person. Thus, we anticipate a similar reduction in T-lymphocyte activation in 
response to caloric restriction. Our recent data indicate that the CD69 mean 
fluorescence intensity (MFI) for lean CD4CD69 cells is 288 (+/45 SD) and obese 
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is 411 (+/31 SD) with an effect size of 2.98 (G-Power). Taking into account our 
range of activation markers, with 95 % power and 5 % alpha, an average of 11 
participants were required to detect a statistically significant change in T-
lymphocyte activation in adipose tissue in response to caloric restriction. This was 
rounded to 12 participants to allow for withdrawal of participants from the study. 
 
5.2.4 Monitoring of energy balance  
Participants were weighed before and after a 1-week period of ‘energy balance’ 
monitoring to ensure weight stability during this period using a digital balance 
(Tanita Corp., Japan). Participants were fitted with a combined heart rate and 
accelerometry monitor (Actiheart™; General Methods, 2.5) to determine habitual 
total energy expenditure (TEE) (Thompson et al., 2006). TEE was adjusted for 
measured resting metabolic rate (RMR) using the protocol described in General 
Methods, 2.6. A weighed food and fluid intake record was used during this period 
to estimate participants’ energy intake (General Methods, 2.7). Participants were 
asked not to make any conscious changes to their normal lifestyle habits/routines 
during this period. Participants were not told that the activity monitoring and food 
records would be used to directly influence the diet prescribed/given during the 3 
day calorie reduction period so as to avoid influencing their habitual routines. 
This analysis was then used to confirm that participants were in a state of ‘energy 
balance’ and to write a 'diet prescription' for the 3-day intervention. The aim was 
to ensure that participants receive 50 % of their 'normal' calorie requirements (i.e. 
average of energy intake and energy expenditure) using foods they would 
normally consume. Since there are errors associated with estimations of total 
energy expenditure (Thompson et al., 2006) and recording dietary intake (in 
particular underreporting) (Poslusna et al., 2009), we stipulated a priori that total 
energy intake and energy expenditure values had to be within 25 % of each other 
and, furthermore, that the prescribed calorie intake had to be within 40-60 % both 
total energy expenditure and dietary intake values. If either of these requirements 
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5.2.5 Calorie restriction protocol 
For 3 consecutive days, participants were instructed to follow a prescribed diet 
calculated to be 50 % of their ‘normal’ energy requirements. To determine the 
exact calorie intake required for the 3 days, an average of energy expenditure and 
dietary intake from the monitoring period was taken. This value was then divided 
in half to give the ‘target’ calorie value for each of the 3 days in the diet. 
Subsequently, three separate days from the participant’s one-week diet record 
were selected and the weight of each item adjusted to meet this daily target kcal 
value whilst maintaining the overall relative proportions so that participants’ 
typical diet composition remained unaltered. A worked example showing how the 
weights of food items were adjusted whilst maintaining overall proportions is 
shown in Appendix 4. During the 3 day intervention, participants were asked to 
record the timing of each food/fluid intake within the prescribed food diary and to 
confirm that they had consumed the correct amount of food to help improve 
compliance with diet instructions. Participants were asked not to make any 
conscious changes to habitual physical activity during the calorie restriction 
period. 
 
5.2.6 Pre-trial requirements 
Participants were asked to refrain from performing any strenuous physical activity 
for 48 hours and from consuming caffeine/alcohol for 24 hours before both trial 
days (i.e., pre- and post-intervention). Trial days were scheduled so participants 
had been free from any self-reported illness for a minimum of 2 weeks in order to 
reduce immune system disturbance.  
 
5.2.7 Trial days  
On both main trial days, participants arrived at the Physiology Resting Laboratory 
in the morning following a 10 hour fast (approximately 8 am) and after 
consuming 1 pint of water upon waking. Participants arrived in the lab at the same 
time on both trial days.  
 
5.2.8 Body composition analysis 
Measurements of height, waist circumferences and body mass (post- void using a 
digital balance (TANITA corp. Japan)) were determined on both trial days. 
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Participants’ body composition was characterised at baseline using dual energy X-
ray absorptiometry (DEXA) and estimates of total and central fat mass (L1-L4) 
and FMI determined as described in General Methods, 2.4.  
 
5.2.9 Blood and adipose sampling 
A cannula was inserted into an antecubital forearm vein and baseline blood 
sample(s) taken for analysis of plasma and serum metabolic/inflammatory 
markers and isolation of peripheral blood mononuclear cells (PBMCs) according 
to the protocols described in General Methods, 2.9 – 2.11.  
 
Subcutaneous adipose tissue samples (~1g) were obtained under local anaesthetic 
(1% lidocaine) approximately 5 cm lateral to the umbilicus using a ‘needle 
aspiration’ technique and processed as described in General Methods, 2.13). 
Approximately 100 mg whole adipose tissue was transferred to an RNase/DNase 
free sterile centrifuge tube and frozen immediately on dry ice and later 
homogenised in Trizol reagent (Invitrogen). The remainder was used for adipose 
tissue culture (General Methods, 2.14) and preparation of the stromavascular 
fraction (SVF; General Methods, 2.15). Due to the limited size of some adipose 
tissue samples, priority was given to preparing tissue for analysis of SVF to 
address the main aim of this study. Lowest priority was given to gene expression 
analysis. Paired samples were available for 9 participants for secretion analysis 
and 7 participants for gene expression analysis.  
 
5.2.10 Oral glucose tolerance test 
Participants were asked to consume a glucose drink consisting of 75 g anhydrous 
glucose (maltodextrin) solution (Polycal, Nutricia, UK) and cannula blood 
samples were taken every 15 minutes for the following 2 hours for measurement 
of plasma glucose and serum insulin (General Methods, 2.12). 
 
5.2.11 Analysis of SVF and PBMCs by flow cytometry 
Flow cytometry (using the FACSverse, Beckton Dickenson) was used to identify 
CD4+/CD8+ T-lymphocytes (CD45+CD3+ cells) and macrophages/monocytes 
(CD45+CD14+ cells) in SVF and PBMCs together with respective levels of 
Chapter 5  Study 3         Study 2 
116 
 
activation using methods and antibody cocktails detailed in General Methods, 
2.16 – 2.18.  
 
5.2.12 RT-PCR 
Total RNA was extracted from whole adipose tissue, quantified and 1 μg reverse 
transcribed to cDNA as described in General Methods, 2.19. Real-time PCR was 
performed using a StepOneTM (Applied Biosystems) with pre-designed primers 
and probes obtained from Applied Biosystems for measurement of leptin 
adiponectin, GLUT4, IRS2, HSL, LPL, PPAR-Ɣ, MCP-1, IL-6, IL-8, IL-1Ra, and 
IL-18 expression (details of specific primer Hs numbers can be found in General 
Methods, 2.19). Peptidylpropyl isomerase A (PPIA) was used as an endogenous 
control (Neville et al., 2011). Results were analysed using the comparative Ct 
method and expression normalized to an internal calibrator specific to each gene 
using the formula 2- ∆∆CT; where ∆∆CT is [(CT gene of interest – CT PPIA) – 
lowest ∆CT for gene of interest] and statistical analysis performed on LN 
transformed values (Livak & Schmittgen, 2001). 
 
5.2.13 Biochemical analysis  
Plasma glucose, serum total cholesterol, HDL cholesterol, triglycerides and CRP 
and ALT activity were measured using commercially available assay kits and 
analyser (Daytona Rx, Randox). ELISA was used for the measurement of serum 
Insulin (Mercodia, Sweden), plasma IL-6, IL-8 and TNFα (R&D Systems, UK)  
and both serum and adipose tissue Leptin and Adiponectin secretion (R&D 
systems). A fluorescent bead (Bio-Plex) multiplex system (Luminex, BIO-RAD) 
was used for the measurement of serum and adipose tissue secretion of G-CSF, 
M-CSF, MCP-1, IP-10, IL-10, IL-1Ra, MIP-1β, IL-18. Luminex was also used for 
the measurement of IL-6, IL-8 and TNFα secreted by adipose tissue. Serum G-
CSF, M-CSF, IL-10 and IL-1Ra were detectable in fewer than 3 individuals so 
results were not included in statistical analysis. Neither IL-18, IL-10 or TNFα 
were detected in media from adipose explants. 
 
5.2.14 Statistical analysis 
All data are presented as mean and standard error of the mean (SEM). Total area 
under the curve, homeostasis model assessment for insulin resistance (HOMA-IR) 
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and insulin sensitivity index (ISI comp/Matsuda index) were calculated using the 
formulae described in General Methods, 2.12). Comparisons were made between 
pre- and post- diet values using paired Student’s T-tests. Statistical analysis was 
performed using Excel 2010 (Microsoft) and SPSS version 20 and p<0.05 was 


































Energy intake was reduced from 2499 ± 119 kcal/day to 1320 ± 52 kcal/day 
during the 3-day calorie restriction period (50 % of mean [energy intake and TEE] 
from energy balance monitoring week). During the 3 day calorie restriction 
period, participants did not change their physical activity levels (PAL 1.54 ± 0.06 
during monitoring period and 1.52 ± 0.06 during the intervention period, 
p=0.549). Changes in anthropometric data and blood markers of metabolism pre- 
and post- diet are shown in Table 5.1. There was a significant reduction in body 
mass, waist circumference, glucose at 2 hours post-OGTT, triglycerides and ALT; 
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 Pre-diet Post-diet Sig. p-value 
Physical characteristics    
Body mass (kg) 93.1 ± 2.8 91.5 ± 2.8 <0.001 
Body mass index (kg/m2) 29.0 ± 0.7 28.5 ± 0.7 <0.001 
Waist circumference (cm) 104.6  ± 1.7 103.6 ± 1.8 <0.001 
Height (m) 1.79 ± 0.03 ND  
L1-L4 fat (%) 33 ± 1 ND  
Fat mass index (kg/m2) 8.2 ± 0.5 ND  
Resting metabolic rate (kcal/day) 1800 ± 30 ND  
PAL 1.54 ± 0.06 ND  
    
Blood related measures of 
metabolism    
Insulin (pmol/L) 46.7 ± 9.5 42.6 ± 9.1 0.114 
Insulin Total-AUCa (pmol*2h/L) 187 ± 42 185 ± 57 0.952 
Glucose (mmol/L) 5.1 ± 0.2 5.1 ± 0.1 0.623 
Glucose Total-AUCa (mmol*2h/L) 14.7 ± 0.7 14.4 ± 0.9 0.742 
Glucose at 2 h (mmol/L) 6.8 ± 0.5 6.0 ± 0.4 0.002 
HOMA-IR 1.8 ± 0.4 1.6 ± 0.4 0.190 
Matsuda-ISIa 6.21 ± 0.37 7.29 ± 1.8 0.020 
ALT (U/L) 40.2 ± 6.0 34.9 ± 5.1 0.051 
Triglycerides (mmol/L) 1.36 ± 0.19 1.05 ± 0.16 0.005 
Non esterified fatty acids (mmol/L) 0.34 ± 0.03 0.55 ± 0.04 <0.001 
Total-Cholesterol (mmol/L) 5.3 ± 0.2 5.6 ± 0.2 0.046 
LDL-Cholesterol (mmol/L) 3.47 ± 0.17 3.86 ± 0.21 0.013 
HDL-Cholesterol (mmol/L) 1.19 ± 0.05 1.22 ± 0.05 0.631 
 
Table 5.1. Anthropometric measures and blood markers of metabolism 
before and after 3 days of 50% caloric restriction. Mean ± SEM shown and 
differences between the two days analysed by two-tailed, paired, Student’s t-tests, 
p-values shown (n=12). aT-AUC for insulin and glucose and Matsuda-ISI 
represent n=11 due to incomplete data. All blood measures are fasting samples 
unless otherwise stated. L1-L4 = central fat estimated between lumbar regions L1-
L4 using DEXA, PAL = physical activity level (total energy expenditure/basal 
metabolic rate), ALT = alanine transaminase. ND = not determined. 
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5.3.1 Changes in leptin and immune cell activation in blood 
As shown in Figure 5.1a, there was a significant reduction in serum leptin of 31 % 
from baseline (range 3 % to 64 %), and the reduction in serum leptin was 
significantly correlated with the percentage improvement in insulin sensitivity 
(Matsuda-ISI; Pearson’s r = -0.629, p=0.028). As a percentage of total cells 
isolated from the blood (PBMCs), CD4+ T-lymphocytes represented 20 ± 2 % 
cells and CD8+ T-lymphocytes represented 7 ± 1 % cells at baseline. Considering 
the activated CD4+ and CD8+ T-lymphocytes present, there was an 8 ± 10 % 
reduction (from 62 ± 3 % to 54 ± 5 %, p=0.016) in the percentage of CD4+CD25+ 
T-lymphocytes (as % total lymphocytes) present in the blood after 3 days of 50 % 
reduction in caloric intake (Figure 5.1b) and the level of CD25 expression (MFI) 
on these CD4+CD25+ lymphocytes was also reduced by 8 ± 4 % (from 3397 ± 
139 to 3107 ± 126, p=0.058; Figure 5.1c). There were no such changes in the 
proportion or levels of activation of CD8+CD25+ T-lymphocytes (Figures 5.1b 
and 5.1c). The proportion of CD4+ and CD8+ cells expressing CD69 was much 
lower than those expressing CD25 (as a percentage of total lymphocytes) and 
there were no changes in either the proportion of cells expressing CD69 (Figure 
5.1b) or its levels of expression after 3 days of 50 % reduction in calorie intake 
(Figure 5.1d).  
 
Levels of expression of the leptin receptor (CD295) and insulin receptor (CD220) 
on activated T-lymphocyte populations were also examined. Although there were 
no changes in leptin receptor expression on activated CD4+ or CD8+ T-
lymphocytes in blood, expression of the insulin receptor, however, was modestly 
increased on CD4+CD25+ (MFI; 86 ± 3 to 99 ± 5, p<0.01) and CD8+CD25+ 













Figure 5.1. Changes in blood leptin and T-lymphocyte activation before and 
after 3 days of 50% calorie restriction. Changes in a) serum leptin 
concentration, b) percentage of T-lymphocytes expressing CD25 and CD69 
activation markers, and levels of expression of c CD25 and d) CD69 on activated 
CD4+ and CD8+ T-lymphocytes (Mean fluorescence intensity) before and after 3 
days of 50% caloric restriction. Mean ± SEM shown and differences between the 
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5.3.2 Changes in leptin and T-lymphocyte activation in subcutaneous adipose 
tissue 
In the abdominal subcutaneous adipose tissue, resident CD4+ T-lymphocytes 
ranged from 1 – 7 % and CD8+ T-lymphocytes from 1 – 3 % as a percentage of 
total cells present in the SVF. Adipose tissue leptin gene expression and leptin 
secretion ex-vivo showed no significant reduction following 3 days of 50 % 
calorie restriction (Figures 5.2a and b respectively). This corresponded with a lack 
of change in the proportion of activated cells present (Figure 5.2c) and levels 
(MFI) of cell surface expression of activation markers CD25 and CD69 on 
adipose tissue resident CD4+ and CD8+ T-lymphocytes (Figure 5.2d and e).  
 
 
Figure 5.2. Changes in adipose tissue leptin and adipose resident T-
lymphocyte activation before and after 3 days of 50% calorie restriction. 
Changes in adipose tissue a) leptin secretion (n=9) and b) relative leptin gene 
expression (normalised to cyclophilin A and internal housekeeper; n=7), c) 
proportions of activated adipose-resident T-lymphocytes and d) levels of 
expression of d) CD25 and e) CD69 on activated CD4+ and CD8+ T-lymphocytes 
before and after 3 days of 50% caloric restriction. Mean ± SEM shown and 
differences between the two days analysed by two-tailed, Paired t-tests (n=12 
unless otherwise stated).  
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5.3.3 Changes to blood monocytes and adipose tissue resident macrophages 
following calorie restriction 
Blood monocytes and adipose resident macrophages (CD45+CD14+ cells) were 
identified by flow cytometry and, at baseline, represented 3 to 9 % of total cells in 
blood (Figure 5.3a) and 2 to 15 % total cells present in the SVF (Figure 5.3c). 
There were no changes in proportions of either blood monocytes or adipose 
resident macrophages following 3 days of calorie restriction. Blood monocytes 
were examined by flow cytometry for their levels of cell surface expression of 
activation markers CD16 and CD14, and receptors for Leptin (CD295) and insulin 
(CD220). Only a reduction in CD14 expression was identified (Figure 5.3b). On 
adipose tissue resident macrophages, cell surface expression (MFI) of CD14 and 
CD163 were examined, however neither were affected following 3 days of calorie 




















Figure 5.3. Proportions of blood monocytes and adipose tissue resident 
macrophages and their respective properties before and after 3 days of 50% 
calorie restriction. a) Proportions of monocytes as a percentage of total cells in 
blood (PBMCs), b) levels of expression of activation markers (CD14 and CD16) 
and receptors (for leptin and insulin) on blood monocytes, c) proportions of 
macrophages as a percentage of cells in adipose tissue SVF, d) Levels of 
activation markers CD163 and CD14 on adipose tissue resident macrophages 
before and after 3 days of 50% calorie restriction, mean ± SEM shown and 
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5.3.4 Changes in plasma adiponectin and measures of inflammation 
Adiponectin and a number of inflammatory cytokines were measured in the blood 
before and after the 3 days of 50 % calorie restriction. Of those that were detected 
in the blood (shown in Table 5.2), only IL-18 and MCP-1 showed significant 
reductions after calorie restriction and the majority of cytokines remained 
unchanged. 
 
 Pre-diet Post-diet Sig. p-value 
Adiponectin µg/mL 6.65 ± 0.78  6.39 ± 0.69 0.206 
CRP mg/L 1.54 ± 0.44 1.51 ± 0.32 0.914 
IL-6 pg/mL 0.67 ± 0.11 0.75 ± 0.11 0.606 
IL-8 pg/mL 5.61 ± 0.55 5.08 ± 0.25 0.408 
TNFα pg/mL 1.21 ± 0.14 1.14 ± 0.12 0.267 
MIP-1b pg/mL 69.6 ± 7.92   72.1 ± 8.4 0.261 
IL-18 pg/mL 95.8 ± 11.9 88.4 ± 11.8 <0.001 
IP-10 pg/mL 347.0 ± 55.5 340.3 ± 61.5 0.737 
MCP-1 pg/mL 49.8 ± 6.3 43.4 ± 5.2 0.016 
 
Table 5.2. Plasma adiponectin and markers of inflammation before and after 
3 days of 50 % calorie restriction. Mean ± SEM values shown and differences 
between the two days analysed by two-tailed, paired, Student’s t-tests (n=12), p-
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5.3.5 Gene expression and secretion of adipokines from subcutaneous AT 
Changes in a selection of genes related to inflammation and glucose/lipid 
metabolism in adipose tissue were investigated. Data for adipose tissue gene 
expression and secretion are not available for all participants due to the limited 
size of some samples. Priority was given to preparing tissue for analysis of SVF to 
address the main aim of this study with lowest priority given to gene expression 
analysis. Paired samples were available for 9 participants for secretion analysis 
and 7 participants for gene expression analysis. Both adiponectin and IL-6 showed 
a significant modest increase and GLUT4 showed a reduction in expression 3 
days after 50 % calorie restriction (Figure 5.4a). There were, however, no 
significant changes in secretion of any of the adipokines measured from whole 
adipose tissue following calorie restriction (Figure 5.4b). 
 
 
Figure 5.4. Gene expression and secretion changes in whole adipose tissue 
before and after 3 days of 50 % calorie restriction. a) Changes in relative gene 
expression of proteins related to metabolism and inflammatory cytokines within 
adipose tissue. Data presented as mean 2
-∆∆Ct 
± SEM and differences between the 
two days analysed by two-tailed, Paired t-tests, *p<0.05 (n=7). b) Cytokine 
secretion by whole adipose tissue explants cultured for 3h. Mean and SEM values 
shown and differences between the two days analysed by two-tailed, Paired t-
tests, *p<0.05 (n=9). 
 
 




In this study, we demonstrate that 3 days of 50 % calorie restriction reduced leptin 
concentrations in blood and this was temporally associated with a reduction in the 
proportion and levels of activation of blood CD4+CD25+ T-lymphocytes. In 
contrast, however, leptin secretion and gene expression in abdominal 
subcutaneous adipose tissue were not reduced and there was also no change in 
adipose tissue resident T-lymphocyte activation. These respective temporal 
associations with leptin in blood suggest this hormone may play a role in the in-
vivo regulation of immune cell activation, however, the divergent changes in T-
lymphocyte activation in blood and adipose tissue probably indicate that there are 
local tissue-specific responses of immune cells to calorie restriction. This study 
provides further novel insight into adipokine changes at the levels of 
subcutaneous adipose tissue and blood following short term ‘severe’ calorie 
restriction. 
 
5.4.1 Changes in T-lymphocyte activation in blood following acute calorie 
restriction 
The reduction in blood leptin was temporally associated with a reduction in CD4+ 
T-lymphocyte activation in blood. This observation is in-keeping with previous 
work by others showing a dose-dependent effect of leptin on CD4+ T-
lymphocytes activation markers in-vitro (Lord et al., 1998; Martin-Romero et al., 
2000; De Rosa et al., 2007) although no changes in CD8+ T-lymphocyte 
activation were apparent in this study. Whether the reduction in blood leptin was 
the direct cause of this reduction in blood T-lymphocyte activation cannot be 
ascertained from the current study. However, leptin appears to be important in 
signaling whether sufficient energy is available to meet the demands for an 
immune response since leptin deficiency/starvation is associated with 
immunosuppression (Lord et al., 1998; Saucillo et al., 2014). Conversely, in 
obesity, high levels of leptin are implicated in the chronic low-grade inflammation 
observed, for example, via induction of proinflammatory Th1 T-lymphocytes and 
stimulation of inflammatory cytokine production (IL-6, TNFα) in adipose tissue 
(Paz-Filho et al., 2012). With reduced levels of leptin and T-lymphocyte 
activation as observed with 3 days of calorie restriction, it is likely that there 
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would be a blunted immune response to immune challenges (e.g., infection) as is 
the case with more chronic starvation (Lord et al., 1998; Paz-Filho et al., 2012). 
 
The reduction in CD4+ T-lymphocyte activation was specifically observed for 
‘late’ activation marker CD25 (according to both proportion of cells expressing 
CD25 and levels of expression of this activation marker). This CD4+CD25+ T-
lymphocyte population would include activated CD4+ effector cells, such as T-
helper cells (Th1 and Th2) and T-regulatory cells. In-vitro work suggests that a 
reduction in leptin or blocking its action would favour proliferation of T-
regulatory cells with a reduction in Th1 T-lymphocytes (Lord et al., 1998; De 
Rosa et al., 2007). It would have been interesting to see whether such skewing 
had taken place in either blood or adipose tissue if sufficient material had been 
available.  
 
The change in leptin alone may not necessarily be the only factor driving the 
reduced activation of CD4+ T-lymphocytes. Leptin is essential for glucose uptake 
in activated effector T-lymphocytes, thus enabling them to perform their correct 
function when activated (Saucillo et al., 2014). The exception to this is T-
regulatory cells which are more dependent on lipid oxidation (Michalek et al., 
2011). Rather than being directly affected by leptin, the reduced levels of 
activation of CD4+CD25+ lymphocytes may also therefore be secondary to the 
reduced exposure to glucose and/or insulin as a consequence of calorie restriction. 
This is supported by  the finding that insulin enhances levels of Th2 CD4+ T-
lymphocyte proliferation (Viardot et al., 2007). We also observed up-regulation of 
the insulin receptor (CD220), which is typically only up-regulated on activated 
compared to ‘resting’ T-lymphocytes (Viardot et al., 2007). This could instead be 
a mechanism to maximize glucose intake in times of calorie restriction and/or 
result from reduced suppression/up-regulation of insulin signalling pathways 
within T-lymphocytes (Saltiel & Kahn, 2001). 
 
5.4.2 Differing leptin responses in blood and adipose tissue to acute calorie 
restriction 
Despite changes in leptin and T-lymphocyte activation in the blood following 
calorie restriction, there were no corresponding changes in adipose tissue. Based 
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on previous results, a change in T-lymphocyte activation in adipose tissue rather 
than blood may have been expected due to the relationship at baseline specifically 
between adipose tissue resident T-lymphocyte activation and leptin (Chapter 3), 
which indeed also held true even across the smaller and narrower range of 
adiposities included in the present study (see Appendix 5). The corresponding 
lack of response in leptin gene expression and secretion in adipose tissue is also of 
interest. In-keeping with our results, it appears that in times of short term calorie 
restriction/starvation, despite a significant reduction in blood leptin 
concentrations, adipose tissue leptin gene expression continues to reflect levels of 
adiposity (Vidal et al., 1996; Liu et al., 2003). Indeed, much longer periods of 
calorie restriction (e.g. >3 weeks) and weight loss are required to elicit changes in 
leptin gene expression (Bastard et al., 1999; Behre et al., 2007). In times of acute 
calorie restriction, the reduction in blood leptin serves as a signal to the brain and 
all systems in the body that there is an energy insufficiency irrespective of 
adiposity (Flier, 2004). It is not clear where or how this reduction in blood leptin 
occurs, and our results suggest there is no change in the secretion of leptin from 
adipose tissue, so one or a combination of specific post-translational 
modifications, clearance or degradation affecting half-life may be responsible for 
the reduced levels of leptin in blood. If the fall in blood leptin is the result of 
accelerated clearance/uptake or degradation, this could go some way to explain 
why there are no changes in adipose tissue T-lymphocyte activation despite an 
initial relationship at baseline. 
 
It is also possible that other adipose tissue depots may respond differently to the 
abdominal subcutaneous adipose depot included in the present study, for example 
visceral and lower body subcutaneous adipose tissue depots have very different 
properties, and the latter depot will represent a significant proportion of total 
adipose tissue mass (Manolopoulos et al., 2010). It is important to highlight that 
the media used for the adipose tissue culture in our ex-vivo model was not 
supplemented with glucose/insulin or other potential stimuli of leptin secretion 
from adipocytes (Cammisotto et al., 2005). This was a deliberate decision but it is 
possible that this may have produced different results to those had the adipose 
tissue remained in situ. Future studies could therefore benefit from measuring 
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arterio-venous differences to see if the total output from the adipose tissue is 
reduced and whether there are depot-specific effects.  
 
To further complicate matters, leptin secretion is pulsatile and has a diurnal 
pattern of secretion with a peak at night. Leptin can be affected by sleep patterns 
which are difficult to control even when scheduling follow up testing for the same 
time of day (Mantzoros et al., 2011). Furthermore, obese individuals may also 
show a lower percentage reduction compared to lean individuals during calorie 
restriction (Haluzik et al., 2001). These potential sources of variability may 
therefore have affected the responses observed in adipose tissue to the calorie 
restriction. Thus, a combination of factors could be responsible for the wide range 
of reductions in blood leptin (3 – 64 %), and divergent responses in blood and 
adipose tissue.  
 
The absence of changes in levels of activation on adipose tissue resident T-
lymphocytes may also be a reflection of the relative proportions of effector and T-
regulatory cells making up the CD4+CD25+ population. We previously found an 
increase in FOXP3 transcripts with abdominal obesity suggesting an increase in 
T-regulatory cells (Chapter 3). Since the preferred fuel of T-regulatory cells is 
lipid  (Michalek et al., 2011; Saucillo et al., 2014), these cells, if indeed present in 
increased number in adipose tissue may not be so sensitive to the reduction in 
glucose availability compared to other effector CD4+ T-lymphocytes.  
 
5.4.3 Adipose tissue responses following acute caloric restriction 
Several findings in the present study support the notion that a starvation-type 
response has been induced following 3 days of 50 % calorie restriction 
characterised by a profound reduction in triglycerides and an increase in NEFA 
seen in the blood. Adipose tissue gene expression of GLUT4 was reduced 
following calorie restriction as occurs in human skeletal muscle during starvation 
(Norton et al., 2007). Following calorie restriction, adipose tissue gene expression 
of adiponectin and IL-6 were increased, however, there were no corresponding 
changes in blood concentrations or secretion of either of these parameters by 
adipose tissue explants. The increase in adiponectin gene expression, but not 
serum levels following acute calorie restriction is consistent with findings from 
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Liu et al. (2003) and serum changes may not be expected until greater weight loss 
(>5 % body weight) is achieved (Varady et al., 2009). In the context of obesity, 
IL-6 is often regarded as a pro-inflammatory cytokine since blood concentrations 
and adipose tissue gene expression are elevated with increased levels of obesity 
(Vozarova et al., 2001; Weisberg et al., 2003) and are reduced following longer 
term calorie restriction (Bastard et al., 2000). IL-6 can have a variety of effects in 
adipose tissue such as stimulation of lipolysis (van Hall et al., 2003), affecting 
tissue remodelling (Ohsumi et al., 1994) and inducing insulin resistance in 
adipocytes (Rotter et al., 2003). Evidence also suggests that IL-6 can have anti-
inflammatory properties (Scheller et al., 2011). In the absence of a corresponding 
increase in secretion, however, it is difficult to determine whether this increase in 
IL-6 gene expression is meaningful or simply useful as a marker of a response to 
acute calorie restriction.  
 
5.4.4 Conclusions 
Short term severe calorie restriction causes a reduction in serum leptin which was 
temporally associated with a reduction in the number and levels of activation of 
CD4+CD25+ T-lymphocytes in the blood. This reduction in T-lymphocyte 
activation in blood seems appropriate given the limited nutrient availability, and 
serum leptin is likely to play an important role in conveying this information to 
the immune system. This confirms previous results seen in-vitro and in animal 
models. However, within subcutaneous adipose tissue there was no such reduction 
in either leptin or T-lymphocyte activation. These discrepancies may be due to 
differing responses of different tissues to calorie restriction and/or may depend on 













Effects of diet and activity modification on T-lymphocytes 
in adipose tissue  
 
6.1 Introduction 
Obesity, caused by adipose tissue expansion, is a major risk factor for type 2 
diabetes and the latest Health Survey for England figures (2011) suggest that 
approximately one third of overweight or obese adults exhibit pre-diabetes 
(Mainous et al., 2014). In addition to adipocytes, adipose tissue contains a whole 
range of other cell types which form the stromavascular fraction (SVF), including 
progenitor cells, endothelial cells and a range of immune cells (Weisberg et al., 
2003; Xu et al., 2003; Curat et al., 2004; Bourlier et al., 2008; Duffaut et al., 
2009a). Current research suggests that the relative proportions of different 
immune cell populations and interactions between the different cell types within 
adipose tissue may be important in the development of type 2 diabetes. In 
particular, relationships have been proposed between an increased number and 
proportion of macrophages in adipose tissue and insulin resistance (Xu et al., 
2003; Apovian et al., 2008), as also demonstrated in Chapter 3, where the 
proportion of macrophages positively correlated with HOMA-IR. The role of T-
lymphocytes in the development of insulin resistance is less clear. In animal 
models, T-lymphocytes have been shown to increase prior to the onset of insulin 
resistance and infiltration of macrophages (Kintscher et al., 2008; Nishimura et 
al., 2009). In humans, differing populations and properties of T-lymphocytes have 
been identified depending on levels of adiposity and insulin resistance, however, 
results have not always been consistent. As suggested in Chapter 3 and by Zeyda 
et al. (2011) there may be an increase in anti-inflammatory T-lymphocytes such 
as T-regulatory cells with increasing levels of adiposity to limit/regulate adipose 
tissue inflammation. In obese participants with impaired glucose tolerance, 
however, T-lymphocytes may be skewed towards a proinflammatory Th1 
phenotype (Goossens et al., 2012). Another recent study, however, suggests there 
may be an increase in Th17 T-lymphocytes in ‘metabolically abnormal’ obese 
participants (Fabbrini et al., 2013). These discrepancies may be partly due to the 
different study populations and control groups used for comparison, so it is 
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currently difficult to understand relationships between levels of glucose control 
and T-lymphocytes in human adipose tissue. One way to further understand the 
roles of T-lymphocytes is to compare people with different levels of glucose 
control with similar magnitude of adiposity. An additional way to investigate the 
effects of glucose control on T-lymphocytes is to experimentally manipulate 
glucose control.  
 
Various acute diet and lifestyle changes have been shown to rapidly improve 
insulin resistance and sensitivity, including very low calorie diets, and low 
carbohydrate diets, either alone or in combination with increased levels of activity 
(Clement et al., 2004; Yokoyama et al., 2004; Boden et al., 2005). However, it 
will be important to avoid a severe calorie deficit and starvation-type response, as 
observed in Chapter 5, since this may mask the effects of manipulating glucose 
control. There are, however, diet and activity modification strategies that can be 
used to rapidly improve glucose control as described below. 
 
One way to manipulate systemic and tissue glucose concentrations is to change 
the type of carbohydrate according to glycaemic index (GI) and glucose load 
(GL). These are systems for classifying carbohydrates based on their relative 
effect on postprandial blood glucose (Jenkins et al., 1981), with GL taking into 
account portion sizes (Willett et al., 2002). Iso-caloric low GI/GL diets can reduce 
postprandial glucose and insulin compared to high GI/GL over the course of a day 
in a laboratory setting (Liu et al., 2012).  Further, they are capable of reducing 
fasting and postprandial glucose responses in free-living individuals with normal 
glucose tolerance and type 2 diabetes after just 1 week (Brynes A. 2005; Brynes 
A. 2003). Diet modifications to include lower GI/GL foods are therefore included 
in recommendations by Diabetes UK for people with type 2 diabetes and impaired 
glucose tolerance/fasting glycaemia (Diabetes UK, 2013). In the present study, it 
was anticipated that the manipulation of GI/GL would improve systemic 
(including adipose tissue) glucose exposure in people with and without IGT. 
 
Another method for improving glucose control that has attracted recent interest is 
the introduction of low/moderate intensity ‘activity breaks’ throughout the day to 
reduce bouts of prolonged inactivity (Dunstan et al., 2012; Latouche et al., 2013; 
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Peddie et al., 2013). These activity breaks are thought to improve glucose control 
by altering gene expression of proteins involved in carbohydrate metabolism in 
skeletal muscle, including those involved in glucose transport (GLUT4) (Latouche 
et al., 2013). The addition of increased regular activity breaks could enhance 
improvements in glucose control if used alongside low GI/GL modifications to 
diet, thereby serving as a means of testing the effects of improved glucose control 
on T-lymphocyte activation in adipose tissue. 
 
The main aim of this study was to determine whether there are important 
differences in adipose tissue lymphocyte populations and inflammatory properties 
between people with normal and impaired glucose tolerance who are well 
matched in terms of adiposity. Additionally, we aimed to determine whether a 
reduction in total glucose exposure brought about by diet and lifestyle 
modifications can reduce T-lymphocyte activation in blood and adipose tissue and 
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6.2 Materials and Methods 
6.2.1 Experimental design 
A total of 19 abdominally overweight/obese males and post-menopausal females 
aged between 45–65 years with a waist circumference >94 cm, or >80 cm 
respectively, were recruited. Following a preliminary screen, participants were 
distributed between 2 groups with either normal glucose tolerance (NGT) or 
impaired glucose tolerance (IGT); based on the results of an oral glucose tolerance 
test (OGTT). Participants were recruited from the local community following 
ethical approval from the South West, Frenchay NHS Research Ethics Committee 
(REC Reference: 13/SW/0267). The study also received support from the Primary 
Care Research Network (Ref: 139443), which allowed GP Practices to perform 
database searches to help identify potentially eligible participants to whom letters 
could be sent with information about the study. After a 1 week period in which 
normal diet, daily activities and continuous glucose levels were monitored, 
participants modified their normal diet by substituting high GI for low GI foods 
and incorporating 15 additional activity breaks, each lasting 2 minutes, to their 
daily routine for 10 days to help reduce postprandial glucose levels. Participants 
attended the laboratory before and immediately after this diet and activity 
modification period for analysis of immune cell activation and measures of 
inflammation and metabolism in blood and adipose tissue. An OGTT was also 
performed at both laboratory visits to assess any changes in glucose metabolism 
following the diet and activity modification period. 
 
6.2.2 Participants 
Participants were abdominally overweight with waist circumference >94 cm 
(males) or >80 cm (females) (Lean et al., 1995), and reported being weight stable 
for more than 3 months (no change in weight +/- 3 %) (Stevens et al., 2006). 
Individuals were excluded from participation if they smoked, had personal history 
of/existing cardiovascular disease or diabetes or were taking medications that may 
influence lipid or carbohydrate metabolism or immune system function. 
Participants were also required to be sedentary i.e. not performing >150 
minutes/week moderate intensity exercise for 3 months before the study since 
regular exercise can affect insulin sensitivity and therefore potential responses to 
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the new lifestyle modifications in this study may be reduced (Latouche et al., 
2013). This was assessed using the health screen questionnaire (Appendix 1). 
 
6.2.2.1 Preliminary screen for eligibility 
An OGTT was performed to determine into which group participants would be 
placed. NGT was defined by a plasma glucose concentration <7.8 mmol/L at 2 
hours following a 75 g glucose drink. IGT was defined by a plasma glucose 
concentration >7.8 mmol/L but <11.1 mmol/L at 2 hours post 75 g glucose drink. 
Individuals would not be eligible to participate if their plasma glucose 
concentration was >11.1 mmol/L and would be advised to seek advice from their 
General Practitioner. (Letters were sent to all participants’ GPs to inform them of 
the results). Glucose values at 2 hours can show great intra-individual variation 
(Christophi et al., 2013). An average glucose concentration at 2 hours post 75 g 
glucose drink was therefore taken from the initial screen and the baseline OGTT 
(first main trial before the intervention) to confirm into which group the 
participants would be placed. No participants with known IGT identified in 
searches performed by the GP practices came forward to participate; therefore, all 
participants in this study with IGT were identified by the preliminary screen. 
Screening/recruitment continued until there were approximately equal numbers of 
participants in both groups. 
 
6.2.3 Sample size determination 
There are no data regarding changes in T-lymphocyte activation in human adipose 
tissue in response to diet and exercise modification. However, we observed 
significant differences in T-lymphocyte activation between lean and obese 
individuals in our previous study (Chapter 3). A short period of adhering to a low-
GI diet can reduce fasting blood glucose levels in patients with type 2 diabetes 
from 8.0 (±1.0) mmol/L to 5.3 (±0.8) mmol/L and is therefore sufficient to reduce 
typical values for an obese person to those of a lean person (Brynes et al., 2003). 
With the additional inclusion of activity breaks, an improvement in glucose 
control of at least this magnitude would therefore be anticipated. Thus, we 
anticipate a similar reduction in T-lymphocyte activation in response to diet and 
activity modification. Our recent data indicate that the CD69 mean fluorescence 
intensity (MFI) for lean CD4CD69 cells is 288 (+/45 SD) and obese is 411 (+/31 
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SD) with an effect size of 2.98. Taking into account our range of activation 
markers, with 95 % power and 5 % alpha, an average of 11 subjects in each group 
would be required to detect a statistically significant change in T-lymphocyte 
activation in adipose tissue in response to diet and activity modification. We 
therefore aimed to recruit 11 participants in each group (NGT and IGT). 




 NGT  IGT p-value 
Males/Females (n) 2/6  2/9  
Age (y) 56 ± 2  58 ± 1 0.415 
Height (m) 1.64 ± 0.04  1.65 ± 1.16 0.868 
BMI (kg/m2) 32.9 ± 1.2 
 
34.2 ± 1.4 0.486 
Waist circumference (cm) 102.2 ± 3.6  106.8 ± 2.9 0.338 
Hip circumference (cm) 116.4 ± 3.2  117.5 ± 3.3 0.803 
FMI (kg/m2) 14.2 ± 1.3  14.8 ± 1.2 0.750 
L1-L4 body fat (%) 43 ± 2  44 ± 2 0.740 
RMR (kcal/day) 1404 ± 41  1510 ± 63 0.178 
Systolic blood pressure (mm 
Hg)1 
122 ± 6  131 ± 6 0.338 
Diastolic blood pressure 
(mm Hg)1 
80 ± 3  83 ± 4 0.631 
 
Table 6.1. Descriptive statistics of participants classified according to either 
NGT (n=8) or IGT (n=11) as defined using an OGTT. Mean ± SEM values 
shown and statistical differences between groups analysed using independent t-
tests, p-values shown. Abbreviations used; BMI = body mass index, FMI = fat 
mass index, L1-L4 = central fat mass estimated between Lumbar regions 1-4 
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6.2.4 Habitual diet, activity and continuous glucose monitoring 
For 1 week, subjects were fitted with a combined heart rate and accelerometry 
monitor (Actiheart™) to determine habitual total energy expenditure (TEE) and 
physical activity levels (PAL) and were asked to record a corresponding diary of 
their physical activity during this period to aid its interpretation (General methods, 
2.5). TEE was adjusted for measured resting metabolic rate (RMR) as described in 
General methods, 2.6, which was determined on the first main trial day.  
 
Participants received a diary and a set of digital weighing scales to record their 
food and fluid intake (General methods 2.7). Diet analysis to estimate 
participants’ energy intake and macronutrient composition was performed using 
Nutritics diet analysis software (Nutritics Ltd, Ireland). The weighted mean for GI 
and the total GL were determined using values in the DIOGENES database 
(Aston et al., 2010). Participants were asked to maintain normal lifestyle 
habits/routines during this period and were not initially told that the activity 
monitoring and food diaries would be used to determine the diet during the 10 day 
diet modification period so as to avoid influencing their habitual routines. The 
participants’ individual diet records were used to identify high GI foods that 
should be swapped for low GI foods for the diet and activity modification period. 
 
Participants were also fitted with a continuous glucose monitor (CGMS; iPro™2, 
Medtronic, MiniMed, USA) to measure interstitial glucose levels in abdominal 
subcutaneous adipose tissue during the monitoring period. An electrochemical 
glucose oxidase sensor (Enlite®, Medtronic, MiniMed) was inserted using an 
automated insertion device (Enlite Serter™, Medtronic, MiniMed) and the 
monitor connected and secured in place with an adhesive plaster (IV3000, Smith 
and Nephew, UK). The monitor was worn for 6 days allowing the first 5 full days 
(midnight-midnight) to be recorded during the monitoring week. Participants were 
instructed to obtain four finger prick samples for glucose per day prior to meals 
using a point of care glucose monitoring device (XT Contour blood glucose 
meter, Beyer), and these were used to retrospectively calibrate the CGMS 
readings. The display of the glucose meter was covered to ensure that participant 
eating habits were not influenced by their perception of the blood glucose 
readings. Analysis was performed using the CareLink™ iPro™ Therapy 
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Management Software for Diabetes (Medtronic, MiniMed) for average daily 
glucose mean, standard deviation, peak and duration above 7.8 mmol/L. 
 
6.2.5 Diet and activity modification protocol 
For 10 consecutive days, participants were given instructions to consume a low 
GI/GL diet and to incorporate 15 activity breaks lasting 2 minutes throughout 
each day. During this period, participants wore an Actiheart for the full 10 days to 
measure changes in activity levels and assess compliance, and were fitted with a 
CGMS for 5 of the final 6 days of the intervention to measure any changes in 
tissue glucose concentrations as a result of the intervention. 
 
In order to reduce dietary GI, participants were given their diets from the 
monitoring week with high GI food items highlighted. Participants were asked to 
replicate entire days, but to replace highlighted high GI foods with the same 
weight of lower GI foods and with no additional or higher calorie food items. 
Specifically they were instructed to swap the main carbohydrate at every meal 
during each of the 10 days; any cereals were to be swapped to All Bran (Kellogs), 
any breads to a soya and linseed bread (Vogels) and potatoes/rice/pizza/etc to 
either whole-wheat pasta or noodles (Sainsburys). Participants were given 
supplies of these food items to be swapped into the diet to help with compliance. 
This method had been successful in reducing fasting and postprandial responses in 
‘healthy’ individuals and those with type 2 diabetes (Brynes et al., 2003; Brynes 
et al., 2005). Additional advice, adapted from www.diabetes.org.uk, was provided 
for information on further food swaps that could be made (but were not essential) 
to help reduce GI/GL, such as exchanging sweets/biscuits for chocolate, 
snacks/puddings for yogurt, dried fruit for fresh fruit, etc. For the first 5 days of 
the modification period participants recorded which food swaps had been made 
and, for the final 5 days, made a detailed record of food and fluid intake to 
interpret alongside the CGMS data. 
 
In addition to the diet modification, participants were instructed to incorporate 15 
‘activity breaks’, lasting 2 minutes during each of the 10 days. Due to the age 
range of the participants and range of physical capabilities, the activity intensity 
was self-selected, and participants were instructed that these could be something 
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as simple as a brisk level walk or walking up and down some stairs continuously 
for 2 minutes (Thompson et al., 2012). Importantly they were instructed that they 
did not need to do anything high impact or anything that would cause pain. 
Regarding the timing of these activity breaks, participants were instructed to take 
one break before consuming each meal during the day, with another 2 minute 
activity break 30-45 minutes after each meal, and a third break a further 30-45 
minutes later to coincide with raised postprandial glucose vales. The remaining 6 
activity breaks were to be spread evenly throughout the day and participants were 
to ensure that they never spent more than 90 minutes sat in any one place at any 
time throughout each day. The breaks had to be additional to usual activity and if 
a ‘usual’ activity coincided with a scheduled activity break, this would not be 
counted and they should schedule another break later in the day. Furthermore, 
participants were advised that fewer breaks lasting for a longer time would not 
count, even if the total duration added up to 30 minutes. Participants recorded the 
timing of each activity break during each of the 10 days in a chart found in the 
new diary. Regular activity breaks have been shown to be as effective at reducing 
blood glucose as 30 minutes continuous physical activity (Latouche et al., 2013; 
Peddie et al., 2013) and it was hoped that these alongside the diet modifications 
would result in the maximum improvement to postprandial glucose concentrations 
to reduce glucose/insulin exposure to the immune cells in blood and adipose 
tissue, whilst avoiding a starvation type response as observed in Chapter 4. 
 
6.2.6 Pre-trial requirements 
Participants were asked to refrain from performing any strenuous physical activity 
and consuming caffeine/alcohol for 48 and 24 hrs before trial days, respectively. 
Trial days were scheduled so participants had been free from any self-reported 
illness for a minimum of 2 weeks in order to reduce immune system disturbance.  
 
6.2.7 Trial days 
On both main trial days participants arrived at the Physiology Resting Laboratory 
in the morning following a 10hr fast and after consuming 1 pint of water upon 
waking. To minimise variation in timing of sample collection, participants arrived 
in the lab at the same time on both trial days (approximately 8.30 am). 
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Participants were also asked to wear the same clothes as on the main trial day 1 to 
minimise weight variations due to clothing differences. 
 
6.2.8 Body composition analysis 
Measurements of height, waist circumferences and body mass (post- void using a 
digital balance (TANITA corp. Japan)) were determined on both trial days. 
Participants’ body composition was characterised at baseline using dual energy X-
ray absorptiometry (General Methods, 2.4).  
 
6.2.9 Blood and adipose sampling 
A cannula was inserted into an antecubital forearm vein and baseline blood 
sample(s) taken for separation into plasma and serum for analysis of 
metabolic/inflammatory markers and isolation of peripheral blood mononuclear 
cells (PBMCs) as described in General methods, 2.9-2.11. A subcutaneous 
adipose tissue sample (~1 g) was then collected approximately 5 cm lateral to the 
umbilicus using a needle aspiration technique (General methods, 2.13) and 
approximately 200mg whole adipose tissue was processed for gene expression 
analysis (General Methods, 2.19). The remaining tissue was used for preparation 
of the SVF according to the protocol described in General Methods, 2.15.  An 
OGTT was then performed as described in General Methods, 2.12. 
 
6.2.10 Analysis of SVF and PBMCs by flow cytometry 
Flow cytometry (using the FACSverse, Beckton Dickenson) was used to identify 
CD4+/CD8+ T-lymphocytes (CD45+CD3+ cells) and macrophages/monocytes 
(CD45+CD14 +) in SVF and PBMCs together with respective levels of activation 
using protocols and antibodies detailed in General Methods, 2.16-2.18.  
 
6.2.11 RT-PCR 
Total RNA was extracted from whole adipose tissue, quantified and 2 µg reverse 
transcribed to cDNA as described in General Methods, 2.19. Real-time PCR was 
performed using a StepOneTM (Applied Biosystems) using pre-designed primers 
and probes obtained from Applied Biosystems for measurement of macrophages 
(CD68), T-lymphocyte populations and subsets (CD3G, CD4, CD8A, FOXP3, 
GATA3 and TBX21) and for expression of various metabolic and inflammatory 
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markers, further details of these are available in General Methods, 2.19. 
Peptidylpropyl isomerase A (PPIA) was used as an endogenous control (Neville et 
al., 2011). Results were analysed using the comparative Ct method and expression 
normalized to an internal calibrator specific to each gene using the formula 2- 
∆∆CT; where ∆∆CT is [(CT gene of interest – CT PPIA) – lowest ∆CT for gene of 
interest] and statistical analysis performed on LN transformed values (Livak & 
Schmittgen, 2001). 
 
6.2.12 Biochemical analysis  
Plasma glucose, serum total cholesterol, HDL cholesterol, triglycerides and CRP 
concentration and ALT activity were measured according to the methods 
described in General Methods, 2.10. This analysis was kindly performed by 
Enhad Chowdhury. Serum insulin was measured by ELISA (Mercodia). 
 
6.2.13 Statistical analysis 
All data are presented as mean and standard error of the mean (SEM). 
Comparisons of participant descriptive statistics available only at baseline, were 
made between the 2 groups using independent Student’s T-tests. Total area under 
the curve (AUC), homeostasis model assessment for insulin resistance (HOMA-
IR) and insulin sensitivity index (ISI comp/Matsuda index) were calculated using 
formulae described in General Methods, 2.12. Comparisons of repeated 
measurements of baseline blood and adipose tissue measures from both groups 
before and after the intervention were made using repeated measures, 2-way 
mixed-model ANOVAs irrespective of normality (Maxwell and Delaney, 1990, 
p109). A repeated measures 3-way mixed-model ANOVA was used to examine 
differences in glucose and insulin responses between the 2 groups at baseline and 
follow up and the nature of their responses. The Greenhouse–Geisser correction 
was applied to intra-individual contrasts where ε < 0.75, and for less severe 
asphericity the Huynh–Feldt correction was selected (Atkinson, 2002). Where the 
3-way mixed-model ANOVAs identified significant interactions, multiple t-tests 
were applied to identify which specific time points were different from baseline 
and to identify the location of any variance between groups at level time points, 
with both methods subject to a Holm–Bonferroni correction (Atkinson, 2002). † 
denotes a main effect of group (i.e. glucose tolerance status), * denotes a main 
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effect of trial (i.e. baseline vs. follow-up) and # denotes an interaction effect 
(group x trial). Statistical analysis was performed using Excel 2010 (Microsoft) 
and SPSS version 20. A p-value of p<0.05 was considered to be statistically 



































6.3.1 Changes to activity, diet and continuous glucose monitoring during the 
intervention period 
Measures of activity, diet composition and continuous glucose monitoring from 
the 1 week monitoring of habitual lifestyle are shown in Table 6.2 together with 
changes evoked during the 10 day diet and activity modification period. The 
increases in TEE and PAL during the diet and activity modification period were 
close to significance (p=0.069, F=3.808 and p=0.070, F=3.778 respectively) and 
both groups increased their activity by a similar number of calories (no interaction 
effects identified for either TEE; p=0.713 or PAL; p=0.683) with both groups 
reporting a similar average number of daily activity breaks (p=0.357).   
 
There were no differences in dietary calorie and macronutrient intake between 
groups during the monitoring period. During the intervention period, participants 
in both groups successfully reduced the average daily GI (p<0.001, F=135) and 
total GL (p<0.001, F=104) of their diets. Additionally, participants unexpectedly 
reduced total calorie intake (p<0.001, F=55.00) with carbohydrate (p<0.001, 
F=71.77), fat (p<0.001, F=26.86) and sugar intake (p<0.001, F=44.05) being 
reduced by a similar amount in both groups.  
 
For 7 participants in each group, CGMS data was available for both monitoring 
periods. The data set was incomplete either due to failure of participants to 
perform the finger-prick measurements to calibrate the CGMS monitor or, for 2 
participants, due to failure of sensor insertion. CGMS did not detect any 
differences between the groups when examining average daily glucose mean, SD, 
peak and duration that glucose remained above 7.8 mmol/L. The increases in 
TEE/PAL and reduced GI/GL and calorie intake, did not lead to an improvement 
in glucose control assessed using CGMS during the diet and activity modification 
period (compared to the monitoring week) according to measures of mean 
glucose, peak glucose or duration that blood glucose remained above 7.8 mmol/L 
in either group. The reduction in standard deviation during the intervention period 
compared to the monitoring week was close to significance across both groups 
(trial; p=0.096, F=3.27).   
 




 NGT IGT  2-way 
Anova 
Effects  Baseline Intervention Baseline Intervention 
Measures of activity      
TEE kcal/day 2492 ± 153 2563 ± 116 2469 ± 102 2574 ± 125  
PAL 1.79 ± 0.08 1.84 ± 0.06 1.65 ± 0.06 1.72 ± 0.08  
Reported activity breaks  14 ± 1  13 ± 3  
 
Measures of dietary intake1 
    
Total kcal 2099 ± 159 1495 ± 172 2289 ± 108 1469 ± 92 * 
Carbohydrate (g) 258 ± 23 161 ± 23 249 ± 18 135 ± 6 * 
Fibre (g) 19 ± 2 25 ± 4 23 ± 2 24 ± 2  
Fats (g) 84 ± 8 59 ± 8 93 ± 8 61 ± 7 * 
Protein (g) 83 ± 4 82 ± 8 93 ± 3 82 ± 3  
Sugars (g) 125 ± 17 87 ± 22 99 ± 9 64 ± 6 * 
Total GL 147 ± 12  76 ± 16 132 ± 8 64 ± 4 * 
Average GI 58 ± 1 48 ± 1 58 ± 1 49 ± 1 * 
 
Continuous glucose monitoring (n=7 in each group) 
   
Mean glucose (mmol/L) 5.7 ± 0.1 5.4 ± 0.3 6.2 ± 0.2 6.0 ± 0.2  
SD glucose 0.67 ± 0.07 0.57 ± 0.08 0.79 ± 0.08 0.69 ± 0.09  
Peak glucose mmol/L 7.50 ± 0.21 7.49 ± 0.47 8.36 ± 0.46 7.92 ± 0.42  
Duration >7.8 mmol/L 
 (% of day) 
1.3 ± 0.6 2.6 ± 2.0 6.9 ±2.7 4.3 ± 2.2  
 
Table 6.2. Measures of activity, diet composition and continuous glucose 
monitoring from the 1 week monitoring of habitual lifestyle and changes 
evoked during the 10 day diet and activity modification period in 
participants with NGT (n=8) and IGT (n=11). Mean ± SEM values shown. 
Results compared using 2-way mixed-model ANOVA; * denotes a main effect of 
trial (i.e. baseline vs. follow-up); p <0.05. 1 note NGT n=7 and IGT n=9 due to 
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6.3.2 Changes in anthropometrics and clinical measures of glucose control 
Baseline and follow-up anthropometric measurements after the 10 day diet and 
activity modification period, together with both fasting and ‘summary’ measures 
of glucose and insulin responses for participants with NGT and IGT are shown in 
Table 6.3. All participants showed a modest reduction in weight (p<0.001, 
F=75.2) and measurement of hip circumference (p=0.037, F=5.101) following the 
diet and activity modification period. Participants in the IGT group had 
significantly elevated fasting insulin (p=0.043, F=4.83), fasting glucose (p<0.001, 
F=19.14) and HOMA-IR (p=0.019, F=6.8) compared to those with NGT. At 
follow up, the reduction in fasting insulin was close to significant (p=0.081, 
F=3.46). In response to the OGTT, participants with IGT showed elevated glucose 
at 2 hours (p=0.002, F=14.69) which was reduced in both groups at follow-up 
(p=0.037, F=5.26). Matsuda-ISI was reduced in IGT compared to NGT 
participants (p=0.003, F=12.96) and was improved in both groups after the diet 
and activity modification period (p=0.014, F=7.77). Insulin at 2 hours (p=0.018, 
F=7.05), glucose peak (p=0.001, F=16.05) and insulin peak (p=0.026, F=6.10) 
were all elevated with IGT and showed no changes in either group after the diet 
and activity modification period. 
 
The temporal glucose response and t-AUC following the OGTT for the NGT and 
IGT groups before and after the 10 day diet and activity modification period and 
are shown in Figures 6.1a and b respectively. The corresponding insulin responses 
and t-AUC are shown for the normal and impaired tolerance groups in Figure 6.1c 
and d respectively. Both parameters were increased in the IGT group compared to 
NGT (insulin p=0.023, F=6.44, glucose p<0.001, F=31.76) and remained elevated 
for longer in the IGT group (timepoint x group interaction, p=0.038, F=3.78 for 
insulin and p=0.001 and F=7.07 for glucose). 
 
For the temporal glucose response the trial x group interaction was close to 
significant (p=0.064, F=4.01) and total area under the curve interaction was also 












Baseline Follow-up Baseline Follow-up 
 
Anthropometrics 
    
Mass (kg) 88.7 ± 4.3 87.2 ± 4.3 92.9 ± 3.9 91.6 ± 4.0 *  
Waist circumference  (cm) 102.2 ± 3.6 101.5 ± 3.6 106.8 ± 2.9 106.7 ± 2.9   
Hip circ. (cm) 116.4 ± 3.2 115.7 ± 3.4 117.5 ± 3.3 116.4 ± 3.4 *  
 
Blood measures of glucose metabolism 
  
 
Fasting Insulin (pmol/L) 42 ± 7 37 ± 9 71 ± 10 62 ± 11 †  
Fasting glucose (mmol/L) 5.34 ± 0.12 5.32 ± 0.12 6.26 ± 0.18 6.27 ± 0.17 † 
Glucose at 2h (mmol/L)1 6.52 ± 0.27 6.28 ± 0.39 9.29 ± 0.38 8.04 ± 0.61 † * 
Insulin at 2h (pmol/L)1 311 ± 68 216 ± 64 1026 ± 197 797 ± 229 † 
HOMA-IR 1.66 ± 0.24 1.42 ± 0.34 3.28 ± 0.42 2.89 ± 0.53 † 
Matsuda-ISI1 5.34 ± 0.81 7.66 ± 1.73 2.14 ± 0.24 2.71 ± 0.33 † * 
Glucose peak (mmol/L)1 8.73 ± 0.44 9.28 ± 0.48 12.84 ± 0.71 12.31 ± 0.72 † 
Insulin peak (pmol/L)1 610 ± 101 459 ± 117 1264 ± 207 1224 ± 277 † 
 
Table 6.3. Anthropometric data and both fasting and summary statistics for 
glucose and insulin during the OGTT in NGT (n=8) and IGT (n=10) 
participants before and after the 10 day diet and activity modification period.  
Mean ± SEM values shown. Results compared using 2-way mixed-model 
ANOVA; † denotes a main effect of group (i.e. glucose tolerance status) and * 
denotes a main effect of trial (i.e. baseline vs. follow-up); p <0.05. 1n=7 NGT and 
10 IGT due to incomplete data. 
 





Figure 6.1. Glucose and insulin responses following a 2h oral glucose 
tolerance test in NGT (n=7) and IGT (n=10) participants before and after the 
10 day diet and activity modification period.  a) glycaemic responses, b) total 
area under the curve for glucose, c) insulinaemic responses and d) total area under 
the curve for insulin in NGT and IGT participants before and after the 10 day diet 
and activity modification period. Mean ± SEM values shown. Results compared 
using 2-way or 3-way mixed-model ANOVA; † denotes a main effect of group 
(i.e. glucose tolerance status) and * denotes a main effect of timepoint (i.e. 
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6.3.3 Changes in blood measures of metabolic and cardiovascular risk 
Clinical blood measures of metabolic health and cardiovascular risk were 
measured before and after the 10 day diet and activity modification period and are 
compared between NGT and IGT participants in Table 6.4. Across both groups 
there was a significant reduction in Total-Cholesterol (p<0.001, F=32.701), HDL-
Cholesterol (p=0.006, F=10.239), LDL-Cholesterol (p=0.012, F=8.196) and 
triglycerides (p=0.002, F=14.91). There were no main effects of group for any of 
these 4 parameters and only HDL-Cholesterol showed a significant interaction 
effect (p=0.050, F=4.553). NEFA was significantly higher in the IGT group 
(p=0.006, F=10.15) and was increased in both groups in the follow-up trial 
(p=0.032, F=5.623). ALT showed no main effect of group (p=0.454), however a 
significant interaction effect was found (group x trial; p=0.050, F=4.404). 
Concentrations of CRP were not different between groups and did not show any 
response in either group to the intervention.  
 
 
NGT IGT 2-way 
Anova 
Effects  
Baseline Follow-up Baseline Follow-up 
Total Cholesterol 
(mmol/L) 
5.63 ± 0.36 5.03 ± 0.35 5.60 ± 0.21 5.18 ± 0.24 * 
HDL Cholesterol 
(mmol/L) 
1.34 ± 0.11 1.32 ± 0.12 1.30 ± 0.05 1.20 ± 0.05 * # 
LDL Cholesterol 
(mmol/L) 
3.63 ± 0.30 3.29 ± 0.33 3.53 ± 0.21 3.39 ± 0.20 * 
Triglycerides 
(mmol/L) 
1.45 ± 0.29 0.90 ± 0.15 1.69 ± 0.20 1.30 ± 0.19 * 
NEFA (mmol/L) 0.47 ± 0.05 0.62 ± 0.08 0.73 ± 0.05 0.83 ± 0.06 † * 
ALT IU/L 32.5 ± 6.4 23.1 ± 2.8 31.0 ± 3.9 33.5 ± 4.4 # 
CRP (mg/L) 1.86 ± 0.35 1.96 ± 0.39 2.86 ± 0.79 3.15 ± 0.88  
 
Table 6.4. Fasting blood measures of metabolic and cardiovascular risk 
before and after the 10 day intervention in participants with NGT (n=7) and 
IGT (n=10). Mean ± SEM values shown. Results compared using a 2-way mixed 
model ANOVA; † denotes a main effect of group (i.e. glucose tolerance status), * 
denotes a main effect of trial (i.e. baseline vs. follow-up) and # denotes in 
interaction effect (group x trial); p <0.05. 
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6.3.4 Adipose tissue resident immune cell populations in participants with 
normal and impaired glucose tolerance and their responses to diet and 
activity modifications  
Gene expression analysis of whole adipose tissue (n=17 paired samples) revealed 
the presence of T-lymphocytes on the basis of CD3, CD4 and CD8 expression in 
both groups (Figure 6.2a). There were no differences in levels of expression of 
these lymphocyte markers according to group and there were no time or 
interaction effects following the intervention period. Further analysis using CD4+ 
lymphocyte lineage markers; FOXP3 (T-regulatory cells), GATA3 (Th2) and 
TBX21 (Th1) were also examined (Figure 6.2b). Each marker was expressed to a 
similar extent in NGT and IGT participants and GATA3 was significantly 
increased in both groups following the 10 day diet and activity modification 
period (p=0.006, F=9.985). Neither FOXP3 nor TBX21, however, changed at 
follow-up in either group. 
  
There was sufficient adipose tissue from 15 of the 19 participants to perform flow 
cytometry of the SVF to characterise T-lymphocyte populations at baseline and 
following the 10 day intervention period. CD4+ and CD8+ T-lymphocyte subsets 
were further characterised using activation markers CD69 and CD25. The 
proportions of activated CD4+ and CD8+ T-lymphocytes, i.e. expressing CD25 
and CD69 showed no differences according to group or trial following the 10 day 
diet and activity modification period (Figure 6.2c). Only the proportion of 
CD8+CD25+ lymphocytes showed a group x trial interaction effect that was close 
to significance (p=0.064, F=4.11). Furthermore, there were no differences in the 
level of expression of the 2 activation markers on CD4+ or CD8+ lymphocytes 









Figure 6.2. Adipose tissue resident T-
lymphocyte phenotype and activation 
before and after diet and activity 
modification in participants with 
NGT (n=6) compared to impaired 
IGT (n=9). a) Relative gene expression 
of cluster differentiation markers to 
identify T-lymphocytes and b) CD4 
lymphocyte  population subsets present 
in adipose tissue. c) Proportions of 
activated cells as a percentage of total 
lymphocytes present and d) their 
respective levels of expression (mean 
fluorescent intensity; MFI) of 
activation markers CD25 and CD69. 
Results compared using 2-way mixed-
model ANOVA, *denotes main effect 
of trial (i.e. baseline vs. follow-up) 
p<0.05.  
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6.3.5 Metabolic and inflammatory properties of adipose tissue 
To further characterise the properties of adipose tissue from the NGT and IGT 
populations, the expression of a number of genes encoding proteins involved in 
insulin signalling were examined (Figure 6.3). No differences in relative gene 
expression of GLUT4, HSL, PPARɣ and IRS2 were found between the NGT and 
IGT groups. After the 10 day diet and activity modification period, there was a 
significant increase in adipose tissue gene expression of HSL in both groups 
(p=0.005, F=10.60) and the increase in IRS2 was close to significance (p=0.073, 
F=3.71).  
 
Figure 6.3. Expression of genes related to insulin signalling pathways in 
participants with NGT (n=7) and IGT (n=10) before and after the 10 day diet 
and activity modification period. Results compared using 2-way mixed-model 
ANOVA, *denotes main effect of trial (i.e. baseline vs. follow-up) p<0.05. 
 
 
A number of pro- and anti- inflammatory cytokines were examined for their gene 
expression in the adipose tissue from the NGT and IGT populations, before and 
after the diet and activity modification period (Figure 6.4). Relative gene 
expression of IL-18 was increased in the IGT group compared to NGT (p=0.008, 
F=9.423) and the increased leptin gene expression with IGT was close to 
significance (p=0.06, F=4.14). After the 10 day diet and activity modification 
period, both groups showed increased gene expression of adiponectin (p=0.007, 
F=9.77) and IL-6 (p=0.019, F=6.91). The increase in MCP-1 in both groups was 
close to significance (p=0.09, F=3.29). A group x trial interaction was also 
identified for IL-1Ra (p=0.033, F=5.52). 














Figure 6.4. Relative gene expression of adipokines before and after the 10 day 
diet and activity modification period in participants with NGT (n=7) and 
IGT (n=10). Mean ± SEM values shown. Results compared using 2-way mixed-
model ANOVA; † denotes a main effect of group (i.e. glucose tolerance status), * 
denotes a main effect of trial (i.e. baseline vs. follow-up) and # denotes in 
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6.3.6 Blood immune cell subsets 
Blood T-lymphocytes and their activation were examined in participants with 
NGT and IGT before and after the 10 day diet and activity modification period 
(Figure 6.5). No significant group or trial effects were identified when examining 
the proportion of activated CD4+ or CD8+ T-lymphocytes (i.e. those expressing 
CD25 and CD69). Neither were there any significant group or trial effects for the 
levels of CD25 or CD69 expression (MFI) on either CD4+ or CD8+ T-
lymphocytes. A significant group x trial interaction was identified for the 
proportion of CD8+CD25+ lymphocytes (p=0.011, F=8.56) and a group x trial 






Figure 6.5. Blood immune cell populations in participants with NGT (n=7) 
and IGT (n=10) before and after the 10 day diet and activity modifications. 
Proportions of activated CD4+ and CD8+ T-lymphocytes according to expression 
of a) CD25 and b) CD69. Levels of expression (MFI) of activation markers c) 
CD25 and d) CD69 on CD4+ and CD8+ T-lymphocytes. Results compared using 
2-way mixed-model ANOVA, # denotes trial x group interaction; p<0.05. 
 
 
Chapter 6  Study 4 
155 
 
6.3.7 Adipose tissue resident macrophages and blood monocytes before and 
after the 10 day diet and activity modification period 
Macrophages were identified in adipose tissue using gene expression analysis of 
CD68 (n=17 paired samples). No effects of group or trial were identified, however 
there was a significant group x trial interaction; p=0.029, F=5.86 (Figure 6.6a). At 
the baseline trial, CD68 expression showed a significant modest correlation with 
fasting plasma glucose (r=0.519, p=0.023) and total area under the curve for 
glucose (r=0.485, p=0.042).  
 
Flow cytometry was used to identify adipose tissue macrophages and blood 
monocytes (CD45+CD14+ cells). Macrophages represented 5 to 21 % of the total 
cells present in the SVF and no differences in the proportions of macrophages (as 
a percentage of total cells present in the SVF) or their expression of CD163 or 
CD14 (MFI) were found based on glucose tolerance status or following the diet 
and activity modification period (Figures 6.6b-c). 
 
There were also no differences in the proportions of monocytes in PBMCs as a 
percentage of total cells in the 2 groups or following the diet and activity 
modification period (Figure 6.6d). Monocyte expression of CD14, CD16, and the 
leptin and insulin receptors were also examined (Figure 6.6e). The insulin 
receptor expression on monocytes was significantly reduced in the IGT compared 
to NGT group (p=0.005, F=11.39) and a group x trial interaction effect was 
identified for monocyte CD14 expression (p=0.021, F=6.79). 
 




Figure 6.6. Adipose tissue macrophages and blood monocytes and measures 
of their activation before and after the 10 day diet and activity modification 
period in NGT and IGT participants. a) CD68 expression in subcutaneous 
adipose tissue, b) proportion of macrophages (CD45+CD14+ cells) in SVF and c) 
expression of CD163 and CD14 on adipose resident macrophages in participants 
with NGT (n=6) and IGT (n=9). d) Proportion of blood monocytes isolated from 
PBMCs and e) their expression of CD14, CD16 and the leptin and insulin 
receptors in participants with NGT (n=7) and IGT (n=10). Mean ± SEM values 
shown. Results compared using 2-way mixed-model ANOVA; † denotes a main 
effect of group (i.e. glucose tolerance status) and # denotes in interaction effect 

















The aims of this study were to examine whether there are differences in T-
lymphocyte populations and inflammatory profiles in adipose tissue from 
individuals with normal and impaired glucose tolerance. Further, we aimed to 
determine whether a reduction in glucose exposure (brought about by a 10 day 
diet and activity intervention) affects T-lymphocyte activation in blood and 
adipose tissue and whether glucose tolerance is a factor in the response.  
 
6.4.1 Characterisation of adipose tissue lymphocytes in participants with 
NGT and IGT 
In this study, the two groups of NGT and IGT participants were very well 
matched according to age, measures of adiposity and clinical blood markers of 
cardiovascular risk.  However, as would be expected based on recruitment criteria, 
the two groups exhibited very different levels of glucose tolerance, as 
characterised by fasting measures of glucose and insulin and measurement of 
glucose and insulin responses during an OGTT. As such, the groups were ideal for 
examining glucose-related differences in immune cell subsets and activation at the 
level of abdominal subcutaneous adipose tissue. 
 
Overweight and obese participants with NGT and IGT were very similar in terms 
of the proportion of CD4+ and CD8+ T-lymphocytes present in abdominal 
subcutaneous adipose tissue and their respective levels of activation. In Chapter 3, 
expression of T-lymphocyte markers CD4 and FOXP3 were elevated with 
increased levels of adiposity from lean through to class I obese, supporting 
findings from Zeyda et al. (2011). Furthermore, activated adipose tissue resident 
CD4+ and CD8+ T-lymphocytes showed greater expression of activation markers 
(CD25 and CD69) with increased adiposity and were related to ‘anti-
inflammatory’ IL-1Ra and IL-10 expression. This suggested that there may be 
protective mechanisms to limit inflammation and insulin resistance with adipose 
tissue expansion. Notably, the two test groups in this study were very well 
matched in terms of adiposity and differed only in levels of glucose tolerance, 
perhaps suggesting that the proportions and activation of T-lymphocytes in 
adipose tissue may be influenced to a greater extent by adiposity rather than 
glucose tolerance status. In a study by Fabbrini et al. (2013) examining 
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lymphocyte populations in adipose tissue, a progressive increase in CD4 mRNA 
was observed across lean, ‘metabolically normal obese’ and ‘metabolically 
abnormal obese’ participants, supporting the findings presented in Chapter 3. 
They also reported that adipose tissue resident T-lymphocytes from metabolically 
abnormal obese were greatly elevated and skewed towards a Th17 and Th22 
phenotype compared to both other groups. However, the subjects in this group had 
a significantly elevated BMI even compared to the metabolically normal obese 
participants, making it impossible to exclude adiposity as a key factor in T-
lymphocyte accumulation to adipose tissue.  
 
The mean adiposity of participants with IGT in this study is comparable to those 
in the study by Goossens et al. (2012) where an increased proportion of Th1 
transcripts were found compared to lean controls. However, no differences in Th1 
transcripts were observed between participants with IGT and NGT where levels of 
adiposity were similar in the present study. In addition to the fact that adiposity 
may be the primary factor as discussed above, it is possible that population 
differences between the studies may account for these discrepancies. Both men 
and women were included in the current study (~80 % women) as compared to 
only men being included in the study by Goossens et al. (2012). These authors 
also found that the expression of inflammasome related genes (NLRP3, IL-18 and 
CASPASE-1) were positively correlated with insulin resistance, which is 
consistent with the elevated expression of IL-18 in the adipose tissue from 
participants with IGT in this study. IL-18 is a product of NLRP3 inflammasome 
activation which contributes to obesity related inflammation and insulin resistance 
and can induce Th1 T-lymphocyte differentiation (Vandanmagsar et al., 2011). 
The NLRP3 inflammasome is particularly active in monocytes and macrophages, 
which although not different in number between groups, may have had different 
inflammatory phenotypes. Macrophages are often skewed towards an M2 anti-
inflammatory profile with obesity, but may represent more of a proinflammatory 
(M1) phenotype in participants with IGT. In the absence of data to fully 
characterise the macrophages we can only speculate that there may be an increase 
in some aspects of inflammation, possibly via the NLRP3 inflammasome, in the 
subcutaneous adipose tissue of participants with IGT. 
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Although the participants did not show differences in the proportion of adipose 
tissue macrophages when grouped according to glucose tolerance (plasma glucose 
at 2 hours during an OGTT), there was a correlation between the expression of 
macrophage marker CD68 with fasting blood glucose at baseline. This may 
suggest that it is the ‘chronic’ aspects of glucose control that are important in 
determining the abundance of macrophages in adipose tissue. This supports work 
presented in Chapter 3 and other published papers (Xu et al., 2003; Apovian et al., 
2008), and suggests that macrophages, again, may have a more direct relationship 
with glucose control than T-lymphocytes.  
 
6.4.2 Changes observed following diet and activity modification  
Participants were instructed to exchange high GI foods for low GI foods and to 
incorporate 15 activity breaks, each lasting 2 minutes, into their daily routines for 
a 10 day period. Certain aspects of glucose control were found to improve in 
participants, including a reduction in glucose 2 hours after an OGTT, the 
Matsuda-ISI index as well as an improvement in fasting insulin that was close to 
significance. These responses were similar between NGT and IGT participants. 
There were no changes to the proportion of activated CD4+ or CD8+ T-
lymphocytes, or their respective levels of activation. However, there was a 
significant increase in GATA3 expression (an indicator of Th2 T-lymphocytes) in 
both NGT and IGT groups along with significant increases in gene expression of 
adiponectin, IL-6 and HSL in adipose tissue which were also unaffected by 
glucose tolerance status. Measures of cardiovascular risk; Total-cholesterol, LDL-
cholesterol and triglycerides were all reduced in both groups along with a 
reduction in HDL-cholesterol and increase in NEFA. 
 
Rather than results at follow-up just reflecting effects of regular activity breaks 
and reduced GI as initially planned, participants also significantly reduced calorie 
intake over the 10 day modification period. The changes in glucose and lipid 
control in blood and metabolic and inflammatory changes in adipose tissue 
observed in the present study may therefore reflect adaptations to a modest calorie 
deficit. The changes to diet and activity were not sufficient to reduce the 
percentage of activated CD4+ T-lymphocytes in blood or to affect their 
expression of CD25 or the insulin receptor, as seen with the severe calorie 
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restriction employed in Chapter 5. Furthermore, the trend towards an increase in 
IRS2 expression may suggest an improvement in adipose tissue insulin sensitivity 
(Shea et al., 2009) rather than a starvation-type response. However, in the absence 
of Western blot analysis to show either changes in IRS protein expression or its 
levels of phosphorylation, this cannot be confirmed. Similar increases in 
adiponectin and IL-6 as observed in Chapter 3, were seen for both NGT and IGT 
participants together with an increase in GATA3 (and a close to significant 
increase in MCP-1). These may reflect additional adaptations made by adipose 
tissue in an extended dynamic phase of weight loss compared to those observed 
after only 3 days of calorie restriction (Chapter 5). Indeed, the early phase of 
weight loss appears to be associated with adipose tissue remodeling and 
inflammation (Capel et al., 2009; Kosteli et al., 2010). The increase in GATA3 
may be suggestive of an increased anti-inflammatory Th2 response, which may 
serve as a mechanism to dampen this inflammation. In the absence of flow 
cytometry data to support an increase in this specific population in adipose tissue, 
however, this hypothesis is purely speculative. The early phase of weight loss is 
also associated with an early increase in macrophage populations in adipose tissue 
(Capel et al., 2009; Kosteli et al., 2010), which are then reduced with further 
weight loss and weight stabilisation (Clement et al., 2004; Capel et al., 2009; 
Kosteli et al., 2010). Murine models suggest that this is to remove excess free 
fatty acids, which are mobilised at an increased rate during an energy deficit 
(Kosteli et al., 2010). The trend towards an increase in MCP-1 expression in 
adipose tissue may support these findings. The divergent changes in adipose tissue 
macrophages identified by the interaction effect for CD68 may reflect an element 
of reduced metabolic flexibility with IGT, since CD68 appeared to increase 
relative to the NGT group. The relative proportion of macrophages in adipose 
tissue, as assessed using flow cytometry, was not increased following the 
intervention, however, and perhaps this would have required a more pronounced 
calorie deficit.  
 
The main purpose of this study was to examine the effects of reduced glucose 
exposure on adipose tissue resident immune cells and it was hoped that the 
addition of activity breaks to a low GI/GL diet would provide a good means of 
maximizing the effect. Due to the unexpected additional reduction in calorie 
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intake, it is not clear whether the observed effects are due to the reduction in 
GI/GL, the increased activity, the total calorie deficit or a combination of all three. 
It would take a great deal of future research to isolate these separate effects. 
Participants lost on average 1.5 kg over the course of the 10 days and this reflects 
the reported energy deficit of ~10,000 kcal (assuming 1 g adipose tissue = 7/8 kcal 
and assuming a similar calorie deficit throughout the intervention (Thompson et 
al., 2012). It is interesting that there was not a greater improvement in glucose 
control despite the relatively good adherence to activity breaks, reduced GI/GL 
and the calorie deficit induced during the intervention. Other studies have reported 
changes in glucose control where only GI was changed and total calorie intake 
remained the same (Brynes et al., 2003; Brynes et al., 2005). In these studies, 
fasting glucose, mean glucose and 24 hour area under the curves were 
significantly reduced after just 1 week of participants adhering to a low GI diet 
and were assessed using only CGMS (Brynes et al., 2003; Brynes et al., 2005). 
These changes were assessed for a single 24 hour period following completion of 
a 1 week low GI diet by which time a larger improvement may have taken place. 
In the present study, it was important to measure glucose exposure to the adipose 
tissue for as long a duration as possible to assess whether glucose control had 
been improved throughout the 10 day period. It is also interesting that CGMS did 
not detect any significant differences between the NGT and IGT groups. Much of 
the literature reports that CGMS can be used to detect differences in participants 
with NGT and IGT, however, the majority of these studies have been conducted 
in specifically Asian populations with an average BMI < 26 kg/m2 (Wang et al., 
2012; Chen et al., 2013; Zhou et al., 2013) or <30kg/m2 (Madhu et al., 2013). 
With greater levels of obesity as observed in the present study, adipose tissue 
expansion leads to reduced adipose tissue blood flow at the per gram level, and 
reduced responsiveness following consumption of a meal (Frayn & Karpe, 2014). 
This is particularly relevant since CGMS measures interstitial fluid in adipose 
tissue and this could represent a key issue and source of increased error in 
measuring differences between NGT and IGT participants and their responses to 
dietary intervention. This hypothesis is supported by a recent study from Salkind 
et al. (2014) who were also unable to detect differences between normal glucose 
tolerant and pre-diabetic morbidly obese participants. Further, this may lead to 
site specific differences in glucose measurements in expanded adipose tissue. 
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CGMS may therefore not be sensitive enough to detect subtle differences in NGT 
and IGT participants with BMI over 30 kg/m2. Although the participants in the 
study by Brynes et al. (2003) had an average BMI over 30 kg/m2 and were still 
able to detect changes following 1 week of low GI diet, these participants had 
type 2 diabetes and so may have been more responsive to a glucose lowering 
intervention. The participants in the present study still have some degree of ability 
to maintain glucose homeostasis and if possible it would have been interesting to 
measure corresponding continuous insulin concentrations for a full picture of their 
insulin sensitivities during the two monitoring periods.   
 
6.4.3 Conclusions 
In this study, participants were recruited to form 2 groups that were well matched 
in terms of adiposity, age and clinical blood markers of cardiovascular risk and 
differed only in their levels of glucose tolerance. Adipose tissue resident immune 
cell populations in participants with NGT and IGT displayed similar properties in 
terms of proportions of CD4+ and CD8+ T-lymphocytes and their respective 
levels of activation.  The weight loss observed in this study may have masked any 
effects of low GI and activity breaks due to the added complexity of adipose 
tissue remodeling and other system adaptations to weight loss. As a result, this 
study has been unable to address whether glucose per se is a key factor in 
determining levels of T-lymphocyte activation and in turn their potential effects 
on glucose control. An alternative study design may have included a cross-over of 
high GI vs low GI diets, either prescribed or given according to energy 

















The overall aim of this thesis was to further characterise aspects of metabolic and 
immune system cross-talk in human subcutaneous adipose tissue, with a particular 
emphasis on the potential role of T-lymphocytes in adipose tissue dysfunction and 
insulin resistance. To address this aim, properties of T-lymphocyte populations 
across varying levels of adiposity and insulin resistance were examined together 
with the effects of acute interventions to examine adipose tissue metabolic and 
inflammatory responses to feeding, severe calorie restriction and glucose lowering 
diet and activity. Specifically, in Chapters 3 and 6, participants covering a range 
of adiposities and levels of glucose control were recruited and T-lymphocytes 
characterised together with activation status. Relationships were examined 
between T-lymphocyte properties with well-established physical and blood 
measures of metabolic health and measures of pro- and anti-inflammatory 
inflammation in adipose tissue. In Chapter 4 postprandial metabolic and 
inflammatory responses were examined across varying levels of adiposity to 
investigate whether the increased metabolic response in blood seen with obesity 
affects postprandial responses in adipose tissue. In Chapter 3, increased T-
lymphocyte activation was identified with increased levels of adiposity. Since T-
lymphocyte activation markers CD69 and CD25 can rapidly respond to 
stimulation in certain situations (Hashemi et al., 1999; Martin-Romero et al., 
2000), this represented an exciting opportunity to examine whether the elevated 
T-lymphocyte activation seen with obesity could be modified through specific 
interventions. In Chapter 5, effects of a dramatic reduction in leptin, achieved by 
short-term calorie restriction on T-lymphocyte activation in adipose tissue and 
blood were examined. In Chapter 6, T-lymphocyte activation was compared 
between participants with normal and impaired glucose tolerance along with their 
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7.2 Summary of findings 
Chapter 3: The impact of adiposity on adipose tissue-resident lymphocyte 
activation in humans 
 With levels of adiposity reflecting lean to common levels of obesity (Class 
I), adipose tissue expansion is characterised not by an increase in the 
proportion of activated T-lymphocytes but rather by a stronger state of 
activation in the T-lymphocytes already expressing CD69 and CD25.  
 Adipose tissue resident T-lymphocyte activation was positively related to 
pro- and anti-inflammatory cytokine production both at the gene 
expression and secretion level, providing further evidence of attempts by 
adipose tissue and resident T-lymphocytes to limit pro-inflammatory 
output from adipose tissue (at least with modestly increased levels of 
overweight/obesity).  
 One of the possible mechanisms that could drive this anti-inflammatory 
compensation is an increased presence of T-regulatory cells, suggested by 
increased FOXP3 expression with increased levels of adiposity.  
 T-lymphocytes are therefore likely to play a key role in the regulation of 
adipose tissue inflammation and important adaptations seen even with 
modestly increased levels of adiposity. 
 
Chapter 4: Metabolic and inflammatory responses to a mixed meal in lean, 
overweight and obese men 
 The same participants from Chapter 3, covering a range of adiposities 
from lean through to class I obese, demonstrated postprandial responses 
for glucose and insulin that were increased in line with increased levels of 
adiposity.  
 In adipose tissue, there were significant increases in MCP-1 and IL-6 gene 
expression and down-regulation of IRS2 at 6 hours after the meal. These 
responses were broadly similar in lean, overweight and obese middle-aged 
men in spite of differences in magnitudes of glucose and insulin responses 
to the meal.  
 A single feeding exposure does not appear to provoke a greater 
inflammatory response in expanded subcutaneous adipose tissue. 
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Chapter 5: Impact of calorie restriction on leptin and T-lymphocyte 
activation in blood and adipose tissue in overweight and obese men 
 Short-term severe calorie restriction causes a reduction in serum leptin 
which was temporally associated with a reduction in the number and levels 
of activation of CD4+CD25+ T-lymphocytes in the blood.  
 Within subcutaneous adipose tissue, however, there was no such reduction 
in either leptin or T-lymphocyte activation.  
 Adipose tissue gene expression of GLUT4 was decreased and IL-6 and 
adiponectin increased following the calorie restriction. 
 These discrepancies may be due to differing responses of different tissues 
to calorie restriction and/or may depend on the specific mechanisms which 
explain the reduction in blood leptin (e.g., modulating the half-life of 
leptin in the blood).  
 
Chapter 6: Effects of diet and activity modification on T-lymphocyte 
activation in adipose tissue 
 Adipose tissue resident immune cell populations in participants with NGT 
and IGT who were well-matched for age and adiposity displayed similar 
properties in terms of proportions of CD4+ and CD8+ T-lymphocytes and 
their respective levels of activation.  
 Following an intervention that aimed to reduce glucose concentrations and 
tissue exposure to glucose, T-lymphocyte activation did not appear to be 
affected in participants with either NGT or IGT.  
 The only difference in adipose tissue between the groups was an increased 
expression of IL-18 in participants with IGT, but this was unaffected by 
the intervention. 
 Following the intervention there was an increase in adipose tissue gene 
expression of GATA3, adiponectin, IL-6, HSL and a trend towards 
increased MCP-1 and IRS2 in participants with NGT and IGT. 
 Whether adipose tissue resident T-lymphocyte activation is influenced by 
glucose exposure per se remains undetermined and the changes observed 
in adipose tissue may be due to an unexpected reduction in calorie intake 
and instead might reflect early changes in dynamic weight loss. 
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7.3 Impact of adiposity and glucose tolerance on immune cell 
populations in adipose tissue 
The results presented in Chapters 3 and 6 characterised T-lymphocyte populations 
present across participants with varying levels of adiposity and levels of glucose 
control respectively. With obesity, the consensus in the current literature appears 
to suggest that CD4+ and CD8+ T-lymphocytes are increased in adipose tissue 
(Kintscher et al., 2008; Duffaut et al., 2009b; Zeyda et al., 2011). These studies 
have typically included obese groups with BMI >40kg/m2 which gives a good 
representation of differences in T-lymphocytes at two extremes. Our results 
presented in Chapter 3 suggest that, even with more modest levels of obesity, 
important changes in adipose resident lymphocyte populations may be taking 
place. Although no differences in proportions of CD4+ and CD8+ T-lymphocytes 
were found, levels of activation were increased in line with levels of adiposity and 
this activation was related to both pro- and anti-inflammatory properties of 
adipose tissue. Furthermore, an increase in FOXP3 transcripts was found 
suggesting there may be an increase in T-regulatory cells with increased levels of 
adiposity which is in line with findings by Zeyda et al. (2011). We did not, 
however, see any reduction in Th2 transcription with obesity, and this difference 
may be a factor of the modest levels of obesity in our cohort compared to those 
examined by Zeyda et al. (2011). Together, these results suggest that there are 
possible anti-inflammatory mechanisms in adipose tissue which may be mediated 
by T-lymphocytes in order to dampen inflammation with increasing obesity. This 
may be linked to observations that macrophages also appear to be increased but 
have an anti-inflammatory phenotype in obesity (Zeyda et al., 2007; Bourlier et 
al., 2008; Fjeldborg et al., 2014).  
 
Importantly, Chapter 3 captured differences in a ‘metabolically healthy’ obese 
population. Few studies have examined differences in T-lymphocyte populations 
specifically in pre-diabetic populations and it is not clear whether there may be an 
increase in pro-inflammatory Th1 T-lymphocytes (Goossens et al., 2012) or Th17 
T-lymphocytes (Fabbrini et al., 2013). Neither of these studies had compared 
differences in participants with normal and impaired glucose tolerance but with 
similar levels of adiposity. This was an aim that we hoped to address in Chapter 6, 
and there did not appear to be a switch in T-lymphocytes in obese individuals with 
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IGT who are age and adiposity matched compared to those with NGT. These 
studies together suggest that adiposity may be more directly linked to the 
accumulation and properties of T-lymphocytes in adipose tissue than glucose 
control. 
 
A consistent finding amongst the Chapters presented in this thesis is that the gene 
expression and proportion of macrophages identified by flow cytometry is more 
directly related to measures of metabolic heath compared to T-lymphocytes. In 
Chapter 3, the expression of CD68 and proportion of macrophages in the SVF was 
elevated with increased adiposity and related to measures of glucose control and 
clinical blood markers of cardiovascular disease risk. In Chapter 6, comparing 
immune cells present with NGT and IGT, CD68 expression was related to 
measures of blood glucose control. Whether macrophages are the cause or 
consequence of obesity-related insulin resistance is not clear. A short term (28 
day) overfeeding study in humans by Tam et al. (2010) showed an increase in 
peripheral insulin resistance in the absence of any changes in adipose tissue 
macrophages. This suggests that, in humans, macrophages may contribute to the 
propagation of insulin resistance later in its development/progression. Due to the 
focus on T-lymphocytes and prioritisation of their markers, it was not possible to 
characterise whether the macrophages were skewed towards a pro- or anti-
inflammatory phenotype and this may have been important, particularly in 
examining differences between the NGT and IGT populations in Chapter 6. 
Although the IGT and NGT groups had the same proportions of macrophages 
present within the SVF, these macrophages may have had very different 
properties. 
 
It is widely described in the literature that adipose tissue gene expression and 
secretion of pro-inflammatory cytokines are increased with adiposity and this was 
observed in Chapter 3. Interestingly, IL-18 was related to both adiposity and T-
lymphocyte activation in adipose tissue and its expression was increased in the 
adipose tissue of participants with IGT compared to those with NGT who 
exhibited similar levels of obesity (Chapter 6). IL-18 is a product of the NLRP3 
inflammasome and is produced/activated mainly in monocytes and macrophages 
(Guarda et al., 2011). The NLRP3 inflammasome is a large cytosolic protein 
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complex which includes Caspase-1; an enzyme required for the activation and 
secretion of pro-inflammatory IL-1β and IL-18 (Grant & Dixit, 2013). It is 
therefore key in the regulation of inflammation. The NLRP3 inflammasome is 
activated by DAMPS, ceramides, free/LDL cholesterol, ROS, hypoxia, necrosis 
which are all increased in obesity and related to the development of insulin 
resistance (Grant & Dixit, 2013). The work in Chapters 3 and 6 appear to support 
the involvement of the NLRP3 inflammasome in obesity related inflammation in 
adipose tissue and a potential involvement in insulin resistance. However, it is 
unknown whether the increased activity of the NLRP3 inflammasome is a cause 
or consequence of insulin resistance.  
 
The cross-sectional relationships observed in Chapters 3 and 6 cannot be used 
definitively to establish whether there is a causal relationship or its direction. 
Thus, it is difficult to untangle precise mechanisms of cross-talk based on these 
observations and this requires more direct intervention and the assessment of 
specific physiological responses. 
  
7.4 Metabolic and immune system adaptations – chronic and 
acute changes to interventions 
To further investigate aspects of metabolic and immune system cross-talk in 
human adipose tissue, a series of acute interventions were conducted. These 
included examining metabolic and inflammatory responses in adipose tissue to 
feeding, short-term calorie restriction to achieve a dramatic reduction in serum 
leptin and responses of participants with NGT and IGT to glucose lowering diet 
and activity modification. There was a particular emphasis in the latter 2 studies to 
examine whether the increased T-lymphocyte activation observed in overweight 
and obese participants found in Chapter 3, could be modified/reduced to levels of 
activation observed in lean participants. In the context of relatively short term 
interventions, T-lymphocytes and levels of activation in adipose tissue appear 
resistant to change, even though expression of CD25 and CD69 can be rapid to 
respond to stimuli (Hashemi et al., 1999; Martin-Romero et al., 2000). The main 
difference compared to the work in this thesis is that these studies were conducted 
in-vitro and this may be a key factor in these discrepancies. With in-vitro work, 
conditions can be manipulated to change one component at a time. However, in-
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vivo, there are many complex interactions to counteract and maintain homeostasis 
amongst other adaptations that may take priority and mask any effects.  
 
Although there were no changes in T-lymphocyte activation, the expression of a 
number of genes encoding specific adipokines were altered following acute 
feeding and dietary interventions. At 6 hours following consumption of a meal in 
Chapter 4, increases in IL-6 and MCP-1 gene expression were observed in 
adipose tissue, although there were no corresponding changes to their secretion 
ex-vivo. Changes in gene expression and secretion may not always coincide with 
each other since there is regulation of protein translation, post-translational 
modifications and secretion as well as temporal differences introduced by the 
sampling framework and methodology. Therefore, the timing of increased gene 
expression may not coincide with an immediate increase in secretion. In Chapter 
4, a further adipose tissue sample at a time-point greater than 6 hours after 
feeding, allowing time for synthesis and secretion, may have shown a 
corresponding increase in MCP-1 and IL-6 secretion and would further support 
these postprandial changes in adipose tissue. It is also possible that earlier changes 
may have been missed. In this context, it would be useful to examine arterio-
venous differences to monitor changes in total adipose tissue output over time. 
This is particularly relevant since, in Chapter 3, results suggested that there may 
be a down-regulation of cytokine secretion at the per gram level to potentially 
limit total inflammatory output to the systemic circulation from the expanded 
adipose tissue. 
 
Results from Chapters 5 and 6 may be suggestive of different acute immune 
system responses occurring with differing severity of calorie restriction. Chapter 5 
suggested that, with severe calorie restriction, there may be an appropriate degree 
of ‘immune suppression’. In both chapters 5 and 6, changes in adipose tissue gene 
expression were observed that were both related to metabolism and immune 
system function. Further alterations to adipose tissue gene expression observed in 
Chapter 6 may reflect the increased duration of less severe calorie restriction 
compared to Chapter 5, and may be involved in the dynamic remodelling of 
adipose tissue in the early stages of weight loss. There are very few studies 
examining acute changes in adipose tissue following calorie restriction in humans 
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for direct comparison. The potential roles of immune cells in these particular 
responses, however, are not clear. No changes in macrophage (CD68) gene 
expression was observed in Chapter 5 following 3 days of severe calorie 
restriction which is comparable to results from Clement et al. (2004) in 
participants after 2 days of very low calorie diet. However, 10 days of a more 
modest calorie deficit may lead to further changes in adipose tissue suggesting an 
increase in macrophages (Capel et al., 2009; Kosteli et al., 2010), possibly 
mediated by an increase in Th2 T-lymphocytes (Chapter 6). Several studies of 
longer duration show improvements in insulin resistance and adipose tissue 
inflammation, especially after period longer than 28 days (Clement et al., 2004; 
Capel et al., 2009). Interestingly, in mice, ‘yoyo’ dieting has suggested that 
subsequent weight gain following a period of weight loss results in increased 
levels of insulin resistance compared to those that maintained their increased 
weight (Anderson et al., 2013). Furthermore, the adipose tissue of the weight-
cycled mice contained an increase in both CD4+ and CD8+ T-lymphocytes in 
adipose tissue and specifically a significant increase in pro-inflammatory Th1 T-
lymphocyte associated genes. Interestingly, there were no differences in 
macrophage accumulation (Anderson et al., 2013). A personal history of weight 
cycling in humans may therefore also be a factor in inconsistencies observed 
between people. The most metabolically un-healthy state for adipose tissue may 
therefore be during dynamic phases of weight gain and weight loss whereby 
continual structural remodelling is taking place. When weight stability is reached, 
adaptations to counteract pro-inflammatory output maybe observed, possibly via 
an increase in anti-inflammatory activity of T-regulatory cells (Chapter 3 and 
Zeyda et al. (2011)) and M2 polarised macrophages (Zeyda et al., 2007; Bourlier 
et al., 2008; Fjeldborg et al., 2014). 
 
7.5 Limitations 
Each of the studies reported in this thesis has tried to capture as much information 
as possible from the adipose tissue of the participants. The ideal study design 
would have as many sampling time-points as possible, however, this may yield 
greater number of artefacts due to changes in adipose tissue physiology induced 
by repeated biopsies. Often, the bruising following sample collection can be quite 
large so follow-up samples are always obtained from the opposite side, away from 
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the initial sample site. With further samples, there is the risk of results being 
affected by tissue damage and repair and infiltration of immune cells for 
remodelling and repair – and thus would not represent changes following an 
intervention. 
 
Clearly one of the main limitations to examining T-lymphocytes in adipose tissue 
is the limited sample size of the material collected when using needle biopsy, 
particularly for work with flow cytometry. Especially when considering that the 
proportion of CD4+ and CD8+ T-lymphocytes represents such a small proportion 
of cells present within the SVF. Gene expression analysis is frequently used as a 
surrogate for identifying relative proportions of immune cells in adipose tissue, 
and are widely compared in the literature (Zeyda et al., 2011; Goossens et al., 
2012). Harman-Boehm et al. (2007) showed that immunohistological staining for 
CD68+ cells highly correlates with CD68 mRNA by RT-PCR. Therefore, using 
gene expression as an indicator of the number of cells may be acceptable to 
correlate with the number of macrophages. Using flow cytometry, the relative 
proportions of cells were examined, however, if all cell numbers were equally 
increased, overall percentages may stay the same and not necessarily give the 
whole picture of changes occurring in adipose tissue. A recent study by Fabbrini 
et al. (2013) attempted to overcome the issues of small adipose tissue samples for 
flow cytometry analysis by expanding T-lymphocyte populations isolated from 
adipose tissue using phytohaemagglutinin and IL-2. However, this may change 
levels of activation and so may be better for identifying immune cell subsets 
rather than their properties. 
 
Contamination of adipose tissue with immune cells from peripheral blood is 
always a possibility with these studies; particularly since there must be a fine 
balance between the time spent cleaning and processing the adipose samples and 
the risks of inducing changes to the integrity of the sample. However 
contamination is unlikely to be a significant factor. A consistent finding amongst 
the studies presented throughout this thesis and amongst other studies by other 
groups (Duffaut et al., 2009b) is that the cells identified have very different levels 
of activation (i.e. MFI for the various markers) and different proportions of 
immune cells are identified in the 2 different tissue types.  
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In both intervention studies presented in Chapter 5 and 6, a definitive answer to 
whether leptin or glucose (respectively) can affect T-lymphocyte activation in 
human adipose tissue could not be reached. This is partly due to complex whole-
body mechanisms that adapt to stresses on the body. In Chapter 6 in particular, 
despite the diet and activity modifications which should have improved glucose 
control, only certain aspects of insulin sensitivity assessed using an OGTT were 
improved. It is possible that the use of a ‘hot box’ to enable measurement of 
arterialised blood may have revealed greater differences in glucose concentrations 
(prior to glucose uptake by the tissues as measured in venous blood). However, it 
is arguably more useful to examine what is measured in a clinical setting for 
greater external validity. 
 
7.6 Future work 
The results presented in this thesis are all representative of differences observed in 
subcutaneous adipose tissue with differing levels of adiposity. Visceral adipose 
tissue is often considered to be more pro-inflammatory in terms of immune cell 
populations present and its cytokine output. Our results show that subcutaneous 
adipose tissue is highly dynamic and T-lymphocytes could be involved in 
important regulatory processes. The subcutaneous adipose tissue should therefore 
not be overlooked as an important depot when considering the pathology of 
obesity-related diseases. Comparatively little is known about immune cell 
populations in gluteo-femoral subcutaneous adipose tissue. Since this depot is 
associated with protection from obesity related insulin resistance, further 
investigation of T-lymphocyte populations within this depot may give greater 
insight into how the immune system may influence adipose tissue properties, 
particularly since T-regulatory and Th2 cells may have an important role in 
limiting inflammation in subcutaneous and visceral adipose tissue (Zeyda et al., 
2011). 
 
The interesting changes in inflammatory gene expression in adipose tissue during 
acute periods of calorie restriction also warrant further investigation. There are 
many studies examining inflammatory changes with long term weight loss, 
however, our studies and other recent studies suggest there could be some 
evidence of increases in inflammation with dynamic weight loss (at least in the 
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short term). The finding in mice that subsequent regain in weight results in an 
increased accumulation of T-lymphocytes (Anderson et al., 2013) is particularly 
relevant to investigate in humans since maintaining weight loss is often not 
achieved and ‘yoyo dieting’ in humans is associated with increased levels of 
insulin resistance (Waring et al., 2010). 
 
Gene expression analysis is currently a very useful tool to examine expression 
profiles relating to a variety of immune cells present in the small adipose tissue 
masses obtained from biopsy. However, these cells can only truly be confirmed 
using flow cytometry and immunohistochemistry. Further investigation into how 
lymphocyte expansion affects cell proportions and activation compared to 
baseline are warranted, since this would represent a means to potentially further 
characterise T-lymphocytes in adipose tissue, for example, using intracellular 
staining for flow cytometry.  
 
Further work is required to address the nature of the ‘cross-talk’ involving 
immune cells and adipocytes in human adipose tissue. In-vitro work using 
conditioned media generated from adipocytes, lymphocytes and macrophages 
from participants covering ranges of adiposities and levels of insulin resistance 
may be useful to gain further insight into these relationships. Particularly 
experiments involving cross-over of lean and obese cells and conditioned media, 
and co-culture experiments will be useful to investigate this cross-talk. In-vivo, 
however, the complex interactions and mechanisms to maintain homeostasis may 
mean that these are not necessarily a true reflection of in-vivo interactions, but in-














The work presented in this thesis has examined aspects of metabolic and immune 
system cross-talk in human adipose tissue and demonstrates that T-lymphocyte 
activation in adipose tissue may be an important factor in regulating the increased 
adipose tissue inflammation seen with modestly increased levels of adiposity. 
Glucose intolerance does not appear to induce a switch in T-lymphocyte 
phenotype or activation so the role of T-lymphocytes in insulin resistance is less 
clear. Interventions including short-term modest and severe calorie restriction did 
not result in a change in T-lymphocyte activation in adipose tissue. However, 
inflammatory changes were observed in adipose tissue suggesting that other 
aspects of the immune system are responsive to metabolic changes. Macrophages 
may have a more direct relationship with insulin resistance, although the potential 
involvement of T-lymphocytes in mediating this relationship is not clear. 
 
In conclusion, T-lymphocytes are likely to have a key role in the regulation of 
adipose tissue inflammation seen with increased levels of adiposity but, based on 
the observations in this thesis, their role in the development of insulin resistance 
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It is important that volunteers participating in research studies are currently in good health 
and have had no significant medical problems in the past.  This is to ensure (i) their own 
continued well-being and (ii) to avoid the possibility of introducing bias into the study 
outcomes. 
Please complete this brief questionnaire to confirm your eligibility to participate: 
1. Age………………………………………………………………...... 
 
2. Do you smoke          Yes       No      
 
3.  At present, do you have any health problem for which you are: 
(a) on medication, prescribed or otherwise ................. Yes      No      
(b) attending your general practitioner ........................ Yes      No      
(c) on a hospital waiting list ........................................ Yes      No      
 
4.  In the past two years, have you had any illness which require you to: 
(a) consult your GP   ................................................... Yes      No      
(b) attend a hospital outpatient department ................. Yes      No      
(c) be admitted to hospital  ......................................... Yes      No      
 
5.  Have you ever had any of the following: 
(a) Convulsions/epilepsy ............................................. Yes      No      
(b) Asthma................................................................... Yes      No      
(c) Eczema .................................................................. Yes      No      
(d) Diabetes ................................................................. Yes      No      
(e) A blood disorder .................................................... Yes      No      
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(f) Head injury ............................................................ Yes      No      
(g) Digestive problems ................................................ Yes      No      
(h) Heart problems ...................................................... Yes      No      
(i) Breathing problems ............................................... Yes      No      
(j) Problems with bones or joints    ............................ Yes      No      
(k) Disturbance of balance/coordination ..................... Yes      No      
(l) Numbness in hands or feet .................................... Yes      No      
(m) Disturbance of vision ............................................. Yes      No      
(n) Ear / hearing problems .......................................... Yes      No      
(o) Thyroid problems .................................................. Yes      No      
(p) Kidney or liver problems ....................................... Yes      No      
(q)   Problems with immune system …………………...Yes              No      
(r) Allergies to any anaesthetics  ................................ Yes      No      
(s) Porphyria  .............................................................. Yes      No      
(t) Myasthenia gravis  ................................................. Yes      No      
(u)  Adam’s-Stokes Syndrome  .................................... Yes      No      
(v)  Wolff-Parkinson-White Syndrome ........................ Yes      No      
 
 
If YES to any question, or if there is any other information you think we should 
know, please describe briefly (eg to confirm problem was/is short-lived, insignificant 
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7.  During a typical 7-Day period (a week), how many times on the average do you do 
the following kinds of exercise for more than 15 minutes during your free time (write on 
each line the appropriate number –e.g. 2 hours total of moderate intensity exercise per 
week = 8 x 15 minutes, so write 8): 
a) STRENUOUS EXERCISE (HEART BEATS RAPIDLY) 
__________________________ 
(e.g., running, jogging, hockey, football, soccer, squash, basketball, judo, roller skating, 
vigorous swimming, vigorous long distance bicycling) 
b) MODERATE EXERCISE (NOT EXHAUSTING) 
________________________________ 
(e.g., fast walking, baseball, tennis, easy bicycling, volleyball, badminton, easy 
swimming, popular and folk dancing) 
c) MILD EXERCISE (MINIMAL EFFORT) 
_______________________________________ 
(e.g., yoga, archery, fishing from river bank, bowling, golf, easy walking) 
 
8.  Has your weight been stable during the last 3 
months................................................................................ 
 
9.  Do you know your birth weight? If so, please specify 
(approximate)……………………………............ 
 
10.  When you were 16 years old, please indicate on this scale with an X where you think 



















Examples of Excel Spreadsheet used to calculate meal composition relative to 




























A standard meal comprising brioche, jam, margarine and milkshake (icing sugar, cream, chocolate milk) plus milk (for tea) was 
devised for an average man of 80 kg to comprise the required total 120g CHO (1.5g/kg body mass). 
The relative ratios of each meal component (Box C) - i.e. how much each item contributes to total CHO content in this optimal 
meal (Box B) were then used to ensure that these meal components would be in the same ratios when meal is relative to RMR. 






Pilot work showing reduction in serum leptin and adipose tissue 






























Diet calculations for participants in Study 3 (Chapter 5).  
 







Correlations between levels of T-lymphocytes activation in adipose tissue, waist 

















 Waist circumference Serum Leptin 
CD4+CD25+ CD25MFI r=0.683, p<0.05 r=0.629, p<0.05 
CD4+CD69+ CD69MFI r=0.376, p=0.229 r=0.639, p<0.05 
CD8+CD25+ CD25MFI r=0.528, p=0.078 r=0.292, p=0.356 
CD8+CD69+ CD69MFI r=0.642, p<0.05 r=0.566, p=0.055 
